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Recent advances with the bacterial CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats) defense system as genome editing tools have opened a new 
avenue for targeting disease-causing mutations. The programmability of the Cas9 
endonuclease by RNA makes it a potentially powerful therapeutic tool to correct such 
mutations. The CRISPR-Cas9 system consists of a Cas9 endonuclease that is guided by 
RNA (sgRNA) to create double-stranded breaks in a target DNA segment 
complementary to the guide. This process is dependent on a 2-8 nucleotide sequence 
(called PAM) that is adjacent to the target and functions as a Cas9 binding signal. Each 
Cas9 ortholog recognizes a unique PAM. 
However, factors such as the size of Cas9 or the frequency of its PAM sequence 
in the genome have hindered its clinical use. The Cas9 from Streptococcus pyogenes 
(SpyCas9) is commonly used in research because its PAM (NGG, where “N” 
symbolizes any nucleotide) is present every ~8 bp in the genome, providing robust 
targeting potential. However, it is too large to fit into typical viral vectors used for in 
vivo delivery, namely adeno-associated vectors (AAV). While several Cas9 orthologs 
have been characterized, none satisfied the need for a compact, accurate Cas9 with a 
short PAM.  
In this thesis, we use two approaches to identify new compact Cas9 orthologs 
with small PAMs, one using anti-CRISPR proteins and one by searching through 
closely related Cas9s. First, we use the presence of anti-CRISPRs (naturally occurring, 
 vi 
phage-encoded peptides that inhibit CRISPR-Cas9 described in chapter 2) in a genome 
as indicators of Cas9s that may be highly active. These orthologs come with the added 
advantage of having inhibitors that can be used as off-switches. We characterize four 
Cas9s that are targeted by anti-CRISPR proteins and show that they recognize diverse 
PAMs in vitro. One of the four Cas9’s, namely HpaCas9 from Haemophilus 
parainfluenzae, induces efficient genome editing in mammalian cells. However, its 
long N4GATTT PAM does not satisfy the short PAM criterion. 
For our second approach, we asked whether closely related Cas9 orthologs with 
drastically different PAM-interacting domains (PIDs, the domain responsible for PAM 
recognition) recognize different PAMs, and if so, can be used for genome editing. To 
this end, we exploited natural variation in the PID of closely related Cas9s to identify a 
compact ortholog from Neisseria meningitidis (Nme2Cas9). Nme2Cas9 recognizes a 
simple dinucleotide PAM (N4CC) that provides a high target site density. All-in-one 
AAV delivery of Nme2Cas9 with a guide RNA into adult mouse liver produces 
efficient genome editing and reduced serum cholesterol with exceptionally high 
specificity. We further expand our single-AAV platform to pre-implanted zygotes for 
streamlined generation of genome-edited mice. Finally, we show preliminary data on 
how CRISPR-Cas9 can be used for therapeutic genome editing for Amytrophic Lateral 
Sclerosis.  Our new findings promise to accelerate the development of genome editing 
tools for biomedical and therapeutic applications. 
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Chapter 5 
In Chapter 5, we present preliminary data on using CRISPR-Cas9 genome editing as a 
therapeutic approach for ALS. This is a collaboration between Sontheimer and 
Mueller labs, particularly with Raed Ibraheim and Karin Meijboom. All data in 
this chapter are unpublished
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CHAPTER 1: Introduction 
1.1 Introduction to CRISPR-Cas 
1.1.1 The biology and diversity of CRISPR-Cas 
Bacteriophages, or viruses that infect bacteria, are the most common biological 
entity on the planet, with an estimated 1031 bacteriophages on earth. As a response, 
bacteria have evolved dozens of defense systems to combat phage infection. One 
category of defense system is CRISPR-Cas [Clustered, regularly interspaced, short 
palindromic repeats along with CRISPR-associated (Cas) proteins], which constitutes 
bacterial and archaeal adaptive immune pathways against phages and other mobile 
genetic elements (MGEs) (Barrangou et al., 2007; Marraffini and Sontheimer, 2008; 
Brouns et al., 2008). CRISPR is present in most archaea and about half of all bacteria 
and provides immunity against MGEs by targeting and degrading their associated 
nucleic acids.  
Thousands of CRISPR-Cas systems have been identified thus far. Despite 
tremendous diversity, the architectures of CRISPR loci share many similarities. 
CRISPR immunity consists of an adaptation phase and an interference phase. The 
adaptation phase provides an immune genetic memory of previous infections in the 
form of DNA. Next, the DNA is transcribed, processed into mature CRISPR RNAs 
(crRNAs, also called crRNA processing) and serves as a guide for Cas endonucleases 
to find and cleave future invaders, a process known as interference (Figure 1.1). A 
 2 
typical CRISPR locus consists of a CRISPR array flanked by Cas genes. The CRISPR 
array consists of a series of identical, short (~25-60) repeat sequences (Shmakov et al., 
2017b) interspaced by MGE-derived spacer sequences of similar length, which are 
complimentary to the target and form the basis of CRISPR immunity. Cas proteins are 
involved in adaptation, crRNA processing, and interference.  
Numerous Cas proteins have been identified to date and can be categorized into 
adaptation, processing and effector modules based on their functions (Koonin and 
Makarova, 2009; Makarova et al., 2015; Koonin and Makarova, 2019). Only Cas1 and 
Cas2, which function in CRISPR adaptation, are nearly universal to all CRISPR-Cas 
systems. In contrast, CRISPR effector modules (i.e. the interference complex) are 
extremely diverse and form the basis of the current classification scheme of CRISPR 
systems, which broadly groups them into two classes (class I and class II) comprising 
six types (Shmakov et al., 2017a). Class I systems employ multi-protein effector 
complexes, whereas Class II CRISPR systems use a single effector protein for 


















Figure 1.1 CRISPR as an adaptive immune pathway 
A typical CRISPR locus consists of a CRISPR array and several Cas proteins. CRISPR 
adaptive immunity begins with the acquisition of a spacer from invading MGEs 
(adaptation) and integrating them into the CRISPR array. CRISPR loci give rise to 
crRNAs (crRNA processing), which guide the effector module Cas proteins to their 







As part of the constant arms race between phages and bacteria, phages have 
evolved many counter measures against CRISPR including mutations and anti-CRISPR 
proteins (Acrs). Acrs are small proteins that bind to CRISPR effectors and render them 
inactive, disarming CRISPR defense and allowing phage propagation. Acrs are highly 
diverse and have been reported to inhibit CRISPR effectors via distinct mechanisms. In 
chapter 2, we will describe some of these Acrs that inhibit CRISPR-Cas9 and provide 











Figure 1.2 Classification and diversity of CRISPR systems 
(A) The basis for class 1 and class 2 CRISPR systems. Class 1 systems are 
characterized by the presence of multiple subunits in their effector complex, while class 
2 systems have a single, RNA-guided nuclease for interference. Cas1 and Cas2 are 
almost universal and are part of the adaptation complex.   
(B) There are three types of CRISPR systems in each class. Dispensable genes (not 
found in all systems) in each type are indicated by a dashed outline. Adapted from 









1.1.2 A brief history of CRISPR 
Like most discoveries in science, CRISPR has a rich history with hundreds of 
scientists involved, building upon the works of the previous scientists to culminate to 
what today has become one of the most important advances in science. Here, I will 
outline some of the key CRISPR discoveries, which is by no means a comprehensive 
history of CRISPR. 
In 1987, Ishino and colleagues were working on the isozyme conversion of 
alkalinephosphatase in E. coli when they came across a series of identical repeats 
flanking their gene of interest. In their discussion, they wrote that “an unusual structure 
was found in the 3’end flanking region of iap [their gene of interest]. Five highly 
homologous sequences of 29 nucleotides were arranged as direct repeats with 32 
nucleotides as spacing” (Ishino et al., 1987). About three decades later, we now know 
that this was the first reference to CRISPR. 
The term CRISPR was coined in 2002 by Ruud Jansen and colleagues, who 
showed that these loci were widespread in bacteria and archaea but are absent in 
eukaryotes (Jansen et al., 2002). These repeats had already captured the attention of 
Francisco Mojica, who studied these repeats and showed that they derive from foreign 
genetic elements and may be involved in defense against MGEs (Mojica et al., 2005). 
In fact, Mojica had initially dubbed these loci as short regularly spaced repeats (SRSRs) 
but later on recommended that Jansen et al. emphasize the palindromic nature of 
repeats, which resulted the arguably catchier acronym, CRISPR. This was followed 
shortly after by the discovery of Cas proteins. 
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Speculations regarding the nature of CRISPR-Cas continued until 2007, when 
the first evidence of CRISPR’s function was shown by Barrangou et al. They 
demonstrated that bacteria exposed to phages could use CRISPR to combat the attack 
(Barrangou et al., 2007). Several mechanistic studies from 2008 to 2012 culminated in 
two papers by Jinek et al. and Gasiunas et al. demonstrating that Cas9 (a type II 
CRISPR-associated endonuclease) is an RNA-guided endonuclease. These biochemical 
studies paved the way for heterologously expressing this bacterial protein to be used for 
genome engineering (Jinek et al., 2012; Gasiunas et al., 2012). The CRISPR craze 
kickstarted with several papers in 2013 establishing Cas9 as a genome engineering tool 
and Cas9 has been widely used ever since (Cong et al., (Esvelt et al., 2013; Mali et al., 









1.2 Type II CRISPR-Cas systems 
The most common and well-studied Class II systems are from type II, which 
uses the Cas9 protein as its effector and will be the primary focus of this thesis. Type II 
CRISPR systems are subdivided into three subtypes based on the degree of homology 
between Cas9 proteins, and on the presence or absence of other Cas proteins besides 
Cas1, Cas2 and Cas9 (Shmakov et al., 2017a). Type II-A systems have an additional 
protein named Csn2, type II-Bs are distinguished by the presence of Cas4, and type II-
Cs are characterized by the absence of both Cas4 and Csn2. Recently, additional 
variants of type II-C CRISPR systems have also been identified in archaea that share 
similarity with type II-C Cas9s but also contain Cas4 (Burstein et al., 2017). Subtypes 
II-A, -B and -C comprise ~55%, ~3% and ~41% of type II systems identified in public 
sequence database (Shmakov et al., 2017a). Like other CRISPR systems, the 
mechanism of CRISPR immunity is still divided into three steps (figure 1.1), 
adaptation, crRNA processing and interference: 
1) Adaptation: Adaptation is the first step in CRISPR immunity.  Most of our 
knowledge of adaptation comes from the type I-E system of Escherichia coli (E. coli), 
and the type II-A systems of S. pyogenes and Streptococcus thermophilus (Jackson et 
al., 2017; Sternberg et al., 2016). In most systems studied to date, Cas1 and Cas2 form 
a complex to capture small fragments of DNA from the MGE and integrate them into 
the CRISPR array. In type II-A systems, Cas9 was also required for successful 
adaptation, in part to enforce PAM specificity of the DNA fragments being captured 
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(Heler et al., 2015). These spacers along with the repeats are then transcribed in the 
second step in CRISPR immunity, also known as crRNA biogenesis. 
2) CRISPR RNA Biogenesis: In most CRISPR-Cas systems, a single pre-crRNA 
transcript spanning the CRISPR locus is initiated from the leader region, and the pre-
crRNA must be processed to yield individual crRNAs (Charpentier et al., 2015; 
Deltcheva et al., 2011). This is also the case for type II-A and II-B systems studied to 
date. In contrast, many type II-C arrays possess internal, independent promoters 
embedded in each repeat sequence, yielding nested sets of pre-crRNAs of varying 
length (Zhang et al., 2013). 
In addition to a crRNA, type II systems require a trans-activating crRNA 
(tracrRNAs) (Figure 1.3). tracrRNAs include a complementary region that hybridizes 
with repeat sequences within pre-crRNAs (Deltcheva et al., 2011). Processing involves 
endonucleolytic cleavage of both strands of the pre-crRNA:tracrRNA duplex by the 
host factor RNase III (Charpentier et al., 2015). 
3) Interference: Cas9 is the sole protein responsible for interference in type II systems. 
Cas9 forms a ribonucleoprotein (RNP) complex with crRNA and a tracrRNA, and this 
complex cleaves DNA in a crRNA-guided manner (Figure 1.3). Self-targeting is 
avoided in all type II systems by requiring a protospacer adjacent motif (PAM) 
sequence for target engagement and cleavage. PAM recognition by Cas9’s PAM 
interacting domain (PIDs) is required before the initiation of dsDNA cleavage 
(Sternberg et al., 2015). In the context of adaptive immunity, PAMs are used to 
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distinguish self vs. non-self DNA. i.e. since the complementary sequence is present in 
both the CRISPR array and the MGE, effector proteins use PAMs to only target the 
MGE. In the case of the spacer in the CRISPR array, the PAM sequence gets removed 
prior to spacer insertion by the adaptation machinery.  
Despite the tremendous diversity of Cas9s, they all share a similar domain 
structure (figure 1.4). First, The N-termini of Cas9s start with the catalytic RuvC-I 
domain, which is responsible for the cleavage of the displaced (crRNA-
noncomplementary) strand of the protospacer. The arginine-rich bridge helix (BH) 
follows the RuvC-I domain and has previously been implicated in guide RNA 
recognition, especially in the region that pairs with the target DNA nucleotides that are 
nearest the PAM (the “seed” region). The α-helical recognition (REC) lobe is 
composed of several REC domains that are involved in the recognition of the target 
protospacer. Next, the HNH (His-Asn-His) endonuclease domain, which cleaves the 
crRNA-complementary DNA strand, is sandwiched between the RuvC-II and RuvC-III 
domains. Lastly, the highly divergent PAM-interacting domain (PID) is found at the C 
terminus, which serves to recognize the diverse PAMs found in type II systems 
(Shmakov et al., 2017a; Mir et al., 2018b). 
Once the RNA is processed and loaded onto Cas9, there are conformational 
changes that result in the ability of Cas9 to recognize the PAM in the target dsDNA. 
Specifically, studies on SpyCas9 have shown several conformational changes within 
the REC and HNH domains upon sgRNA loading and DNA binding (Sternberg et al., 
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2015). The cleavage of target strand by the HNH domain is immediately followed by 
the cleavage of the non-target strand by the RuvC domain. The DSBs thwart the 




Figure 1.3: The biology of type II CRISPR systems 
A typical type II-A system is shown. These crRNA guides are initially transcribed into 
longer pre-crRNAs that are then processed into their mature forms. The spacers within 
the CRISPR locus derive from previously encountered MGEs and are incorporated by a 




Among type II CRISPR subtypes, type II-C is the simplest and often possesses 
relatively smaller Cas9s (Figure 1.4A). The smaller size of these orthologs makes them 
suitable for Adeno-associated virus (AAV) delivery, which has limited packaging 
capacity (see section 1.4.1) (Lino et al., 2018). Of the ~4,000 Cas9 orthologs currently 
in the NCBI database, ~1,500 are type II-C (Shmakov et al., 2017a). These type II-C 
systems are found in diverse bacterial species that grow in extremely different 
environments, from acidic hot springs in Yellowstone National Park (Acidothermus 
cellulolyticus), to the respiratory tract of pigs (Pasteurella multocida), and to waste 
waters in Thailand (Tisterilla mobilis) (Mir et al., 2018b). This environmental breadth 
likely drives the evolution of the unique and diverse Cas9 orthologs observed. In fact, 
an analysis of type II-C systems reveals substantial sequence diversity among 
components of type II-C loci, including their Cas9 orthologs (Chylinski et al., 2014). 
Specifically, the diversity within type II-C PIDs suggests the recognition of divergent 
PAMs. This is demonstrated by type II-C Cas9 PAMs defined to date (Figure 1.4B). 
Interestingly, type II-C Cas9 orthologs in closely related species of Campylobacter (e.g. 
C. jejuni and C. lari) can recognize highly dissimilar PAMs (Ran et al., 2015; Kim et 
al., 2017).  
Another peculiar aspect of some type II-C Cas9 orthologs is that their associated 
PAMs can extend relatively far from the crRNA-complementary sequence (often up to 
8 nt). The long PAMs may influence target site choice and off-target effects of type II-
C Cas9s, as discussed further below. 
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Figure 1.4 Domain architecture and diversity of type II-C Cas9s 
(A) The domain architecture of type II-C Cas9s. The individual domains are colored 
separately and labeled. (B) A phylogenetic tree of in vitro validated type II-C Cas9s. 
The reported PAMs and the protein sizes of Cas9s are also listed. Cas9s validated for 

































Parvibaculum lavamentivorans NNNCAT 1037 N Ran et al. (2015)
Acidothermus cellulolyticus NNNCC 1138 N Tsui et al. (2017)
Actinomyces naeslundii ? 1101 N Ma & Harrington et al. (2015)
Corynebacterium diphtheriae NGG 1084 N Ran et al. (2015), Ma & Harrington et al. (2015)
Campylobacter jejuni NNNNRYAC 984 Y Fonfara et al. (2014), Kim, Koo & Park et al. (2016), Yamada & Watanabe et al. (2017)
Campylobacter lari NNGGGT 1003 N Ran et al. (2015)
Brevibacillus laterosporus NNNNCNDD 1092 Y Karvelis et al. (2015)
Geobacillus stearothermophilus NNNNCNAA 1087 Y Harrington et al. (2017)
Neisseria cinerea NNNNGTA? 1082 N Ran et al. (2015)
Neisseria meningitidis NNNNGNTT 1082 Y Hou & Zhang et al. (2013), Esvelt & Mali et al. (2013), Fonfara et al. (2014), Lee et al. (2016)
Pasteurella multocida GNNNCNNA 1056 N Fonfara et al. (2014)




1.3 CRISPR-Cas9 genome engineering 
1.3.1 Applications of CRISPR-Cas9 in biomedical sciences 
The ability to modify the genome can provide the opportunity to study and treat 
human disease. Genetic disorders caused by abnormalities in a gene(s) are widespread 
throughout the world. Online Mendelian Inheritance in Man (OMIM) estimates that 
over 6500 different diseases are the result of monogenic mutations, often with a single 
nucleotide difference between patients and healthy individuals. Consequently, genome 
editing i.e. the ability to make changes to a target DNA of interest can be used to model 
or treat such diseases. It is therefore not surprising that several genome editing 
approaches have been devised in the past few decades. Most of these approaches are 
based on a nuclease that can be programmed to a target of interest. For example, zinc-
finger nucleases are engineered by fusing a DNA binding domain to a DNA cleavage 
domain. DNA cleavage triggers the cellular repair machinery to repair the break, which 
forms the basis of genome editing applications (see chapter 1.3.3 for mechanistic 
details of repair outcomes). However, these methods were expensive, time consuming 
and often inefficient. As a result, the advent of Cas9 genome editing was timely, which 
will be discussed below. 
CRISPR-Cas has revolutionized biomedical sciences and enumerating its uses 
would encompass hundreds of pages, so here I will just list a handful of its applications. 
The ability to target sites using RNA-DNA complementarity rather than protein 
engineering is the transformative feature of Cas9 and other RNA-programmable Cas 
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proteins. Nuclease Cas9 has been successfully used in model organisms such as Mus 
musculus (mice), Caenorhadbitis elegans (round worm), Escherichia coli (bacterium), 
Saccharomyces cerevisiae (yeast), Arabidopsis thaliana (plant). Applications include 
creating gene knockouts by simply inducing indels or creating a desired outcome by 
providing donors for homologous recombination (Doudna and Charpentier, 2014). In 
addition, Cas9 has been used to generate disease models in human induced pluripotent 
stem cells (iPSCs), which can be differentiated into the cell type of interest (Musunuru, 
2013).  
Genome-wide CRISPR screens have been powerful in identifying disease-
associated protein functions in a systemic manner. Most CRISPR screens use thousands 
of guide RNAs to knock out genes across millions of cells while applying a selective 
pressure, and then identify protospacer sequences that are either enriched or depleted in 
the selected cell population relative to control. For example, Wang et al used a library 
of 73,000 sgRNAs to generate knockout collections and performed screens to identify 
essential genes in DNA mismatch repair pathways (Wang et al., 2015). While CRISPR 
screens require detectable phenotypic (often survival) outcomes, they have proven 
powerful in untangling complex pathways and uncovering important genes in cancer 
and other diseases. 
In addition to wildtype Cas9 (wtCas9), catalytically dead Cas9 (dCas9) has been 
used to deliver other enzymes to a locus of interest. Fusion of dCas9 to transcriptional 
activators (CRISPRa) and repressors (CRISPR interference, CRISPRi) has resulted in 
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fine-tuned, reversible transcriptional regulation in bacteria and eukaryotes (Qi et al., 
2013; Larson et al., 2013). dCas9 has also been fused to fluorescent proteins for 
visualization of genetic loci of interest (Chen et al., 2013). The advent of base editing is 
another outcome of the CRISPR revolution. Base editors consist of Cas9 fused to a 
cytidine deaminase, guided to a locus of interest resulting in an ultimate C-G à T-A 
conversion without a DSB (Komor et al., 2016). More recently, an RNA adenosine 
deaminase was evolved to deaminate deoxyadenosine, and was fused to dCas9 for A-
TàG-C conversion (Gaudelli et al., 2017). In summation, Cas9-based applications 
have helped scientists throughout the world to uncover basic molecular mechanisms of 














1.3.2 Clinical applications of CRISPR-Cas9 
CRISPR-Cas9 has already been used for therapeutic and diagnostic purposes. 
Proof-of-concept experiments have demonstrated that Cas9 editing in human embryos 
can correct deleterious mutations. For example, scientists used Cas9 to correct 
MYBPC3 mutations (causes hypertrophic cardiomyopathy) and similar efforts were 
done on the β-globin gene (Ma et al., 2017; Liang et al., 2015). There is also ongoing 
work on treating genetic defects in adults. Due to the outstanding delivery challenges 
(see chapter 1.4), most of the current trials rely on ex vivo approaches. Such approaches 
consist of editing patient cells outside of the body and reintroducing the cells with 
corrected gene(s). For example, there are currently multiple clinical trials for ex vivo 
therapeutics of β thalassemia and sickle cell disease, two life-threatening afflictions 
(clinicaltrials.gov, 2019). 
The rapid implementation of CRISPR technologies has generated controversy 
regarding safety and ethics. In 2016, scientists in China injected CRISPR-edited cells 
into the lungs of a lung cancer patient to arm T-cells to better fight cancer (Cyranoski, 
2016). In 2018, the birth of the first ever genetically edited humans was reported, 
leading to considerable controversy and ethical debate. Although controversial, these 





 1.3.3 The mechanism of CRISPR-Cas9 genome engineering 
The RNA programmability of Cas9 has made it a powerful genome editing tool 
in biotechnology and medicine (Cho et al., 2013; Esvelt et al., 2013; Mali et al., 2013; 
Cong and Zhang, 2015). In engineered systems (e.g. for genome editing), the crRNA 
and tracrRNA can be fused into a single-guide RNA (sgRNA). Cas9 is guided to the 
locus of interest to induce a double-stranded break (DSB, when both strands of the 
DNA double-helix are cut). DSBs are inherently dangerous for the cell, as they could 
lead to rearrangements and loss of genetic information. Cells have evolved repair 
pathways to deal with DSBs and taking advantage of these repair pathways enables 
editing of specific loci. 
Since DSBs threaten the integrity of the genome, Cas9-mediated cleavage 
triggers a repair response (Figure 1.5). In most mammalian cells, DSBs are frequently 
repaired via an imprecise process called non-homologous end-joining (NHEJ). 
Sometimes, the NHEJ machinery ligates the blunt ends of the Cas9-cleaved DNA, 
restoring the original sequence that is susceptible to another round of cleavage. On the 
other hand, sometimes NHEJ inserts or deletes a few bases prior to ligation. This results 
in nucleotide insertions/deletions (indels) that inactivate the target gene (Lino et al., 
2018). Creating indels in a gene of interest is powerful, since we can study gene 
function and in the case of a disease-causing gene, knockout its function. 
An alternative repair pathway is homology-directed repair (HDR), which 
requires that a donor DNA is provided and is often less efficient than NHEJ (Figure 
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1.5). The template DNA can be either from an uncut allele in the genome, or 
exogenously supplied dsDNA or ssDNA donors. The HDR pathway is crucial in 
repairing disease-causing mutations that need to be precisely repaired and NHEJ 
knockout is not sufficient. Consequently, the naturally low rates of HDR is a hindrance 
to some therapeutic applications. To this end, mutations in Cas9 nickases, in which the 
active sites of either the HNH or RuvC domain is mutated, have been used to improve 
HDR and to improve genome editing specificity via DSB induction by dual nickases 
(Ran et al., 2015) (Mali et al., 2013). 
Theoretically, any sequence in the genome that is adjacent to a PAM can be 
targeted. However, editing varies considerably from site to site, depending on sgRNA 
expression, DNA accessibility and other factors. Furthermore, some Cas9 orthologs 
have the propensity to cleave near-cognate sites (known as “off-target” events, 





Figure 1.5 DNA repair outcomes in mammalian cells 
Following Cas9-mediated cleavage, most mammalian cells repair the double-strand 
break via NHEJ, which could lead to Indels(left). Alternatively, cells can repair the 
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1.3.4 Methods to quantify CRISPR-Cas9 genome editing  
It is important to accurately quantify genome editing outcomes and assess the 
spectrum of indels (in the case of NHEJ) or the rate of HDR at genomic loci. For 
example, if gene knockout is desired, it is important to measure what percent of the 
cells have indels and what percent of the indels result in in-frame vs out-of-frame 
mutations. Different methods to detect indels have been devised and these can be 
broadly divided into sequencing-based and denaturation-based. In this thesis, we 
employ three of the most established methods to quantify genome editing events, 
illustrated in Figure 1.6. 
The T7 endonuclease assay, also known as the T7E1 or the surveyor assay, is a 
denaturation-based method that takes advantage of the ability of T7E1 to cleave 
mismatches in DNA heteroduplexes. It consists of amplifying the target locus of 
interest via polymerase chain reaction (PCR), followed by denaturation and reannealing 
to create heteroduplexes. Next, the PCR fragments are subjected to T7E1 cleavage and 
the products can be visualized on an agarose gel. This is a rapid and cost-effective 
approach to measure NHEJ events from a population of cells. However, it is not very 
sensitive; it underestimates events due to the inefficiency of T7E1 in cleaving single 
nucleotide mismatches, and it does not reveal the spectrum of indels (Germini et al., 
2018).  
We also used two sequencing-based methods in this thesis to more accurately 
measure indels. Targeted deep sequencing is one of the most accurate method to 
quantify genome editing events. It consists of two rounds of PCR of the target locus, 
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one to amplify the segment and the second to add the appropriate tags and barcodes for 
the high-throughput sequencer to enable multiplexing. Targeted deep sequencing has 
the added advantage of reliably revealing the nature of indels (the length as well as the 
sequence) and can sensitively detect indels as low as 0.1%, depending on the DNA and 
sequencing quality. The disadvantages of deep sequencing include long processing 
time, high costs and requiring extended analysis. 
Tracking of Indels by Decomposition (TIDE) is an algorithm devised by 
Brinkman et al. that uses trace decomposition from Sanger sequencing to measure 
indels (Brinkman et al., 2014). TIDE has a lower detection limit of ~1-2%, and highly 
correlates with deep sequencing data (Germini et al., 2018). Relying on Sanger 
sequencing provides a rapid and relatively cheap method of quantifying indels, 







Figure 1.6 Methods used in this thesis to quantify genome editing by Cas9 
Two sequencing-based methods (shown in purple) are used, namely targeted deep 
sequencing and TIDE. Targeted deep sequencing requires two rounds of PCR followed 
by sequencing using a next generation sequencer. TIDE is an algorithm to decompose 
Sanger sequencing trace files to estimate indels. We also used the T7E1 assay (shown 
in blue), a rapid method to quantify indels by taking advantage of T7 endonuclease’s 












1.4 Methods for in vivo Cas9 delivery 
Before Cas9 can cleave its target, it needs to be delivered to the target cell of 
interest. Current delivery methods of Cas9 to cells can be divided broadly into cell 
culture/ex vivo approaches and in vivo delivery. For the purpose of this thesis, ex vivo 
refers to editing cells outside of the organism and reintroducing them. In vivo refers to 
editing that occurs inside of an organism. All experiments in cell culture are so 
indicated. 
In cell culture and ex vivo, there are many viral and non-viral ways to efficiently 
deliver Cas9-sgRNA into cells. Delivery methods such as chemical transfection of 
plasmids, lentiviral transduction, and ribonucleoprotein (RNP) electroporation have 
been used to deliver Cas9-sgRNA into various cell types (Lino et al., 2018). Most non-
viral approaches rely on the temporary disruption of the cell membrane to introduce 
plasmids/mRNAs/RNPs. Viral delivery often consists of the recognition of surface 
receptors that lead to uptake. In most cases, Cas9 is fused to a nuclear localization 
signal (NLS) that mediates intranuclear uptake. While efficient editing in certain 
primary cells still remains a challenge, delivering Cas9 in cell culture is relatively 
straightforward compared to in vivo. 
In vivo delivery (particularly in humans) is an even a greater challenge due to 
need for high safety and precision. Some of the potential approaches include Adeno-
associated virus (AAV), lentivirus, lipid nanoparticles/liposomes, DNA nanoclew, and 
gold nanoparticles (Liu et al., 2017). While every approach has unique advantages and 
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disadvantages, some have stood the test of time more than others. For example, 
lentiviruses may result in genome rearrangements and are highly immunogenic. There 
has been tremendous progress in lipid and nanoparticle delivery methods, but they still 
suffer from low stability, poor distribution and lysosomal degradation (Liu et al., 2017; 
Lino et al., 2018). While all of these approaches have been used to deliver Cas9, AAV 
delivery has been the gold standard for in vivo Cas9 delivery since 2013. 
1.4.1 AAV delivery of Cas9 
AAV was discovered accidentally during electron microscopy screening of 
adenovirus preparations in the 1960s (Keeler and Flotte, 2019). Ever since, AAV 
delivery has been one of the most promising approaches, with decades of research on 
its safety and efficacy. AAV is a small virus that infects primates without causing any 
diseases. It has a packaging capacity of ~4700 bp and can be engineered to persist 
extrachromosomally with minimal integration into the host genome (Lino et al., 2018). 
AAV vectors can infect both dividing and postmitotic cells, expanding their use to cells 
like neurons. Furthermore, there are different serotypes of AAV (serotypes differ in the 
receptors they bind) which enable delivery to the desired target tissue (Lau and Suh, 
2017). These advantages have led to dozens of ongoing clinical trials using AAV as the 
delivery vector of choice, with the first AAV drug approved by the FDA in 2017 
(Luxturna) to treat Leber's congenital amaurosis. This was followed by Zolgensma in 
2019 to treat Spinal Muscular Atrophy. Taken together, AAV holds tremendous 
potential as the delivery method of choice for CRISPR-Cas9 therapeutics. 
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Several proof-of-concept studies have used AAV to deliver Cas9 for therapeutic 
applications in model organisms. For example, Duchenne muscular dystrophy (DMD) 
is a devastating disease caused by mutations in the dystrophin gene. AAV-based Cas9 
treatment of a mouse model with mutants in the dystrophin gene led to restoration of 
gene function and improved muscle function (Nelson et al., 2016). More recent 
therapeutic approaches often take advantage of smaller Cas9 orthologs to facilitate 
single-AAV delivery (For the purpose of this thesis, single-AAV delivery and all-in-
one AAV delivery are used interchangeably and refer to fitting Cas9, sgRNA and 
promoters into a single AAV). For example, single-AAV delivery of Cas9 has been 
used to target PCSK9 in the livers of adult mice to reduce serum cholesterol levels (Ran 
et al., 2015; Ibraheim et al., 2018b).   
Despite this tremendous potential, there are disadvantages to AAV delivery. Its 
packaging limit constraints the size of the cargo so that some Cas9 orthologs (~ 1200 
amino acids or larger) have difficulty being packaged along with their guides into a 
single vector. Furthermore, AAV persists for long periods in the target tissue, which 
may result in prolonged Cas9 expression and unintended off-targets. Finally, while 
immunogenicity is low, there is potential for the activation of the immune system at 
least by some serotypes. For example, some studies suggest that AAVs are detected by 
Toll-like receptors in mammals (Keeler and Flotte, 2019; Martino et al., 2011; Zaiss et 
al., 2002). Although some of these limitations apply regardless of the Cas9 ortholog, 
factors such as the size limit and increased off-target hinder some Cas9s more than 
others.  
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1.4.2 Currently-used Cas9 orthologs for AAV delivery  
While at least a dozen Cas9 orthologs have been characterized, only a handful 
have been used for in vivo genome editing (Table 1.1). To date, in addition to SpyCas9 
(type II-A), several <1,100 aa Cas9 orthologs have been validated for in vivo genome 
editing, including from strains of N. meningitidis (NmeCas9, 1,082 aa) (Ibraheim et al. 
2018), S. aureus (SauCas9, 1,053 aa) (Ran et al., 2015), C. jejuni (CjeCas9, 984 aa) 
(Kim et al., 2017), and Streptococcus thermophilus (Agudelo et al., 2019). All existing 
approaches have limitations such as long PAMs and/or high off-targets, which will be 
discussed further in section 1.5 and addressed in chapters 3 and 4. The features of these 










Table 1.1 Cas9 orthologs validated for genome editing by AAV 
Five Cas9 orthologs have been validated for in vivo genome editing using AAV. All 
except for SpyCas9 are compact enough for single-AAV delivery, while only NmeCas9 
and CjeCas9 are compact and less prone to off-target editing. However, the PAMs of 






















Streptococcus pyogenes (Spy) NGG
Staphylococcus aureus (Sau) NNGRRT
Campylobacter jejuni (Cje) NNNNRYAC
Neisseria meningitidis (Nme) NNNNGATT
Streptococcus thermophilus (st1) NNAGAAW N/A
Geobacillus stearothermophilus (Geo) NNNNCRAA N/ANeisseria meningitidis (Nme)
NNNNGMTT
Amrani et al, Genome Biology, 2018
Kim et al, Nat Comm 2017 
Ran et al, Nature 2015 
Ibraheim et al, Genome Biology 2018 
Carter et al, BioRxiv 2018 
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SpyCas9 
Owing to its high efficiency and the fact that it was the first Cas9 characterized, 
SpyCas9 has been used extensively for AAV delivery. Despite its relatively large size 
and high number of off-targets, several different approaches have been used to deliver 
SpyCas9 via AAV. SpyCas9 and its sgRNA are ~ 4.2 kb in size, and when promoters 
and tags are added, it extends well above 5kb in length. Considering the packaging 
limit of ~4.7 kb for AAV and the reduced packaging efficiency of larger constructs 
(Keeler and Flotte, 2019), single-AAV delivery of SpyCas9 has been challenging. To 
overcome this, several approaches have been devised. For example, dual AAV delivery 
of Cas9 and sgRNA in separate vectors has been used to study gene function in the 
mouse brain (Swiech et al., 2015). Such dual AAV delivery methods are more 
complex; both vectors must infect the same cell, and higher doses may be required to 
achieve similar outcomes. Furthermore, the current high cost of AAV production makes 
dual-AAV approaches less desirable. Finally, the long persistence of AAV (at least 6-
12 months) results in prolonged expression of transgenes (Berns and Muzyczka, 2017) 
and in the case of SpyCas9, this results in higher propensity of off-target cleavage. 






NmeCas9 has a canonical 5′-NNNNGATT-3′ PAM, though considerable 
variation from this consensus is permissive in vitro and several PAM variants are 
functional in mammalian cells as well (Amrani et al., 2018b; Esvelt et al., 2013; Hou et 
al., 2013; Zhang et al., 2015). In addition, NmeCas9 exhibits extremely clean off-target 
profiles in mammalian cells, even when editing sites whose guides are highly prone to 
off-targeting with wild-type SpyCas9 (Amrani et al., 2018b; Lee, Cradick and Bao, 
2016).More importantly, NmeCas9 single-AAV delivery has been used to target 
disease-causing loci in vivo (Ibraheim et al., 2018b). Although NmeCas9’s relatively 
long PAM limits the number of potential target sites in a locus of interest, its compact 
size and high accuracy make it an ideal candidate for AAV gene therapy applications. 
CjeCas9 
At 984 aa, CjeCas9 is among the smallest Cas9 orthologs identified to date. Its 
PAM was initially defined as NNNNACA (Fonfara et al., 2014; Yamada et al., 2017) 
and for several years, no reports emerged regarding its efficacy in mammalian genome 
editing. More recently, Kim et al. reassessed the PAM requirements and found an 
additional nucleotide (NNNNRYAC) to contribute to editing efficiency (Kim et al., 
2017). When genome-wide CjeCas9 editing specificity was compared to that of 
SpyCas9 and SauCas9 (using sites that were edited at comparable frequencies), 
CjeCas9 showed much lower off-target cleavage at multiple tested sites (on average 10-
fold less). This report further established CjeCas9 all-in-one AAV vectors as effective 
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delivery vehicles for genome editing, e.g. in the eye, again with little or no off-
targeting, even after eight months post-delivery (Kim et al., 2017). More recently, 
CjeCas9’s in vivo AAV application was expanded to rescue dystrophin deficiency in a 
mouse model of DMD (Koo et al., 2018). The small size of CjeCas9 allows for the 
packaging of the Cas9, sgRNA and DNA donors that are several hundred nucleotides in 
length and has the potential to be used for single-AAV HDR applications.  
SauCas9 
SauCas9 was the first compact Cas9 ortholog developed for single-AAV 
genome editing and has been widely used (Ran et al., 2015). It has an NNGRRT PAM 
and at 1053 amino acids, it is the amenable to single-AAV delivery. SauCas9 falls in 
the middle of the accuracy spectrum; while it is not as accurate as some type II-C 
orthologs such as NmeCas9 and CjeCas9, it has fewer off-targets than its type II-A 
counterpart SpyCas9. These properties have made it the second most widely used 
ortholog; SauCas9 single-AAV vectors have been used in mouse models of diseases 
such as DMD and liver metabolic diseases (Nelson et al., 2016; De Caneva et al., 
2019). However, the complex PAM of SauCas9 limits its applications. A SauCas9 
mutant (SauCas9KKH) that has reduced PAM constraints (N3RRT) has been 
developed, though this increase in targeting range often comes at the cost of reduced 





St1Cas9 is the latest addition to the single-AAV CRISPR toolbox. St1Cas9 is 
1121 amino acids in length and recognizes NNAGAA and NNGGAA PAMs in 
mammalian cells. Single-AAV Delivery of St1Cas9 to the mouse liver led to the 
phenotypic rescue of a mouse model of hereditary tyrosinemia. However, the PAM is 
relatively long, similar to the other compact orthologs described above. Preliminary 
studies suggest that it may be more accurate than SpyCas9 (Muller et al., 2016), the 
genome-wide off-target profile of St1Cas9 remains to be investigated. 
Taken together, while all the Cas9 orthologs mentioned above have their 
advantages, none satisfies all the requirements to be the ideal ortholog for AAV 
delivery. These limitations will be further discussed below and addressed in chapters 3 









1.5 Current limitations of CRISPR-Cas9  
The safety and efficacy of CRISPR-Cas9 is of paramount importance before its 
widespread use in therapeutics. There are limitations that apply to almost all Cas9 
orthologs. The bacterial origin of Cas9 and its relatively large size mean that the human 
body could mount an immune response against it. Furthermore, many of the 
characterized Cas9s to date are from human commensal/pathogenic bacteria, with the 
possibility of pre-existing antibodies against some of these orthologs. Indeed, analysis 
of 125 blood donors revealed that more than half of the donors had antibodies against 
two of the most commonly used Cas9s, namely SauCas9 and SpyCas9 (Charlesworth et 
al., 2019). Although this is probably not a concern for orthologs that originate from 
other sources (e.g. GeoCas9 (Harrington et al., 2017)), the immune response to Cas9 
must be studied and remedied before in vivo clinical use. 
Another major hurdle has been the number of off-targets, i.e. Cas9 inducing 
DSBs at sites similar to the intended target, which may have undesired deleterious 
consequences. Wild-type SpyCas9, the most widely used for editing, has a high degree 
of off-target activity in most cell types. There has been extensive characterization and 
engineering to minimize the tendency to edit such near-cognate, off-target sites (Tsai 
and Joung, 2016; Tycko, Myer and Hsu, 2016; Chen et al., 2017). Such engineered 
Cas9s and more naturally accurate orthologs promise to pave the way for the future of 
genome editing. Nevertheless, regardless of the Cas9 ortholog used, careful selection of 
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target sites and extensive evaluation of off-targeting is essential for safe genome 
editing.  
In addition to off-targets, there is an inherent risk associated with creating DSBs 
in the genome. Repair outcomes are often unpredictable and context dependent. 
Specifically, in line with the dependence of Cas9 on cellular repair machinery, certain 
cell types are inherently recalcitrant to genome editing, particularly to HDR (Jasin and 
Haber, 2016). For example, precise editing of post-mitotic neurons has been 
challenging, and while AAV-mediated HDR has been achieved (Nishiyama, Mikuni 
and Yasuda, 2017), the efficiency varies in different brain regions. In some contexts, 
such as in human pluripotent stem cells, Cas9-induced DSBs activate the P53 repair 
pathway with detrimental consequences, including cell death (Haapaniemi et al., 2018). 
Finally, delivery of CRISPR components to the target tissue of interest remains 
a challenge. While the delivery problem is not unique to Cas9, the relatively large size 
of some Cas9s makes delivery even more cumbersome. Several delivery avenues 
including viral and non-viral vectors have been tested to deliver Cas9 in mice. 
Nevertheless, delivering Cas9 to the desired tissue remains a challenge.  
In summary, while CRISPR-Cas9 has the potential to improve our 
understanding of biology and treat diseases, in vivo applications are limited due to 
potential safety issues and pitfalls of current tools. In this thesis, we will present our 
efforts to overcome some of these hurdles by identifying new Cas9 orthologs and their 
off-switches. 
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CHAPTER 2: Phage-encoded inhibitors of CRISPR-Cas9  
2.1 Introduction:  
As discussed previously, CRISPR is an RNA-guided system, where Cas 
proteins are programmed to target and destroy phage nucleic acids. CRISPR-Cas 
adaptive immunity is present in 90% of archaea and ~50% of all bacteria. As part of the 
constant arms race between bacteria and phages, that phages have evolved anti-
CRISPR strategies to overcome CRISPR immunity. While phages can temporarily 
escape the sequence-specific targeting by CRISPR through mutations, evolutionary 
studies showed that the only way for a phage to escape extinction is by the expression 
of an anti-CRISPR gene (van Houte et al., 2016). In other words, mutations alone are 
likely not enough to overcome CRISPR immunity. Anti-CRISPR (Acr) proteins 
provide one way to disarm CRISPR-Cas systems by directly inhibiting interference. 
The first Acrs were discovered in phages that successfully infect Pseudomonas 
aeruginosa strains despite the presence of an active type I CRISPR-Cas system 
(Bondy-Denomy et al., 2013). While Acrs themselves are often poorly conserved, they 
are frequently encoded upstream of transcriptional regulator genes known as anti-
CRISPR-associated (aca) genes (Pawluk et al., 2014).  
In addition to the biologic significance of discovering Acrs against Cas9, such 
Acrs may have the potential to modulate Cas9’s activity in genome engineering 
applications. For example, off-target cleavage resulting from prolonged Cas9 
expression can be remedied by expressing an Acr off-switch to limit the duration of 
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editing. HDR rates can be enhanced by limiting Cas9’s activity for precise editing, by 
inhibiting Cas9 during the G1 phase of the cell cycle, when HDR pathways are 
suppressed in most cell types (Orthwein et al., 2015). Finally, Cas9 has been used for 
gene drives, i.e., propagation of a desired gene via non-Mendelian forced inheritance 
(Gantz et al., 2015). However, it is imperative to be able to switch off Cas9 if needed, 
and Acrs can be used for this purpose. This chapter will describe the discovery of the 
first type II-specific Acrs in 2016 (Pawluk et al., 2016) and our efforts since to uncover 

















2.2.1 The discovery of Anti-CRISPR proteins against NmeCas9 
While the first Acr proteins were reported in 2013, none had been reported to 
inhibit type II CRISPR-cas systems that used Cas9 as their effector enzyme (Pawluk, 
Davidson and Maxwell, 2018). This is in part due to the lack of Acr conservation. 
However, the lab of Dr. Alan Davidson at the University of Toronto took advantage of 
the conservation of aca genes and found that they are conserved among diverse phyla, 
some of which possessed Cas9s. Using previously discovered Aca1 and Aca2 (from 
type I Acrs), the Davidson lab identified a candidate anti-CRISPR gene in a Brackiella 
oedipodis putative conjugative element that encoded a small hypothetical protein which 
was directly upstream of an aca2 gene (Figure 2.1A). This putative anti-CRISPR had 
several homologs encoded in MGEs of diverse bacteria, including Neisseria 
meningitidis. The aca associated with this Acr (aca3) was used to find two other Acr 
proteins in other meningococcal strains, bringing the total to three putative Acrs. 
Because N. meningitidis has the best-established type II-C CRISPR-Cas system and our 
lab had worked on it for several years, it was the ideal system to test these proteins’ 











Figure 2.1: Putative type II-C acrs specifically inhibit NmeCas9 in vitro 
(A) Schematic representation of candidate type II-C acr and aca genes within putative 
MGEs in the genomes of strains of B. oedipodis and N. meningitidis. Homologous 
genes are color-matched, with percent amino acid identities indicated. Annotation of 
relevant genes is as follows: Rep, plasmid replication protein; Reg, transcriptional 
regulator; Tra, conjugal transfer protein; Rec, recombinase; Tail, phage tail structural 
protein; Lysis, phage lysis cassette. Genes colored in gray have MGE-related functions 
and/or show clear evidence of horizontal transfer. 
(B) Linearized plasmid DNA bearing a protospacer adjacent to a PAM sequence 
was subjected to in vitro digestion by purified, recombinant, sgRNA-programmed 
NmeCas9 (upper panel) or SpyCas9 (lower panel). Where indicated at the top of each 
lane, Cas9 was pre-incubated with purified anti-CRISPR proteins as indicated with 
AcrE2 as a negative control. Molar equivalents of anti-CRISPR protein (relative to 
Cas9) are shown at the top of each lane, and mobility of input and cleaved DNAs are 








To address this question, we tested the ability of Cas9 to cleave targets in vitro 
using recombinant NmeCas9 in the presence of these Acrs. The reaction consists of 
forming a complex between an in vitro transcribed sgRNA and recombinant Cas9, 
followed by the addition of each Acr protein at different molar ratios, and finally 
adding the target DNA. We used a type I-E inhibitor (AcrE2) (Pawluk et al., 2014) as a 
negative control Acr (Figure 2.1B) All three families of Acr proteins inhibited 
NmeCas9 in a dose-dependent manner (Figure 2.1B, top). We also found that these 
Acrs are highly specific, since they were unable to inhibit SpyCas9 (~25% homology) 
at even 10:1 molar ratio (Figure 2.1B, bottom). These results signify the discovery of 














2.2.2 Anti-CRISPRs are found in diverse bacterial species: 
The initial discovery of Acrs against Cas9 paved the way for the discovery of 
such proteins in other bacterial strains. Again, work spearheaded by the Davidson lab 
led to the discovery of Acrs associated with aca2 in two species: Haemophilus 
parainfluenzae and Simonsiella muelleri. These aca orthologs share 38% and 36% 
identity to B. oedipodis aca2, respectively, and 51% identity to each other (Figure 
2.2A), with putative Acrs upstream. Both strains encode predicted type II-C CRISPR-
Cas machineries with Cas9 orthologs that exhibit 59% and 62% identity with 
NmeCas9, respectively. Based on these similarities and our previous work indicating 
that type II anti-CRISPRs could inhibit Cas9 orthologs outside their host species/strain, 
we first tested for Acr activity against the well-characterized NmeCas9 in vitro. We 
cloned each candidate Acr sequence into a bacterial expression vector, purified 
recombinant proteins from E. coli, and tested their abilities to prevent DNA cleavage by 
NmeCas9 in vitro at a 10:1 ratio of Acr:Cas9-sgRNA. We found that both Acrs 
efficiently inhibited NmeCas9, corroborating the existence of Acr proteins in diverse 
phages. As per the unified resource for naming Acr proteins (Bondy-Denomy et al., 










Figure 2.2 Identification and in vitro validation of two anti-CRISPR protein 
families.  
(A) Schematic of candidate anti-CRISPR proteins and aca2 genes in the genomic 
context of H. parainfluenzae (AcrIIC4Hpa) and S. muelleri (AcrIIC5Smu). Gray genes are 
associated with mobile DNA, and known gene functions are annotated as follows: 
“Reg” is a transcriptional regulator, “Tail” is involved in phage tail morphogenesis, and 
“Tra” is a transposase. The B. oedipodis aca2 gene is used as a query for pBLAST 
searches, and percent identities of aca2 orthologs are denoted. Arrows are not drawn to 
scale.  
(B) In vitro cleavage of target DNA by the NmeCas9-sgRNA complex in the presence 
of anti-CRISPR protein. Preformed NmeCas9-sgRNA RNP complex was incubated 
with purified anti-CRISPR proteins as indicated with AcrE2 as a negative control, 
AcrIIC1 as a positive control, and candidate Acrs. Then, a linearized plasmid with a 
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To compare the potency of these Acrs with the previously discovered AcrIIC1 
family, we performed a similar in vitro cleavage assay with increasing concentrations 
of Acrs. When each of the purified candidate Acrs was added to parallel reaction 
mixtures, cleavage was inhibited in a concentration-dependent manner, with complete 
inhibition being reached at ∼20-fold (AcrIIC4Hpa) and ∼7-fold (AcrIIC5Smu) molar 
excess of Acrs (Figure 2.3). Incubation with our negative control AcrE2 did not affect 
target DNA cleavage by NmeCas9.  
Once we confirmed the anti-CRISPR inhibition of sgRNA-guided NmeCas9 
DNA cleavage in vitro, we then addressed the mechanisms of NmeCas9 inhibition by 
AcrIIC4Hpa and AcrIIC5Smu. We tested whether the new Acrs prevent sgRNA loading or 
DNA target binding. First, we checked whether sgRNA loading onto NmeCas9 is 
inhibited by either anti-CRISPR. We carried out electrophoretic mobility shift assays 
(EMSAs) by incubating NmeCas9 and sgRNA with or without Acr, and then 
visualizing sgRNA mobility after native gel electrophoresis by SYBR Gold staining. In 
the absence of any anti-CRISPR, incubation of NmeCas9 with its cognate sgRNA 
resulted in a gel shift that indicates formation of a stable RNP complex (Fig 2.3B) 
When NmeCas9 was incubated with a negative-control anti-CRISPR (AcrE2) before 
the addition of sgRNA, NmeCas9:sgRNA complex formation was unaffected. 
Similarly, when incubated with AcrIIC4Hpa and AcrIIC5Smu, efficient NmeCas9:sgRNA 
complex formation was again observed, suggesting that neither Acr protein 
significantly affected RNP assembly. 
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To test if target DNA engagement by the NmeCas9:sgRNA complex is 
prevented by either AcrIIC4Hpa or AcrIIC5Smu, we performed EMSAs and fluorescence 
polarization assays after incubating the RNP with each Acr, before adding target DNA 
To inhibit DNA target cleavage, we omitted divalent metal ions from the reaction 
mixtures. The target DNA exhibited the expected mobility shift in the absence of Acr, 
or in the presence of AcrE2 or AcrIIC1Nme (as controls). Our results indicate that both 
AcrIIC4Hpa and AcrIIC5Smu prevented NmeCas9 RNP binding to the target DNA. 
We then tested the ability of these Acrs to inhibit NmeCas9 genome editing in 
mammalian cells. To do this, we cotransfected HEK293T cells transiently with 
plasmids expressing anti-CRISPR protein, NmeCas9 and sgRNAs targeting genomic 
sites. We then used targeted deep sequencing to estimate genome editing efficiency 
(Kai Xiong et al, 2013). In agreement with our in vitro data, expression of all five ACR 
families inhibited NmeCas9-mediated mutagenesis to undetectable levels. In contrast, 
they had no effect on SpyCas9 genome editing at the same site. Indel frequencies were 
measured by targeted deep sequencing of PCR-amplified genomic DNA collected after 
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Figure 2.3 The new Acr families inhibit NmeCas9 in vitro and in cells 
(A) In vitro cleavage of target DNA by the NmeCas9-sgRNA complex in the presence 
of anti-CRISPR protein.  
Preformed NmeCas9-sgRNA RNP complex was incubated with purified anti-CRISPR 
proteins as indicated with AcrE2 as a negative control, AcrIIC1 as a positive control, 
and candidate Acrs. Then, a linearized plasmid with a protospacer and PAM sequence 
was added to the reaction mixture. Molarities of anti-CRISPR protein (relative to 
constant Cas9 molarity) are shown at the top of each lane, mobilities of input and 
cleaved DNAs are denoted on the right, and cleavage efficiencies (“% cleaved”) are 
given at the bottom of each lane.  
(B and C) A native gel of the sgRNA visualized by SYBR gold staining (B) and of the 
FAM-labeled target DNA (C), both of which were added last to NmeCas9 + Acr (and in 
panel C, + sgRNA) incubation.  
(D) Indel frequencies measured by targeted deep sequencing of PCR-amplified 

















2.2.3 AcrIIC1 is a broad-spectrum inhibitor of CRISPR Cas9 
AcrIIC1 putative orthologs identified by PSI-BLAST suggest that it may be part 
of a family of proteins in diverse bacterial species (Pawluk et al., 2016). This diversity 
is mirrored in the Cas9 orthologs from the bacterial genomes containing AcrIIC1 
family of Acrs in prophages. We hypothesized that AcrIIC1 may be promiscuous with 
respect to the Cas9 orthologs it can inhibit. We had already established that it was 
unable to inhibit SpyCas9 (type II-A), so we focused on the two other type II-C 
orthologs that had been validated for genome editing, namely CjeCas9 and GeoCas9, 
which are 36% and 42% identical to NmeCas9 respectively (Kim et al., 2017; 
Harrington et al., 2017). In vitro cleavage data shows that in addition to NmeCas9, the 
AcrIIC1 from N. meningitidis (AcrIIC1Nme) exhibits robust inhibition of GeoCas9 and 
CjeCas9 (figure 2.4B). By contrast, AcrIIC2Nme and AcrIIC3Nme were both highly 
specific for NmeCas9, having no noticeable impact on CjeCas9- or GeoCas9-catalyzed 
DNA cleavage. 
To determine whether inhibition by AcrIIC1 can disable CjeCas9 in genome-
editing applications, we transfected HEK293T cells with plasmids expressing 
NmeCas9, CjeCas9 or SpyCas9 and their respective sgRNAs targeting identical loci in 
the presence or absence of AcrIIC1 (figure 2.4C). Similar to the in vitro cleavage 
assays, CjeCas9 was inhibited by AcrIIC1 but not by AcrIIC3. Expressing AcrIIC1Nme 
or the AcrIIC1Boe (not shown) resulted in efficient inhibition of CjeCas9, indicating that 
this promiscuity is not unique to the AcrIIC1Nme ortholog. In a similar experiment, the 
Doudna lab showed that AcrIIC1 is also a potent inhibitor of GeoCas9 in mammalian 
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cells. The robust inhibition of both CjeCas9 and GeoCas9, in addition to NmeCas9, 
suggested that AcrIIC1 exploits a conserved feature of the Cas9 protein. 
Mechanistic and structural studies by the Doudna lab show that AcrIIC1 family 
indeed binds to a conserved region of Cas9’s active site. A 1.5-Å resolution crystal 
structure of AcrIIC1Nme bound to the HNH domain of NmeCas9 revealed that AcrIIC1 
binds directly to the HNH active site (Figure 2.4E), restricting it from accessing the 
target DNA. AcrIIC1 binds to the active site interface of the HNH domain through 
several ionic and hydrogen-bonding interactions. Mapping amino acid conservation 
onto the structure revealed that residues within the binding interface of both the HNH 
domain and AcrIIC1 are highly conserved (Figures 2.4D). In contrast to this observed 
conservation, antagonistic binding interfaces often evolve rapidly, leading to lower 
conservation (Franzosa and Xia, 2011), suggesting that AcrIIC1 is targeting a highly 






























Figure 2.4. AcrIIC1 inhibits Cas9 orthologs by binding to the HNH domain 
(A)Schematic representation of putative AcrIIC1 orthologs identified by PSI-BLAST 
and their genomic contexts. The species in which each is found and its predicted 
genomic region classification (i.e. prophage, integrated conjugative element) are 
indicated. Gene arrows are not drawn to scale.  
(B) DNA cleavage assays conducted by several Cas9 orthologs in the presence of 
AcrIIC1, AcrIIC2, and AcrIIC3 (−Cas9, no Cas9 added; +Cas9, Cas9 and sgRNA 
added. 
(C) T7E1 assay analyzing indels produced by CjeCas9 and NmeCas9 shows that 
CjeCas9 genome editing is inhibited by AcrIIC1Nme, but not AcrIIC3Nm in HEK293T 
cells. 
(D) Binding interfaces of NmeCas9 HNH domain and AcrIIC1 show residue 
conservation. Conservation was calculated using multiple sequence alignments of 
AcrIIC1 orthologs and Cas9 HNH domains. Conserved residues are colored red (1, 
100% sequence identity), and non-conserved residues are colored white (0). (E) Model 
of AcrIIC1 inhibiting cleavage of both target and non-target strands. NmeCas9 HNH 
domain (purple) was modeled into a “docked” position using dsDNA-bound SpyCas9 
structure (PDB: 5F9R) as a reference for a homology model of NmeCas9. Placement of 
AcrIIC1 (orange) between the HNH domain and the target strand (red) prevents target 














2.2.4 Acrs can be highly specific or broad-spectrum 
Our results on AcrIIC1 prompted us to test all previously reported type II-C 
Acrs against a diverse set of Cas9 orthologs. In addition to CjeCas9 and GeoCas9, we 
tested the Acrs on Cas9s from Haemophilus parainfluenzae (HpaCas9), Brackiella 
oedipodis (BoeCas9) and Kiloniella laminariae (KlaCas9) with 66%, 46% and 24% 
sequence homology to NmeCas9 (See chapter 3 for in-depth characterization of these 
orthologs). First, we performed in vitro cleavage of a target DNA using CjeCas9 in the 
presence of previously described Acr proteins. Based on the previous data suggesting 
that CjeCas9 is only inhibited by AcrIIC1 family and not by AcrIIC2 or AcrIIC3, we 
focused only on AcrIIC4 and AcrIIC5, and used AcrIIC1 as a positive control. Our in 
vitro results corroborated that AcrIIC1 inhibits CjeCas9, while neither AcrIIC4 nor 
AcrIIC5 prevented target DNA cleavage by CjeCas9. We also performed the same in 
vitro cleavage assay on all the Cas9s mentioned above, using AcrIIC1 as a control. A 
protospacer was cleaved in vitro using the Cas9-sgRNA complex of each CRISPR 
system in the presence or absence of Acrs, and the product was run on an agarose gel to 
visualize cleaved vs. uncleaved bands similar to figure 2.2B.  The results are 
summarized in table 2.1.  
While AcrIIC1 family inhibited all type II-C orthologs tested, the other four 
families of Acrs are relatively specific. All five families inhibited NmeCas9, HpaCas9 
and SmuCas9, suggesting that the target potential binding site(s) for each Cas9 is 
conserved among these three orthologs. For example, it was recently shown that 
AcrIIC2 inhibits sgRNA loading by binding to the bridge helix of NmeCas9, which is 
 52 
not highly conserved among type II-C orthologs (Thavalingam et al., 2019). In addition 
to the three closely-related orthologs, AcrIIC4 is also able to inhibit BoeCas9, 
suggesting a more diverged area being targeted. Taken together, these data suggest that 


















Cas9 Identity to NmeCas9 (%) IIC1 IIC2 IIC3 IIC4 IIC5 
NmeCas9 100      
HpaCas9 66      
SmuCas9 62      
BoeCas9 46      
GeoCas9 42      
CjeCas9 36      
KlaCas9 28      
Figure 2.5. in vitro cleavage with diverse Cas9s in the presence of AcrIIC families 
(A) Phylogenetic tree of Cas9, those with more than 90% identity have been depicted as 
one. The Cas9s used previously and in this study are marked. Clades are colored by 
Cas9 sub-type. 
(B) Summary of in vitro cleavage data by each Cas9 in the presence of type II-C Acr 
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2.3 Discussion 
We have shown widespread occurrence of type II-C Acrs across diverse 
bacterial phyla. While the evolutionary origin of Acrs remain unclear, their widespread 
presence suggests a strong selective pressure imposed by CRISPR-Cas9. It is also 
unclear how the long-term exposure to Acrs shaped the evolution of CRISPR. There is 
undoubtedly a staggering diversity among Acr proteins, presumably even more than 
their CRISPR counterparts. The pace of phage evolution and the lack of conservation 
among Acr proteins suggest a rapid, convergent evolution against CRISPR.  
Our guilt-by-association approach is limited due to its dependence on the 
presence of the aca gene. To address this bias, other methods of Acr discovery have 
been implemented by groups throughout the world. For example, an approach was 
developed to find bacterial genomes with CRISPR systems that contained self-targeting 
spacers, i.e. spacers that should be lethal due to targeting the bacterial genome (Rauch 
et al., 2017). The presence of such spacers indicates a mechanism, possibly an Acr, by 
which the CRISPR system is deactivated. This approach led to the discovery of several 
Acr proteins in Listeria monocytogenes that target type II-A CRISPR-Cas9 systems. 
Using these various approaches, there are about 40 different families of Acrs 
discovered to date (Stanley and Maxwell, 2018). Nevertheless, considering the 
perpetual fight between phages and bacteria/archaea, we have definitely only scratched 
the surface of Acr diversity. Future Acr studies will not only focus on the diversity of 
these proteins, but the outcome of a CRISPR system once it has been inhibited by an 
Acr. Several intriguing possibilities exist regarding the bacterial response: 1) The 
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bacterium could respond by evolving the CRISPR component that is the target of the 
Acr on an evolutionary timescale. For example, if the Acr binds to the PID of Cas9, 
there could be selective pressure to evolve a novel PID. However, in cases where the 
Acr binds to a highly conserved region (such as AcrIIC1 binding to the HNH catalytic 
residues), evolutionary escape may not be an easy option. 2) The bacterium could 
respond by evolving proteins to disarm the Acr, an anti-anti-CRISPR. However, no 
such enzyme has been reported to date. 3) Finally, the presence of an Acr may render 
CRISPR obsolete and result in the elimination of selective pressure to maintain a 
CRISPR system. In fact, as much as 12% of CRISPR systems are incomplete or 
mutated (Makarova et al., 2015), which may be in part due to the presence of Acrs . For 
example, the CRISPR locus of Simonsiella muelleri, which co-exists in the same 
genome that AcrIIC5Smu is derived from, appears to be degenerate (see chapter 3 for 
details). 
Acrs exhibit broad mechanistic diversity. In addition to binding to the HNH 
domain like AcrIIC1, some of the strategies include mimicking DNA, preventing 
sgRNA loading, and inhibition of target cleavage (Stanley and Maxwell, 2018). 
Interestingly, no Acr has been found to inhibit adaptation, the first stage of CRISPR 
immunity. This may be due to the fact that by targeting interference, Acrs ensure that 
any RNP complex already present from previous infections gets inhibited. Furthermore, 
at least in type II-A systems, Cas9 is essential for adaptation and it is very likely that by 
inhibiting Cas9 (Heler et al., 2015), both adaptation and interference are inactivated, 
and not interference alone. 
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In addition to the biological significance of Acrs against Cas9, their potential 
applications in biotechnology are just being realized. For example, while Cas9-
facilitated gene drive is a powerful means of potentially controlling populations of 
insect-borne diseases such as malaria, the possibility of runaway drive has hindered 
current applications and tools such as Acrs may prove beneficial in controlling drive. In 
2018, Basgall et al. reported the use of Acrs in inhibiting gene drives in yeast (Basgall 
et al., 2018). Another application of Acrs was recently described by our group, where 
Acrs restricted genome editing in vivo to a specific tissue by silencing Cas9 in ancillary 
tissues. Finally, Acrs that inhibit DNA binding of Cas9 can be used for dCas9-based 
tools. A recent study took advantage of a type IIA Acr to temporally restrict dCas9-
Tet1 activity to modulate the timing of methylation (Liu et al., 2018). Overall, we have 












2.4 Materials and methods 
Vectors used in this chapter 
NmeCas9 was cloned into the pMCSG7 vector containing a T7 promoter 
followed by a 6XHis tag and a tobacco etch virus (TEV) protease cleavage site using 
Gibson Assembly cloning. The GeoCas9-expressing plasmid (expressing the GeoCas9 
ortholog from G. stearothermophilus strain ATCC 7953) was obtained from Addgene 
(#87700) and similarly cloned into the pMCSG7 vector. For construction of sgRNA 
scaffolds for GeoCas9, the tracrRNA was predicted by crRNA repeat complementarity 
as well as homology to the NmeCas9 tracrRNA. These sgRNA scaffolds were ordered 
as gBlocks (IDT) along with overhangs to clone into pLKO.1 plasmid using Gibson 
Assembly. The CjeCas9 sgRNA was also cloned into pLKO based on the sequence 
from Kim et al. All sgRNA scaffolds were used as the templates to create in vitro-
transcribed sgRNAs. 
DNA sequences encoding candidate anti-CRISPR proteins were synthesized 
and cloned into a pUC57 mini (AmpR) vector with an N. meningitidis 8013 Cas9 
promoter sequence for bacterial work. For anti-CRISPR protein purification, the Acr 
insert was amplified and inserted into the pMCSG7 backbone by Gibson Assembly 
(NEB), resulting in pMCSG7-Acr.  
For editing of genomic dual target sites by both SpyCas9 and NmeCas9, we 
used Cas9 and cognate sgRNA expression vectors that were described previously in 
Pawluk et al. (2016). To generate the Acr expression vector, the Acr ORF was 
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amplified from pUC57-Acr and inserted into XhoI-digested pCSDest2 by Gibson 
Assembly. 
Expression and purification of NmeCas9 
The NmeCas9 pMCSG7 construct (deposited on Addgene #71474) was 
transformed into the Rosetta 2 DE3 strain of E. coli. Expression of NmeCas9 was 
performed as previously described for SpyCas9 with some modifications (Jinek 2012). 
Cells were grown in Terrific Broth (TB) medium at 37C to an optical density (OD600 
nm) of 0.6-0.8 Protein expression was induced by the addition of 1 mM IPTG for 16 hr 
at 16C. Cells were lysed by sonication in 50 mM Tris pH 7.5, 500 mM NaCl, 20 mM 
imidazole, 0.5 mM DTT and 5% glycerol supplemented with 0.5 mM PMSF, lysozyme 
and protease inhibitor cocktail (Sigma). Clarified lysates were bound in batch to Ni-
NTA agarose (QIAGEN), and bound protein was eluted with 300 mM imidazole. 
Purified Cas9:sgRNA was dialyzed into 20 mM HEPES pH 7.5, 250 mM NaCl, 5% 
glycerol, 1 mM DTT and 1 mM PMSF) for protein interaction experiments. 
 
Expression and purification of Acr proteins 
6×His-tagged Acrs were expressed in E. coli strain BL21 Rosetta (DE3). Cells 
were grown in LB at 37°C to an optical density (OD600) of 0.6 in a shaking incubator. 
Next, the bacterial cultures were immediately cooled to 18°C, and protein expression 
was induced by adding 1 mM IPTG. Bacterial cultures were grown overnight at 18°C 
(∼16 h), after which cells were harvested and resuspended in lysis buffer (50 mM Tris-
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HCl [pH 7.5], 500 mM NaCl, 5 mM imidazole, 1 mM DTT) supplemented with 
1 mg/ml lysozyme and protease inhibitor cocktail. Cells were lysed by sonication, and 
the supernatant was then clarified by centrifugation at 18,000 rpm for 30 min. The 
supernatant was incubated with preequilibrated Ni-NTA agarose (Qiagen) for 1 h. The 
resin was then washed twice with wash buffer (50 mM Tris-HCl [pH 7.5], 500 mM 
NaCl, 25 mM imidazole, 1 mM DTT). The proteins were eluted in elution buffer 
containing 300 mM imidazole. For Acr proteins, the 6×His tag was removed by 
incubation with His-tagged tobacco etch virus (TEV) protease overnight at 4°C 
followed by a second round of Ni-NTA purification to isolate successfully cleaved, 
untagged anti-CRISPRs (by collecting the unbound fraction). 
In vitro DNA cleavage 
For all in vitro DNA cleavage experiments, sgRNA targeting a PCR fragment 
was generated by in vitro T7 transcription, using the sgRNA transcription kit from 
NEB. Cas9 (300-500 nM) was incubated with purified, recombinant anti-CRISPR 
protein in cleavage buffer [20 mM HEPES-KOH (pH 7.5),150 mM KCl, 10% glycerol, 
1 mM DTT, and 10 mM MgCl2] for 10 min. Next, sgRNA (1:1, 300-500 nM) was 
added and the mixturewas incubated at room temperature for another 15 min. DNA 
containing the target protospacer was generated by restriction digestion of a plasmid or 
generated by PCR amplification. The target DNA was added to the Cas9/sgRNA 
complex at 5-10 nM final concentration. The reactions were treated with 1U proteinase 
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K from NEB, incubated at 37C for 30 min and visualized after electrophoresis in a 1% 
agarose/1xTAE gel. 
For the Acr titration experiment, (150 nM) was incubated with purified, 
recombinant anti-CRISPR protein (0 to 5 µM) in cleavage buffer (20 mM HEPES-KOH 
[pH 7.5], 150 mM KCl, 1 mM DTT) for 10 min. Next, sgRNA (1:1, 150 nM) was added 
and the mixture was incubated for another 15 min. Plasmid containing the target 
protospacer NTS4B was linearized by ScaI digestion. Linearized plasmid was added to 
the Cas9/sgRNA complex at 3 nM final concentration. The reaction mixtures were 
incubated at 37°C for 60 min, treated with proteinase K at 50°C for 10 min, and 
visualized after electrophoresis in a 1% agarose/1× TAE gel. 
Cas9-Acr copurification 
Cas9 proteins were expressed from plasmid pMCSG7 with an N-terminal 6×His 
affinity tag in E. coli Rosetta cells. Untagged Acrs were coexpressed in the same cells 
from plasmid pCDF1b. Cells were grown in LB to an OD600 of 0.8, and protein 
production was induced with 2 mM IPTG overnight at 16°C. Cells were collected by 
centrifugation, resuspended in binding buffer (20 mM Tris, pH 7.5, 250 mM NaCl, 
5 mM imidazole), and lysed by sonication, and cellular debris was removed by 
centrifugation. The cleared lysates were applied to Ni-NTA columns, washed with 
binding buffer supplemented with 30 mM imidazole, and eluted with 300 mM 
imidazole. Protein complexes were analyzed by SDS-PAGE followed by Coomassie 
staining. 
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Electrophoretic mobility shift assay (EMSA) 
NmeCas9 (1 µM) was incubated with 1 µM sgRNA in 1× binding buffer 
(20 mM Tris-HCl [pH 7.5], 150 mM KCl, 2 mM EDTA, 1 mM DTT, 5% glycerol, 
50 µg/ml heparin, 0.01% Tween 20, 100 μg/ml BSA) for 20 min at room temperature to 
form the RNP complex. Acrs were added to a final concentration of 10 µM and 
incubated for an additional 20 min. Finally, the FAM-tagged NTS4B protospacer 
oligonucleotide was added to the mixture and incubated at 37°C for 1 h. The mixture 
was loaded onto a native 6% acrylamide gel, and the FAM-tagged DNA was visualized 















CHAPTER 3: Characterization of compact Cas9 orthologs  
3.1 Introduction:  
As discussed in chapter 1, in vivo applications of some Cas9s are hindered by 
large size (limiting delivery by AAV vectors), off-target editing, or complex 
protospacer-adjacent motifs (PAMs) that restrict the density of recognition sequences in 
the target of interest. Table 1.1 shows all Cas9 orthologs validated for in vivo genome 
editing using AAV. In the case of SpyCas9, packaging and administration of two 
separate AAV vectors are required, resulting in an increased dose and reduced 
therapeutic efficiency. The compact orthologs discussed in chapter 1 are all amenable 
to all-in-one AAV delivery, but they possess longer PAMs: N4GATT for NmeCas9, 
N2GRRT for SauCas9 and N4RYAC for CjeCas9 where R and Y stands for purines and 
pyrimidines, respectively. Longer PAMs reduce the number of targetable sites at a 
given locus. This is especially important in certain cases such as editing of small targets 
(e.g., miRNAs), correction of mutations by base editing (Rees and Liu, 2018) or during 
precise editing via HDR [which is most efficient when the rewritten bases are close to 
the cleavage site (Gallagher and Haber, 2018)]. Because of these PAM restrictions, 
many editing sites cannot be targeted using all-in-one AAV vectors for in vivo delivery.  
While there are thousands of Cas9 orthologs found in nature, only a dozen 
orthologs have been characterized, and a handful validated for genome editing. This is 
partially due to the difficulty in characterizing new orthologs and is compounded by the 
fact that not all orthologs are functional in human cells. Previously, Cas9 orthologs 
were selected randomly from known pathogens or laboratory bacteria. In the search for 
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a more rational approach, we utilized our knowledge of Acrs as indicators of type II-C 
Cas9 orthologs that are highly active. Specifically, we hypothesized that the existence 
of an Acr protein against a Cas9 ortholog signifies a viable and active Cas9. Here, we 
characterize four compact Cas9 orthologs and test their ability to provide CRISPR 




















3.2.1 Selection of compact Cas9 orthologs to be characterized 
We selected four orthologs with the following properties: A) The genus to 
which the Cas9 belongs possesses either a validated acr gene or has an ortholog of a 
validated acr gene (shown in green and purple, respectively); B) The Cas9 is from 
bacteria that could be handled in a BSL2 lab; and C) Cas9s that are compact (>1150 aa) 
which would be amenable to single-vector AAV delivery. This resulted in selection of 
four Cas9 orthologs (indicated by * in figure 3.1A) from diverse bacteria: Haemophilus 
parainfluenzae (HpaCas9), Simonsiella muelleri (SmuCas9), Brackiella oedipodis 
(BoeCas9) and Kiloniella laminariae (KlaCas9). The size of these Cas9s and their % 
identity to NmeCas9 is shown in Figure 3.1B.  
S. mueller and H. parainfluenzae are closely-related to Neisseria species. All 
three genera are found as human commensals in the nasopharynx and likely evolved 
from a recent common ancestor (Norskov-Lauritsen, 2014). For example, S. muelleri 
and Neisseria dendrificans 16S rDNAs show high similarity levels of ~96% (Hedlund 
and Staley, 2002). The other two orthologs come from bacteria that are much more 
divergent. B. oedipodis is a rod-shaped bacterium that infects the hearts of the 
endangered Cotton-Topped Tamarin (Sanguius oedipus) and causes endocarditis 
(Willems et al., 2002). K. laminariae is an alphaproeobacterium from a marine sugar 
kelp (Laminaria saccharina). K. laminariae grows optimally at room temperature and 
lower pH (pH 5.5) and relatively high salt. It has a unique phylogenetic position and is 
highly diverged from other Alphaproteobacteria (Wiese et al., 2009). These 
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characteristics suggest that the Cas9 orthologs from these bacteria may have unique 
properties.  
In addition to Cas9, there are three other components that must be known before 
characterizing the activity of these unknown Cas9s. These include the crRNA, 
tracrRNA and the PAM. Absent any RNA-seq data available from these bacteria, we 
relied on bioinformatic predictions to identify the crRNA and the tracrRNA. To do so, 
the CRISPR loci were predicted using CRISPRfinder (Grissa, Vergnaud and Pourcel, 
2007). The crRNAs were identified using the homology of the repeats to the N. 
meningitdis locus (see Appendix 1 for sequences) (Zhang et al., 2013). For the 
tracrRNA prediction, we relied on complementarity to the constant region of the 
crRNA, conservation with known tracrRNAs, and the presence of a putative promoter 
and terminator (Figure 3.2A, HpaCas9 shown as an example, see Appendix 1 for all 
sgRNAs) (Lesnik et al., 2001). We were able to predict a sgRNA scaffold for every 
Cas9 except for SmuCas9. In fact, the CRISPR-Cas locus of S. muelleri ATCC 29453 
appears to be degenerate (Figure 3.2B). There is no apparent cas1, and the cas2 lacks a 
canonical ATG start codon. However, the Cas9 ORF (1,065 aa) is intact and has all the 
predicted functional domains found in other Cas9 orthologs, which suggested that 
SmuCas9 itself might be active. When we attempted to define an appropriate guide 
RNA scaffold for SmuCas9, we could not predict its tracrRNA (based in part on crRNA 
complementarity) from nearby genomic sequences. Instead, we found an IS5 integrase 
upstream of cas9, where a tracrRNA locus is often observed (Figure 3.2B). Although 
we sequenced ∼2 kb flanking the CRISPR locus to fill gaps in the genome assembly, 
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we could not detect a tracrRNA sequence. As an alternative, we took advantage of the 
nonorthogonality of sgRNAs to closely related Cas9 orthologs [guides from closely 
related Cas9s can be used interchangeably with some compromise in Cas9 activity 












Cas9 Host Length (aa) 
Identity to 
NmeCas9 (%) 
Neisseria meningitidis (Nme) Humans 1082 100 
Haemophilus parainfluenzae (Hpa) Humans 1052 66 
Simonsiella muelleri (Smu) Humans 1065 62 
Brackiella oedipodis (Boe) Cotton-Topped Tamarin   1148 46 
Kiloniella laminariae (Kla) sugar kelp 1091 28 
Figure 3.1 Selection of compact Cas9 orthologs to be characterized 











Figure 3.2 Characterization of new type II-C Cas9 orthologs.  
(A) Predicted crRNA:tracrRNA structures for NmeCas9 and HpaCas9. Nucleotides that 
are different between the two orthologs are underlined.  
(B) Genomic architectures of CRISPR-cas loci of H. parainfluenzae DSM 8978 and S. 
muelleri ATCC 29453. The sequence of the HpaCas9 tracrRNA is shown in the inset. 








3.2.2 The selected Cas9 orthologs recognize unique PAM sequences 
PAMs are often difficult to predict and in most cases, PAMs must be identified 
empirically. To identify the PAMs of our selected Cas9 orthologs, we used in vitro 
PAM identification (Kim et al., 2017). The method consists of using recombinant Cas9, 
along with an in vitro transcribed sgRNA that targets a pool of DNA fragments 
containing a protospacer followed by a 10-bp randomized sequence cleaved in vitro 
(Figure 3.3A). The reaction products are then gel purified followed by library 
preparation and deep sequencing. We followed a modified deep sequencing protocol 
designed for strand-specific libraries (Zhang et al., 2012). We used SpyCas9 as a 
positive control and retrieved the canonical NGG PAM, as expected (Figure 3.3B). The 
analysis of cleaved fragments revealed the PAMs of each Cas9 ortholog: N4GATTT for 
HpaCas9, N4C for SmuCas9 (using NmeCas9 sgRNA), N4CC for BoeCas9 and 
NGGGGA for KlaCas9. To the best of our knowledge, the PAM of SmuCas9 is the 
shortest PAM ever recorded for a naturally occurring Cas9. Conversely, HpaCas9 and 
































Figure 3.3 The new Cas9 orthologs recognize diverse PAMs 
(A) Experimental workflow of the in vitro PAM discovery assay with a 10-bp 
randomized PAM region. Following in vitro digestion, adapters were ligated to cleaved 
products for library construction and sequencing.  
(B and C) Sequence logos resulting from in vitro PAM discovery (B) reveal the 
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Figure 1: Phylogenetic tree of Cas9 orthologs and PAM Definition
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3.2.3 Heterologous expression of the characterized Cas9s provides immunity 
After our initial biochemical characterization, we wanted to establish an in vivo 
activity assay to test the ability of each ortholog to interfere with phage infections. 
Previous work has shown that heterologous expression of a CRISPR system in another 
host results in efficient CRISPR interference (Sapranauskas et al., 2011), given the 
mobile nature of CRISPR systems acquired through horizontal gene transfer or 
plasmids (Makarova et al., 2011). In fact, plasmid-based expression of NmeCas9 in E. 
coli with a sgRNA targeting another plasmid results in efficient interference (not 
shown). NmeCas9 also provides immunity against phages in E. coli.  
To test our new Cas9 orthologs in vivo, we cloned each Cas9 into bacterial 
expression vectors along with sgRNAs targeting phage Mu (Morgan et al., 2002). We 
used NmeCas9 as a positive control. A non-targeting sgRNA leads to efficient plaque 
formation by the phage, as evident in the plaque assay shown in Figure 3.4. In contrast, 
plasmid-mediated expression of HpaCas9, BoeCas9 and KlaCas9 (at 30 °C, see below) 
and an sgRNA designed to target E. coli phage Mu leads to significant reduction in 
plaque formation, suggesting highly active CRISPR interference. We did not detect any 
significant interference with SmuCas9, perhaps due to the use of the noncognate 
sgRNA from NmeCas9 (not shown). 
It is important to note that our initial attempts at performing this assay using 
KlaCas9 at 37C were unsuccessful (not shown). We reasoned that the aquatic origin of 
KlaCas9 may mean a lower optimal temperature, although it functioned at 37 °C in 
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Figure 3.4 The new CRISPR-Cas9 orthologs provide immunity against phage Mu 
Representative phage Mu plaque assays for each of the Cas9 systems tested. 10-fold 
serial dilution of phage lysate were plated on E. coli lawns expressing each Cas9. The 
non-targeting sgRNA allows robust phage plaquing, while the phage Mu targeting 

























3.2.4 The search for an optimal SmuCas9 sgRNA  
The apparent single-nucleotide PAM of SmuCas9 makes it a promising 
candidate with high target site density for human genome editing applications. 
However, our initial results revealed that although SmuCas9 is functional with the 
sgRNA from NmeCas9 in vitro, it fails to efficiently cleave DNA in E. coli. We 
hypothesized that sgRNA incompatibility (i.e. low affinity between SmuCas9 and Nme 
sgRNA in cells) may be the reason for this inefficiency. To address this, we sought to 
identify an sgRNA from an ortholog that is more similar to SmuCas9 with the potential 
to improve complex formation for genome editing. A BLASTN search revealed that no 
other Simonsiella species has been sequenced, and the most closely related Cas9s are 
only ~70% identical (compared to ~60% with NmeCas9). Nevertheless, we selected the 
locus from Bergeriella dendrificans (BdeCas9, 70% identity to SmuCas9) due to an 
easily identifiable tracrRNA. We first performed an in vitro cleavage using SmuCas9 
with in vitro transcribed Bde and Nme sgRNAs to compare the kinetics of cleavage. As 
expected, SmuCas9 more efficiently cleaves a target in vitro with the Bde sgRNA (not 
shown).  
Next, we performed the in vitro PAM discovery assay using SmuCas9-Bde 
sgRNA to uncover any additional nucleotides that might be required. To capture the 
most efficient PAMs for cleavage, we performed the assay at the lowest possible 
concentration possible for a signal (30nM Cas9-sgRNA) and we stopped the reaction 2, 
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5 and 15 minutes after the DNA was added. This revealed a slight bias for a T at 




Figure 3.5 SmuCas9 cleaves N4C PAMs in vitro with Bde sgRNA 
(A) BLASTN results showing the most closely related Cas9s to SmuCas9.  
(B) In vitro PAM identification (same as Figure 3.3A) using SmuCas9-BdeSgRNA at 3 
timepoints to identify possible preferences other than the C at the 5th position.  
(C) In vitro cleavage of protospacers bearing N4CA, N4CG, N4CC and N4CT PAMs. 
Cleaved bands are marked with *.  
 
Figure 2: Characterization of SmuCas9
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2F: SmuCas9 cleaves NNNNCX PAMs in vitro
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2F: SmuCas9 cleaves NNNNCX PAMs in vitro






































To test the ability of SmuCas9 to cleave sites with N4CN PAMs in vitro, we 
performed in vitro cleavage on substrate with N4CA, N4CG, N4CC and N4CT PAMs. 
We used standard concentrations of Cas9 (30nM) vs target (10nM) that we used 
previously for our other in vitro studies, as high concentrations may mask potential 
preference (Figure 3.5C). The results suggest that SmuCas9 is capable of efficiently 
cleaving N4CN PAMs in vitro using the sgRNA from Bergeriella dendrificans and can 

















3.2.5 Genome editing with the characterized Cas9 orthologs 
To test the ability of the characterized Cas9s in editing the human genome, we 
cloned each Cas9 from bacterial gDNA into a mammalian expression plasmid 
previously used for NmeCas9 (containing NLSs and appropriate promotors). However, 
transfection of these into HEK293T cells showed that all Cas9 orthologs were 
expressed poorly (not shown), possibly due to the fact that they are not codon 
optimized for mammalian cells. 
Several studies have used a ribonucleoprotein (RNP) consisting of recombinant 
Cas9 and the sgRNA into cells for robust genome editing, circumventing the need for 
expression from a plasmid. We cloned these Cas9s along with NLSs into a bacterial 
expression vector, recombinantly expressed and purified them. We electroporated 
HEK293T cells with a preformed RNP complex of each Cas9 along with in vitro 
transcribed sgRNAs. We designed at least two sgRNAs for each ortholog to account for 
the possibility of a nonfunctional sgRNA, targeting several loci throughout the genome 
with the appropriate PAMs (table 3.1). Considering that SmuCas9’s PAM is potentially 
only 1 nucleotide long, we designed 10 guides to test several combinations. 72 hours 
after electroporation, we isolated gDNA from cells, amplified the target locus and 
performed TIDE analysis. Our results showed that HpaCas9 efficiently induced indels 
at two of the four sites tested. While we had initially postulated that its PAM was 
identical to that of NmeCas9 (N4GATT), we only observed editing at N4GATTT. 
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However, more careful analysis is required and more sites must be tested to confirm 
this observation. SmuCas9 was functional at 2 of the 10 sites tested, albeit at a very low 
efficiency of 1-1.5%. We attribute this low efficiency to the lack of a cognate sgRNA. 
However, we did not detect indels by KlaCas9 and BoeCas9, suggesting they are not 
active in our experimental setup. KlaCas9’s low efficiency could be attributed to poor 




















Name Locus Target protospacer PAM Editing (%) 
SmuTS1 AAVS1 TCCTCCTTCCTAGTCTCCTGATAT TCGTCTAA 0 
SmuTs2 AAVS1 CAAAATCAGAATAAGTTGGTCCTG AGTTCTAA 0 
SmuTS3 AAVS1 GGGAGACATCCGTCGGAGAAGG CCATCCTA 0 
SmuTS4 mTLR ATCACCTGCCTCGTGGAATACGGTAAACCTA TAAACCTA 0 
SmuTS5 mTLR TCACCTGCCTCGTGGAATACGGTAACCTAC AAACCTAC 1.5 
SmuTS6 mTLR GAGACAAATCACCTGCCTCGTGGAATACGGT AATACGGT 0 
SmuTS7 mTLR CCGGCTTTGGCGAGACAAATCACCTGCCTCG CTGCCTCG 1 
SmuTS8 mTLR GTTCAGCGTGTCCGGCTTTGGCGAGACAAA GAGACAAA 0 
SmuTS9 mTLR TTCCACGAGGCAGGTGATTTGTCTCGCCAAA TCGCCAAA 0 
SmuTS10 mTLR ATTCCACGAGGCAGGTGATTTGTCTCGCCAA CTCGCCAA 0 
HpaTS1 LINC01588 GGACAGGAGTCGCCAGAGGCCGGT GGTGGATTT 35 
HpaTsS2 CYBB GCTGGATTACTGTGTGGTAGAGGG AGGTGATTA 0 
HpaTS3 AAVS1 TTTGCCTGGACACCCCGTTCTCC TGTGGATTC 0 
HpaTS4 mTLR TAGGTTTACCGTATTCCACGAGGC AGGTGATTT 24 
BoeTS1 AAVS1 GGGAGACATCCGTCGGAGAAGG CCATCCTA 0 
BoeTS2 mTLR ATTCCACGAGGCAGGTGATTTGTCTCGCCAA CTCGCCAA 0 
BoeTS3 mTLR ATCACCTGCCTCGTGGAATACGGTAAaccta TAAACCTA 0 
KlaTS1 AAVS1 TATCCAAGGTTAAGCAAAAGAG AGGGGA 0 
KlaTS2 AAVS1 CTTGGCAGGGGGTGGGAGGGAAGG GGGGGA 0 










Although HpaCas9’s PAM is relatively long, this could offer higher accuracy at 
sites that are targetable. The efficient editing by HpaCas9 allowed us to test the ability 
of all previously discovered Acrs in preventing genome editing by HpaCas9. Based on 
our in vitro results in Figure 2.5, we expected all type II-C Acrs to inhibit HpaCas9 
genome editing. To address this question, we delivered a preformed RNP complex of 
HpaCas9, sgRNA, and each Acr to HEK293T cells by electroporation. Then, we 
confirmed genome editing inhibition using TIDE (Figure 3.5). Acrs displayed 
variations in activities even with RNP delivery, suggesting differences in protein 
stability, off-rate, or other intrinsic properties. Of note, however, AcrIIC1, AcrIIC2 and 
AcrIIC4 exhibited strong inhibitory potency against HpaCas9 in HEK293T cells and 





Figure 3.5: Genome editing with HpaCas9 in the presence of Acrs  
 
Indels (%) of editing efficiencies measured by TIDE analysis upon RNP delivery of 
HpaCas9-sgRNA and each Acr into HEK293T cells. AcrIIA4 was used as a negative 
control, which is specific to type II-A CRISPR systems (Rauch et al., 2017) and would 
























In this chapter, we characterized compact Cas9 orthologs and tested them for 
genome editing applications. Instead of a random approach, we used Acr proteins as 
indicators for Cas9 orthologs that have higher activities. In fact, while all Cas9s worked 
in vitro and demonstrated a wide diversity of PAM recognition, only one (HpaCas9) 
functions in human cells. This is in line with previous efforts to characterize new Cas9 
systems for genome editing (Ran et al., 2015), suggesting that not every active Cas9 
ortholog is functional in human cells. It is currently not possible to predict whether a 
novel Cas9 will be functional for editing in human cells or not, and although our Acr-
directed approach yielded Cas9s that functioned in vitro, most were unsuccessful for 
editing in HEK293T cells.  
The short PAM of SmuCas9 and the non-zero, albeit very low editing makes it 
of interest for future efforts. We hypothesize that the low editing efficiency can be 
attributed to the Bde sgRNA’s loading/affinity for SmuCas9. Sequencing of more 
Simonsiella genomes may make possible to find a closely-related ortholog that harbors 
the right sgRNA for SmuCas9. 
HpaCas9’s N4GNTTT PAM is, to our knowledge, the longest PAM of any Cas9 
reported for genome editing (5 nucleotides long). Despite the fact that the long PAM 
limits the number of targetable sites in the human genome (even more so than for other 
compact Cas9s), it may target such sites with very high accuracy, similar to the extreme 
accuracy that has been documented for NmeCas9.  
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3.4 Materials and methods: 
Plasmids and construct cloning 
For genome editing experiments, plasmids expressing NmeCas9, SpyCas9 and their 
respective sgRNAs targeting the DTS3 site, as well as plasmids expressing AcrE2 
(Addgene #85677), AcrIIC1Boe (Addgene #85678) and AcrIIC1Nme (Addgene 
#85679), were previously described (Pawluk et al.,2016a, 2016b). AcrIIA4 expressing 
plasmid (Addgene #86842) was described previously (Rauch et al., 2017). The 
CjeCas9-expressing plasmid (PX404) was acquired from Addgene (#68338). For 
CjeCas9 sgRNA expression, the published sgRNA sequence (Kim et al., 2017) was 
synthesized as a gBlock (IDT), and was used to replace the NmeCas9 sgRNA cassette 
in pLKO.1-puro plasmid[(Pawluk et al., 2016b); Addgene #85715] by Gibson 
Assembly. The resulting plasmid (pEJS676) contains the CjeCas9 sgRNA cassette with 
BfuAI sites that can be used to insert any spacer of interest. Next, two previously 
validated guide sequences [targeting the AAVS1 locus (TS2 and TS6; (Kim et al., 
2017)] were inserted into the CjeCas9 sgRNA expression construct, yielding plasmids 
pEJS677 and pEJS678, respectively. 
HEK293T electroporation and indel analysis 
HpaCas9 was delivered into HEK293T cells as RNP complex using Neon 
electroporation system. 2uL of Purified HpaCas9 protein [10uM] was complexed with 
1uL of 3.3Ug/uL gRNA. When Acr is tested, 2uL of purified Acr proteins [50uM] was 
added. Electroporation parameters (voltage, width, number of pulses) were 1150 V, 20 
ms, 
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2 pulses. Electroporated cells were plated in 24-well plate and incubated for 48 hours 
before cells were harvested and gDNA was extracted. Indel analysis was performed by 
TIDE. 
 
Purification of Cas9 
6xHis-Cas9:sgRNA was expressed in E. coli Rosetta (DE3). Cells were grown in 
Terrific Broth (TB) medium at 37 °C to an optical density (OD600 nm). Protein 
expression was induced by the addition of 1 mM IPTG for 16 h at 16 °C. Cells were 
lysed by sonication in 50 mM Tris pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.5 mM 
DTT and 5% glycerol supplemented with 0.5 mM PMSF, lysozyme and protease 
inhibitor cocktail (Sigma). Clarified lysates were bound in batch to Ni-NTA agarose 
(Qiagen), and bound protein was eluted with 300 mM imidazole. Purified Cas9:sgRNA 
was dialyzed into 20 mM HEPES pH 7.5, 250 mM NaCl, 5% glycerol, 1 mM DTT and 
1 mM PMSF) for protein interaction experiments.  
 
In vitro DNA cleavage 
NmeCas9 sgRNA derived from spacer 25 (Zhang et al., 2015) was generated by in vitro 
T7 transcription (Epicentre). NmeCas9 (500 nM) was incubated with purified, 
recombinant anti-CRISPR protein in cleavage buffer [20 mM HEPES-KOH (pH 7.5), 
150 mM KCl, 10% glycerol, 1 mM DTT, and 10 mM MgCl2] for 10 minutes. Next, 
sgRNA (1:1, 500 nM) was added and the mixture was incubated for another 15 
minutes. Plasmid containing the target protospacer 25 (pEJS560) was linearized by 
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ScaI digestion. Linearized plasmid was added to the Cas9/sgRNA complex at ~5 nM 
final concentration. The reactions were incubated at 37 °C for 30 minutes and 
visualized after electrophoresis in a 1% agarose/1xTAE gel. 
 
In vitro PAM determination 
A library of a protospacer with randomized PAM sequences was generated using 
overlapping PCRs, with the forward primer containing the 10-nt randomized sequence 
flanking the protospacer. The library was subjected to in vitro cleavage by purified 
recombinant HpaCas9 or SmuCas9 proteins as well as in vitro-transcribed sgRNAs. 
Briefly, 300 nM Cas9:sgRNA complex was used to cleave 300 nM target fragment in 
1× reaction buffer (NEBuffer 3.1) at 37°C for 60 min. The reaction mixture was then 
treated with 1 U proteinase K (NEB) at 50°C for 10 min and run on a 4% agarose gel 
with 1× TAE. The segment of a gel where the cleavage products were expected to be 
was purified and subjected to library preparation as described previously (Zhang et al., 
2012). The library was sequenced using the Illumina NextSeq500 sequencing platform 








CHAPTER 4: Nme2Cas9 as a compact, accurate Cas9 with a dinucleotide PAM 
4.1 Introduction: 
As mentioned previously, in vivo applications of some Cas9s are hindered by 
large size, off-target editing, or complex PAMs that restrict the density of recognition 
sequences in target DNA. Our efforts in chapter 3 yielded several compact Cas9 
orthologs with novel PAMs, but most were unable to execute efficient genome editing 
in mammalian cells, or had long PAMs, or both. 
We continued our search for an ideal Cas9 ortholog for single-AAV delivery 
using an evolutionary approach. PAM mutations often enable phages to escape from 
type II immunity (Paez-Espino et al., 2015), placing these systems under selective 
pressure not only to acquire new CRISPR spacers, but also to evolve new PAM 
specificities. In addition, as shown in chapter 2, some phages and MGEs express Acr 
proteins that inhibit Cas9, sometimes by PID interactions that could confer selective 
pressure for PID variation (Pawluk, Davidson and Maxwell, 2018; Shin et al., 2017; 
Dong et al., 2017). Cas9 PIDs can evolve such that closely related orthologs recognize 
distinct PAMs, as illustrated recently in two species of Geobacillus (Harrington et al., 
2017).  
We exploited natural variation in the PAM-interacting domains (PIDs) of 
closely related Cas9s to identify a compact ortholog from Neisseria meningitidis, 
Nme2Cas9, that recognizes a simple dinucleotide PAM (N4CC) that provides for high 
target site density. All-in-one AAV delivery of Nme2Cas9 with a guide RNA targeting 
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Pcsk9 in adult mouse liver produces efficient genome editing and reduced serum 
cholesterol with exceptionally high specificity. We further expand our single-AAV 
system to pre-implanted zygotes for streamlined generation of genome-edited mice. 














4.2 RESULTS  
4.2.1 Closely related orthologs of NmeCas9 recognize different PAMs  
We and others have shown that NmeCas9 is an efficient and accurate Cas9 for 
genome editing applications. Given that numerous N. meninigitidis strains are 
sequenced, we sought closely related NmeCas9 orthologs with divergent PIDs. We 
focused on Cas9s with >80% overall identity to that of strain 8013 (Zhang et al., 2013), 
which we will hereafter refer to as Nme1Cas9. Alignments revealed three clades of 
orthologs, each with >98% identity in the N-terminal ~820 amino acid (aa) residues, 
which include all regions of the protein other than the PID (Figure 4.1A). All of these 
Cas9s are 1,078–1,082 aa in length. The first clade (group 1) includes orthologs in 
which the >98% aa sequence identity with Nme1-Cas9 extends through the PID. In 
contrast, the other groups had PIDs that were significantly divergent from that of 
Nme1- Cas9, with group 2 and group 3 orthologs averaging 52% and 86% PID 
sequence identity with Nme1Cas9, respectively (Figure 4.1B). We selected one 
meningococcal strain from each group —De11444 from group 2 and 98002 from group 
3— for detailed analysis, and we refer to their Cas9 orthologs as Nme2Cas9 (1,082 aa) 
and Nme3Cas9 (1,081 aa), respectively (see Appendix for sequences). The CRISPR-
Cas loci from these two strains (Figure 4.1 C) have repeat sequences and spacer lengths 
identical to those of strain 8013, suggesting that their mature crRNAs also have 24-nt 
guide sequences and 24-nt repeat sequences (Zhang et al., 2013). Similarly, the 
tracrRNA sequences of De11444 and 98002 were 100% identical to the 8013 tracrRNA 
(Figure 4.1C). These observations imply that the same sgRNA sequence scaffold can 
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guide all three Cas9s and we will likely not encounter problems regarding sgRNA 
prediction seen in chapter 3.  
To test whether these Cas9 orthologs have distinct PAMs, we replaced the PID 
of Nme1Cas9 with that of either Nme2Cas9 or Nme3Cas9 and used these recombinant 
chimeras for in vitro PAM identification described in chapter 3. The expected N4GATT 
consensus was recovered for Nme1Cas9, validating our workflow (Figure 4.2A). The 
PID-swapped derivatives strongly preferred a C in the 5th position (Figure 4.2B), but 
other PAM nucleotides could not be confidently assigned due to the low cleavage 
efficiencies of the chimeric proteins under the conditions used (Figure 4.2C). To further 
resolve the PAMs, we repeated the in vitro assay but on a 7-nt randomized library 
possessing an invariant C at the 5th PAM position (NNNNCNNN). This strategy 
yielded a much higher cleavage efficiency (Figure 4.2C), and the results indicated that 
the Nme2Cas9 and Nme3Cas9 PIDs recognize NNNNCC(a) and NNNNCAAA PAMs, 
respectively (Figure 4.2D). Finally, we repeated our tests using the full-length 
Nme2Cas9 with the NNNNCNNN DNA pool, and again we recovered a NNNNCC(a) 
consensus (Figure 4.2D), though with more efficient cleavage (Figure 4.2C). These data 
suggest that one or more of the 15 aa changes in Nme2Cas9 (relative to Nme1Cas9) 
outside of the PID support efficient activity (Figure 4.2C). Because the 2- to 3-
nucleotide PAM of Nme2Cas9 affords a higher density of potential target sites than the 
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Figure 4.1 Three closely related Neisseria meningitidis Cas9s have distinct PIDs 
(A) Unrooted phylogenetic tree of meningococcal Cas9 orthologs. Groups 1 (blue), 2 
(orange), and 3 (green) have PIDs with >98%, 52%, and 86% identity to Nme1Cas9, 
respectively. Three representative Cas9 orthologs (one from each group) (Nme1Cas9, 
Nme2Cas9, and Nme3Cas9) are indicated. 
(B) Schematic showing mutated residues (orange spheres) between Nme2Cas9 (left) 
and Nme3Cas9 (right) mapped onto the predicted structure of Nme1Cas9, revealing the 
cluster of mutations in the PID (black). 
(C) Schematic showing the CRISPR-Cas loci of the strains encoding the three Cas9 
orthologs (Nme1Cas9, Nme2Cas9, and Nme3Cas9) from (A). Percent identities of each 
CRISPR-Cas component with N. meningitidis 8013 (encoding Nme1Cas9) are shown. 










































Nme1 PID Nme3 PID Nme2 PID 
Nme2Cas9 
N10 pool





























































Nme1 PID Nme3 PID Nme2 PID 
Nme2Cas9 
N10 pool
































































Nme1 PID Nme3 PID Nme2 PID 
Nme2Cas9 
N10 pool











































98 52 99 86
D
Nme2 PID Nme3 PID Nme2 PID 
Nme2Cas9Nme1Cas9Nme1Cas9





























































































































































































































PID Group 1 (>98% to Nme1)
PID Group 2 (~52% to Nme1)
PID Group 3 (~86% to Nme1)
Nme3Cas9
Nme2Cas9










98 52 99 86
D
Nme2 PID Nme3 PID Nme2 PID 
Nme2Cas9Nme1Cas9Nme1Cas9





























































































































































































































PID Group 1 (>98% to Nme1)
PID Group 2 (~52% to Nme1)

























































Figure 4.2 Three closely related Cas9s recognize different PAMs 
(A) Sequence logos resulting from in vitro PAM discovery reveal the enrichment of a 
N4GATT PAM for Nme1Cas9, consistent with its previously established specificity. 
(B) Sequence logos indicate that Nme1Cas9 with its PID swapped with that of 
Nme2Cas9 (left) or Nme3Cas9 (right) requires a C at PAM position 5. The remaining 
nucleotides were not determined with high confidence due to the modest cleavage 
efficiency of the PID-swapped protein chimeras (see figure 4.D) 
(C) Normalized read counts (% of total reads) from cleaved DNAs from the in vitro 
assays for intact Nme1Cas9 (grey), for chimeras with Nme1Cas9’s PID swapped with 
those of Nme2Cas9 and Nme3Cas9 (mixed colors), and for full-length Nme2Cas9 
(orange), are plotted. The reduced normalized read counts indicate lower cleavage 
efficiencies in the chimeras.  
(D) Sequence logos from the in vitro PAM discovery assay on an NNNNCNNN PAM 
pool by Nme1Cas9 with its PID swapped with those of Nme2Cas9 (left) or Nme3Cas9 
(right). 












4.2.2 Nme2Cas9 editing at N4CC PAMs in human cells  
To test the efficacy of Nme2Cas9 in human genome editing, we cloned full-
length (not PID-swapped), human-codon-optimized Nme2Cas9 into a mammalian 
expression plasmid, with the same appended nuclear localization signals (NLSs) and 
linkers validated previously for Nme1Cas9 in chapters 2 and 3 (Amrani et al., 2018a). 
For our initial tests, we used a modified, fluorescence-based Traffic Light Reporter 
(Certo et al., 2011). This reporter consists of a disrupted GFP followed by an out-of-
frame T2A peptide and mCherry cassette. When DNA double-strand breaks (DSBs) are 
introduced in the broken-GFP cassette, a subset of non-homologous end joining 
(NHEJ) repair events leave +1-frameshifted indels, placing mCherry in frame and 
yielding red fluorescence that can be easily quantified by flow cytometry (Figure 4.3A). 
[Homology-directed repair (HDR) outcomes can also be scored simultaneously by 
including a DNA donor that restores the functional GFP sequence, yielding green 
fluorescence (Certo et al., 2011).] Because some indels do not introduce a +1 
frameshift, the fluorescence readout generally provides an underestimate of the true 
editing efficiency. Nonetheless, the speed, simplicity, and low cost of the assay makes 
it useful as an initial, semi-quantitative measure of genome editing in HEK293T cells 
carrying a single TLR2.0 locus incorporated via lentivector. 
For our initial tests, we transiently co-transfected Nme2Cas9 plasmid with one 
of fifteen sgRNA plasmids carrying spacers that target TLR2.0 sites with N4CC PAMs. 
No HDR donor was included, so only NHEJ-based editing (mCherry) was scored. Most 
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sgRNAs were in G23 format (i.e. a 5’-terminal G to facilitate transcription, followed by 
a 23nt guide sequence], as used routinely for Nme1Cas9 (Ibraheim et al., 2018b). No 
sgRNA and an sgRNA targeting an N4GATT PAM were used as negative controls, and 
SpyCas9+sgRNA and Nme1Cas9+sgRNA co-transfections (targeting NGG and 
N4GATT protospacers, respectively) were included as positive controls. Editing by 
SpyCas9 and Nme1Cas9 was readily detectable (~28% and 10% mCherry, 
respectively) (Figure 4.3B). For Nme2Cas9, all 15 sgRNAs targeting sites with N4CC 
PAMs were functional, though to various extents ranging from 4% to 20% mCherry. 
These fifteen sites include examples with each of the four possible nucleotides in the 
7th PAM position (after the CC dinucleotide), indicating that the slight preference for 
an A residue observed in vitro (Figure 4.1B) does not reflect a PAM requirement for 
editing applications in human cells. The N4GATT PAM control yielded mCherry signal 
similar to no-sgRNA control (Figure 4.3B).  
To determine whether both C residues in the N4CC PAM are important for 
editing, we also tested a series of N4DC (D = A, T, G) and N4CD PAM sites in TLR2.0 
reporter cells (Figure 4.3C and 4.3D). We found no detectable editing at any of these 
sites, providing an initial indication that both C residues of the N4CC PAM consensus 
are required for efficient Nme2Cas9 activity.  
To further corroborate the dinucleotide PAM, we took advantage of an eGFP 
knock-out reporter system. Targeting sites within the eGFP ORF in HEK293T cells 
(stably expressing eGFP) results in loss of eGFP which can be scored by flow 
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cytometry. We electroporated a plasmid expressing Nme2Cas9 along with sgRNAs 
targeting 16 N4CC sites throughout the eGFP ORF.  All N4CC targeted sites showed 
reduced eGFP expression compared to no sgRNA control, confirming that Nme2Cas9 
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Figure 4.3 Characterization of Nme2Cas9 in mammalian cells 
(A) Schematic depicting transient transfection and editing of HEK293T TLR2.0 cells, 
with mCherry+ cells detected by flow cytometry 72 hours after transfection.  
(B) Nme2Cas9 editing of the TLR2.0 reporter. Sites with N4CC PAMs were targeted 
with varying efficiencies, while no Nme2Cas9 targeting was observed at an N4GATT 
PAM or in the absence of sgRNA. SpyCas9 (targeting a previously validated site with 
an NGG PAM) and Nme1Cas9 (targeting N4GATT) were used as positive controls.  
(C) Nme2Cas9 targeting at N4CD sites in TLR2.0, with editing estimated based on 
mCherry+ cells. Four sites for each non-C nucleotide at the tested position (N4CA, 
N4CT and N4CG) were examined, and an N4CC site was used as a positive control.  
(D) Nme2Cas9 targeting at N4DC sites in TLR2.0 [similar to (C)].  
(E) Targeting sites within the eGFP ORF in HEK293T cells (stably expressing eGFP) 
results in loss of eGFP. Electroporation of sgRNAs targeting 16 N4CC sites throughout 
the eGFP ORF was used to determine Nme2Cas9 efficiency.  All N4CC targeted sites 
showed reduced eGFP expression compared to no sgRNA control, confirming that 
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Figure 4.4 Further characterization of Nme2Cas9 and its application using TLR  
(A) The effect of spacer length on the efficiency of Nme2Cas9 editing. An sgRNA 
targeting a single TLR2.0 site, with spacer lengths varying from 24 to 20 nts (including 
the 5’-terminal G required by the U6 promoter), indicate that highest editing 
efficiencies are obtained with 22-24 nt spacers. 
(B) Nme2Cas9 targeting efficiency is differentially sensitive to single-nucleotide 
mismatches in the seed region of the sgRNA. Data show the effects of walking single-
nucleotide sgRNA mismatches along the 23-nt spacer in a TLR2.0 target site. 
(C) An Nme2Cas9 dual nickase can be used in tandem to generate NHEJ- and HDR-
based edits in TLR2.0. Nme2Cas9- and sgRNA-expressing plasmids, along with an 
800-bp dsDNA donor for homologous repair, were electroporated into HEK293T 
TLR2.0 cells, and both NHEJ (mCherry+) and HDR (GFP+) outcomes were scored by 
flow cytometry. HNH nickase, Nme2Cas9D16A; RuvC nickase, Nme2Cas9H588A. 
Cleavage sites 32 bp and 64 bp apart were targeted using either nickase. The HNH 
nickase (Nme2Cas9D16A) yielded efficient editing, particularly with the cleavage sites 
that were separated by 32 bp, whereas the RuvC nickase (Nme2Cas9H588A) was not 











The length of the spacer in the crRNA differs among Cas9 orthologs and can 
affect on- vs. off-target activity (Cho et al., 2013; Fu et al., 2014). SpyCas9’s optimal 
spacer length is 20 nts, with truncations down to 17 nts tolerated (Fu et al., 2014). In 
contrast, Nme1Cas9 prefers 24-nt spacers with truncations down to 18-20 nts tolerated 
(Lee, Cradick and Bao, 2016; Amrani et al., 2018b). To test the spacer length 
requirements for Nme2Cas9, we created guide RNA plasmids each targeting a single 
TLR2.0 site, but with varying spacer lengths (Figure 4.4A). We observed comparable 
activities with G23, G22 and G21 guides, but significantly decreased activity upon 
further truncation to G20 and G19 lengths (Figure 4.4A).  These results validate 
Nme2Cas9 as a genome editing platform, with 22-24 nt guide sequences, at N4CC 
PAM sites in HEK293T cells.  
Studies in previously characterized Cas9s have identified a specific region 
proximal to the PAM where Cas9 activity is highly sensitive to sequence mismatches. 
This 8 to 12-nt region is known as the seed sequence and has been observed among all 
Cas9s characterized to date (Gorski, Vogel and Doudna, 2017).To determine whether 
Nme2Cas9 also possesses a seed sequence, we performed a series of transient 
transfections each targeting the same locus in TLR2.0, but with a single-nucleotide 
mismatch at different positions of the guide (Figure 4.4B). We observed a significant 
decrease in the number of mCherry-positive cells for mismatches in the first 10-12 nts 
proximal to the PAM, suggesting that Nme2Cas9 possesses a seed sequence in this 
region.  
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As described previously, Cas9 enzymes use their HNH and RuvC domains to 
cleave the guide-complementary and non-complementary strand of the target DNA, 
respectively. SpyCas9 nickases (nCas9s), in which either the HNH or RuvC domain is 
mutationally inactivated, have been used to induce homology-directed repair (HDR) 
and to improve genome editing specificity via DSB induction by dual nickases. To test 
the efficacy of Nme2Cas9 as a nickase, we created Nme2Cas9D16A (HNH nickase) 
and Nme2Cas9H588A (RuvC nickase), which possess alanine mutations in catalytic 
residues of the RuvC and HNH domains, respectively (Esvelt et al., 2013; Zhang et al., 
2013). We then used TLR2.0 cells, along with a GFP donor dsDNA, to determine 
whether Nme2Cas9-induced nicks can induce precise edits via HDR. We used target 
sites within TLR2.0 to test the functionality of each nickase using guides targeting 
cleavage sites spaced 32 bp and 64 bp apart (Figure 4.4C). Wildtype Nme2Cas9 
targeting a single site showed efficient editing, with both NHEJ and HDR as outcomes 
of repair. For nickases, cleavage sites 32 bp and 64 bp apart showed editing using the 
Nme2Cas9D16A (HNH nickase), but neither target pair worked with 
Nme2Cas9H588A. These results suggest that Nme2Cas9 HNH nickase can be used for 
efficient genome editing, as long as the sites are in close proximity.  
We next tested Nme2Cas9’s ability to function in different mammalian cell 
lines. As an initial test, we targeted 40 different sites (29 with a N4CC PAM, and 11 
sites with a N4CD PAM) (Appendix 2) throughout the human genome in HEK293T 
cells using transient transfections. 72-hours post transfection, cells were harvested, 
followed by genomic DNA extraction and selective amplification of the targeted locus. 
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We used TIDE to measure indel efficiency at each locus (see Figure 1.5; Brinkman et 
al, 2014). Nme2Cas9 editing was detectable at most of these sites, even though 
efficiencies varied depending on the target sequence (Appendix 2). 14 sites with N4CC 
PAMs were analyzed in triplicate, and consistent editing was observed (Figure 4.5A). 
In addition, editing efficiency could be improved significantly by increasing the 
quantity of the Nme2Cas9 plasmid delivered (Figure 4.5B). 
We next tested the ability of Nme2Cas9 to function in mouse Hepa1-6 cells 
(hepatoma-derived). For Hepa1-6 cells, a single plasmid encoding both Nme2Cas9 and 
an sgRNA (targeting either Rosa26 or Pcsk9) was transiently transfected and indels 
were measured after 72 hrs. Editing was readily observed at both sites (Figure 4.6A, 
left). We also tested Nme2Cas9’s functionality when stably expressed in human 
leukemia K562 cells. To this end, we created a lentiviral construct expressing 
Nme2Cas9 and transduced cells to stably express Nme2Cas9 under the control of the 
SFFV promoter. This stable cell line did not show any visible differences with respect 
to growth and morphology in comparison to untransduced cells, suggesting that 
Nme2Cas9 is not toxic when stably expressed. These cells were transiently 
electroporated with plasmids expressing sgRNAs and analyzed by TIDE after 72 hours 
to measure indel efficiencies. We observed efficient (>50%) editing at all three sites 
tested, validating Nme2Cas9’s ability to function upon lentiviral delivery in K562 cells 








Figure 4.5 Genome editing at endogenous sites in HEK293T cells 
(A) Nme2Cas9 genome editing of endogenous human sites in HEK293T cells 
following transient transfection of Nme2Cas9- and sgRNA-expressing plasmids. 40 
sites were screened initially (Table S1); the 14 sites shown (selected to include 
representatives of varying editing efficiencies, as measured by TIDE) were then re-
analyzed in triplicate. An Nme1Cas9 target site (with an N4GATT PAM) was used as a 
negative control.  
(B) Increasing the dose of electroporated Nme2Cas9 plasmid (500 ng, vs. 200 ng in 
Figure 3A) improves editing efficiency at two sites (TS16 and TS6). Data provided in 
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Figure 4.6 Editing by Nme2Cas9 in different cells and via different delivery 
methods 
(A) Left panel: Transient transfection of a single plasmid expressing both Nme2Cas9 
and sgRNA (targeting the Pcsk9 and Rosa26 loci) enables editing in Hepa1-6 mouse 
cells, as detected by TIDE. Right panel: Electroporation of sgRNA plasmids into K562 
cells stably expressing Nme2Cas9 from a lentivector results in efficient indel 
formation. 
(B, C and D) Nme2Cas9 can be electroporated as an RNP complex to induce genome 
editing. 40 picomoles Cas9 along with 50 picomoles of sgRNAs targeting three 
different loci were electroporated into cells. Indels were measured after 72h using 
TIDE. In (C) 80 picomoles Cas9 along with 100 picomoles were used. 
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Ribonucleoprotein (RNP) delivery of Cas9 and its sgRNA is also useful for 
some genome editing applications, and the greater transience of Cas9’s presence can 
minimize off-target editing (Zuris et al., 2015). Moreover, some cell types (e.g. certain 
immune cells) are recalcitrant to DNA transfection-based editing (Schumann et al., 
2015). To test whether Nme2Cas9 is functional by RNP delivery, we cloned 6xHis-
tagged Nme2Cas9 (fused to three NLSs) into a bacterial expression construct and 
purified the recombinant protein, which we then loaded with T7 RNA polymerase-
transcribed sgRNAs targeting three previously validated sites. Electroporation of the 
Nme2Cas9:sgRNA complex induced successful editing at each of the three target sites 
in HEK293T cells, as detected by TIDE (Figure 4.6B). To test for editing in cells that 
are intrinsically unreceptive to DNA, we used RNP electroporations to target several 
validated sites in primary human dermal fibroblasts adult cells (HDFa) and IMR90 lung 
fibroblasts. We observed editing at all sites targeted (Figure 4.6C and D), suggesting 
that Nme2Cas9 RNP complex can be used for editing in primary and difficult-to-
transfect cells. Collectively these results indicate that Nme2Cas9 can be delivered 






4.2.3 Several Acr families can be used as off-switches for Nme2Cas9 
To date, five families of Acrs from diverse bacterial species have been shown to 
inhibit Nme1Cas9 in vitro and in human cells (Lee et al., 2018; Pawluk et al., 2016) 
Considering the high sequence identity between Nme1Cas9 and Nme2Cas9, we 
reasoned that at least some of these Acr families should inhibit Nme2Cas9. To test this, 
we expressed and purified all five families of recombinant Acrs, and tested 
Nme2Cas9’s ability to cleave a target in vitro in the presence of a member of each 
family (10:1 Acr:Cas9 molar ratio). We used an inhibitor for the type I-E CRISPR 
system in E. coli (AcrE2) (Pawluk et al., 2014) as a negative control, while Nme1Cas9 
(Pawluk et al., 2016) was used as a positive control. As expected, all 5 families 
inhibited Nme1Cas9, while AcrE2 failed to do so (Figure 4.6A, top). AcrIIC1Nme, 
AcrIIC2Nme, AcrIIC3Nme, and AcrIIC4Hpa completely inhibited Nme2Cas9. Strikingly, 
however, AcrIIC5Smu (the most potent of the Nme1Cas9 inhibitors) did not inhibit 
Nme2Cas9 in vitro even at a 10-fold molar excess, suggesting that it likely inhibits 
Nme1Cas9 by interacting with its PID (Figure 4.6A, middle). To further test this, we 
performed the same in vitro cleavage assay on the Nme1Cas9/Nme2Cas9 chimera 
[Nme1Cas9 with the PID of Nme2Cas9 (Figure 4.2B). Due to the reduced activity of 
this hybrid, we used a ~30x higher concentration of Cas9 to achieve a similar cleavage 
efficiency while maintaining the 10:1 Acr:Cas9 molar ratio. We observed no inhibition 
by AcrIIC5Smu on this protein chimera (Figure 4.6A, bottom), providing further 
evidence that AcrIIC5Smu likely interacts with the PID of Nme1Cas9. Regardless of the 
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mechanistic basis for the differential inhibition by AcrIIC5Smu, our results indicate that 
Nme2Cas9 is subject to inhibition by the other four type II-C Acr families.  
Based on our in vitro data, we hypothesized that AcrIIC1Nme, AcrIIC2Nme, 
AcrIIC3Nme, and AcrIIC4Hpa could be used as off-switches for Nme2Cas9 genome 
editing. To test this, we performed Nme2Cas9/sgRNA plasmid transfections in 
HEK293T cells (targeting TS16) in the presence or absence of Acr expression 
plasmids. We co-transfected 150 ng of each plasmid, as most Acrs inhibited Nme1Cas9 
at those plasmid ratios (Pawluk et al., 2016). As expected, AcrIIC1Nme, AcrIIC2Nme, 
AcrIIC3Nme and AcrIIC4Hpa inhibited Nme2Cas9 genome editing, while AcrIIC5Smu had 
no effect (Figure 4.7B). We observed complete inhibition by AcrIIC3Nme and 
AcrIIC4Hpa, suggesting that they have high potency against Nme2Cas9 compared to 
AcrIIC1Nme and AcrIIC2Nme. To further compare the potency of AcrIIC1Nme and 
AcrIIC4Hpa, we repeated the experiments at various ratios of Acr plasmid to Cas9 
plasmid (Figure 4.7C). We observe that the AcrIIC4Hpa plasmid is especially potent 
against Nme2Cas9. Together, these data suggest that several Acr proteins can be used 























Figure 4.7 Nme2Cas9 is inhibited by a subset of Acrs 
(A) In vitro cleavage assay of Nme1Cas9 and Nme2Cas9 in the presence of five 
previously characterized anti-CRISPR proteins (10:1 ratio of Acr:Cas9). Top: All five 
previously characterized type II-C Acr families inhibited Nme1Cas9, as expected. 
Middle: Nme2Cas9 inhibition mirrors that of Nme1Cas9, except for the lack of 
inhibition by AcrIIC5Smu. Bottom, In vitro cleavage by the Nme1Cas9-Nme2Cas9PID 
chimera in the presence of previously characterized Acr proteins. 
(B)  Genome editing in the presence of the five previously described anti-CRISPR 
families.  
(C) Acr inhibition of Nme2Cas9 is dose-dependent with distinct apparent potencies. 
Nme2Cas9 is fully inhibited by AcrIIC1Nme and AcrIIC4Hpa at 2:1 and 1:1 mass 
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4.2.4 Nme2Cas9 is hyper-accurate in mammalian cells 
As discussed previously, Nme1Cas9 demonstrates remarkable editing fidelity in 
cells and mouse models, and the similarity of Nme2Cas9 to Nme1Cas9 over most of its 
length suggests that it may likewise be hyper-accurate. However, the higher number of 
sites sampled in the genome as a result of the dinucleotide PAM could create more 
opportunities for Nme2Cas9 off-targeting in comparison with Nme1Cas9 and its less 
frequently encountered 4-nucleotide PAM. To assess the off-target profile of 
Nme2Cas9, we used GUIDE-seq (genome-wide, unbiased identification of double-
stranded breaks enabled by sequencing) to identify potential off-target sites empirically, 
in an unbiased fashion (Tsai et al., 2014). Even the best off-target prediction algorithms 
are prone to false negatives, necessitating empirical target site profiling methods (Tsai 
and Joung, 2016). GUIDE-seq relies on the incorporation of double-stranded 
oligodeoxynucleotides (dsODNs) into DNA double-stranded break sites throughout the 
genome. These insertion sites are then detected by amplification and high-throughput 
sequencing.  
Because SpyCas9 is by far the best-characterized Cas9 ortholog, it is useful for 
multiplexed applications with other Cas9s, and as a benchmark for their editing 
properties (Jiang and Doudna, 2017). We cloned SpyCas9 and Nme2Cas9 into identical 
plasmid backbones, with the same UTRs, linkers, NLSs, and promoters, for parallel 
transient transfections (along with similarly matched sgRNA-expressing plasmids) into 
HEK293T cells. First, we confirmed that the guides for SpyCas9 and Nme2Cas9 are 
 110 
orthogonal, i.e. that Nme2Cas9 sgRNAs do not direct editing by SpyCas9, and vice 
versa (Figure 4.8C), as expected based on earlier results with Nme1Cas9 (Fonfara et 
al., 2014).Next, to enable the use of SpyCas9 as a benchmark for GUIDE-seq, we took 
advantage of the fact that SpyCas9 and Nme2Cas9 have non-overlapping PAMs and 
can therefore potentially edit any dual site (DS) flanked by a 5’-NGGNCC-3’ sequence, 
which simultaneously fulfills the PAM requirements of both (Figure 4.8A). This 
enables side-by-side comparisons of off-targeting with guides that edit the exact same 
on-target site (Figure 4.8A). We targeted 28 DSs at multiple loci throughout the 
genome using plasmids expressing each Cas9 and their respective sgRNAs.  72 hours 
after plasmid delivery, we performed TIDE analysis on the sites targeted by each 
nuclease. Nme2Cas9 induced indels at 19 sites, albeit at low efficiencies (<5%) at three 
of them, while SpyCas9 induced indels at 23 of the sites (Figure 4.8B, left). While 
SpyCas9 is usually more efficient, both enzymes have similar efficiencies at most sites 
(Figure 4.8B, right).  
For GUIDE-seq, we selected DS2, DS4 and DS6 to sample off-target cleavage 
with Nme2Cas9 guides that direct on-target editing as efficiently, less efficiently, or 
more efficiently than the corresponding SpyCas9 guides, respectively (Figure 4.9A). In 
addition to the three dual sites, we added one of the most efficiently edited Nme2Cas9 
target sites (TS6, with 30-50% indel efficiency depending on the cell type; see Figure 
4.5 and 4.6), along with the mouse Pcsk9 and Rosa26 Nme2Cas9 sites (Figure 4.6A). 
We performed plasmid transfections of each Cas9 along with their cognate sgRNAs 
and the dsODNs, and prepared GUIDE-seq libraries. GUIDE-seq analysis (Tsai et al., 
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2014; Zhu et al., 2017) revealed efficient on-target editing for both Cas9 orthologs 
(Figure 4.9B), with relative efficiencies (as reflected by GUIDE-seq read counts) that 
are similar to those observed by TIDE. For off-target identification, the analysis 
revealed that the DS2, DS4, and DS6 SpyCas9 sgRNAs appeared to direct editing at 93, 
10, and 118 candidate off-target sites, respectively, in the normal range of off-targets 
when plasmid-based SpyCas9 editing is analyzed by GUIDE-seq (Fu et al., 2014). In 
striking contrast, the DS2, DS4, and DS6 Nme2Cas9 sgRNAs appeared to direct editing 
at 1, 0, and 1 off-target sites, respectively (Figure 4.9C). When compared to the 
GUIDE-seq read counts for the SpyCas9 off-targets (Figure 4.9D), those of Nme2Cas9 
were very low (Figure 4.9E), further suggesting that Nme2Cas9 is highly specific. 
Nme2Cas9 GUIDE-seq analyses with the TS6, Pcsk9, and Rosa26 yielded similar 
results (0, 0, and 1 off-target sites, respectively, with a modest read count for the 















Figure 4.8 Comparing the efficiencies of Nme2Cas9 and SpyCas9 
(A) Schematic depicting dual sites (DSs) targetable by both SpyCas9 and Nme2Cas9  
(B) Nme2Cas9 and SpyCas9 efficiencies vary based on the locus and target site. Box-
and-whisker plots indicate editing efficiencies at 28 dual sites by Nme2Cas9 and 
SpyCas9 (left). The sites that showed no editing were excluded from the analysis. 
Relative efficiencies of Nme2Cas9 and SpyCas9 show that Nme2Cas9 is, on average, 
less efficient than SpyCas9 (right). Editing efficiencies by both Cas9 orthologs at all 28 
sites were included in the analysis of relative efficiencies on the right.  
(C) Nme2Cas9 and SpyCas9 guides are orthogonal. 
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To validate the off-target sites detected by GUIDE-seq, we performed targeted 
deep sequencing to measure indel formation at the top off-target loci following 
GUIDE-seq-independent editing (i.e. without co-transfection of the dsODN). While 
SpyCas9 showed considerable editing at most off-target sites tested (in some instances, 
more efficient than that at the corresponding on-target site), Nme2Cas9 exhibited no 
detectable indels at the lone DS2 and DS6 candidate off-target sites (Figure 4.10A). 
With the Rosa26 sgRNA, Nme2Cas9 induced ~1% editing at the Rosa26-OT1 site in 
Hepa1-6 cells, compared to ~30% on-target editing (Figure 4.10A). It is noteworthy 
that this off-target site has a consensus Nme2Cas9 PAM (ACTCCCT) with only 3 
mismatches at the PAM-distal end of the guide-complementary region (i.e. outside of 
the seed) (Figure 4.10B). These data support and reinforce our GUIDE-seq results 
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Figure 4.9 Nme2Cas9 is highly accurate in human cells 
(A) DS2, DS4 and DS6 were selected for GUIDE-Seq analysis as Nme2Cas9 was 
equally efficient, less efficient and more efficient than SpyCas9, respectively, at 
these sites. 
(B) Nme2Cas9 and SpyCas9 exhibit comparable on-target editing efficiencies as 
assessed by GUIDE-seq. Bars indicate on-target read counts from GUIDE-Seq at the 
three dual sites targeted by each ortholog. Orange bars represent Nme2Cas9 and black 
bars represent SpyCas9. 
(C) Numbers of off-target sites detected by GUIDE-Seq for each nuclease at 
individual target sites are shown. In addition to dual sites, we analyzed TS6 (because 
of its high on-target editing efficiency) and Pcsk9 and Rosa26 sites in mouse Hepa1-
6 cells (to measure accuracy in another cell type). 
(C) SpyCas9’s on-target vs. off-target read counts for each site. Orange bars represent 
the on-target reads while black bars represent off-targets.  












To further corroborate our GUIDE-Seq results, we used CRISPRseek (Zhu et 
al., 2014) to computationally predict potential off-target sites for two of our most active 
Nme2Cas9 sgRNAs (targeting TS25 and TS47, both of which are also in VEGFA). We 
selected three (TS25) or four (TS47) of the most closely matched predicted sites, five 
with N4CC PAMs and two with N4CA PAMs; each had 2-5 mismatches, mostly in 
their PAM-distal, non-seed regions (Figure 4.10C). We then compared on- vs. off-
target editing (after Nme2Cas9+sgRNA plasmid transfections into HEK293T cells) by 
targeted amplification of each locus, followed by TIDE analysis. Consistently, no 
indels could be detected at those off-target sites for either sgRNA by TIDE, while 
efficient on-target editing was readily detected in DNA from the same populations of 
cells. Taken together, our data indicate that Nme2Cas9 is a naturally hyper-accurate 












Figure 4.10 Deep-sequencing and CRISPRSeek confirm Nme2Cas9’s accuracy 
(A) Targeted deep sequencing to detect indels in edited cells confirms the high 
Nme2Cas9 accuracy indicated by GUIDE-seq.  
(B) Sequence for the validated off-target site of the Rosa26 guide, showing the PAM 
region (underlined), the consensus CC PAM dinucleotide (bold), and three 
mismatches in the PAM-distal portion of the spacer (red). 
(C) Bar graphs showing indel efficiencies (measured by TIDE) at potential off-target 
sites predicted by CRISPRSeek. On- and off-target site sequences are shown on the left, 
with the PAM region underlined and sgRNA mismatches and non-consensus PAM 
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4.2.5 Nme2Cas9 is functional in vivo and ex vivo by all-in-one AAV delivery 
The compact size, small PAM, and high fidelity of Nme2Cas9 offer major 
advantages for in vivo genome editing using AAV. To test whether effective Nme2Cas9 
genome editing can be achieved via single-AAV delivery, we cloned Nme2Cas9 with 
its sgRNA and their promoters (U1a and U6, respectively) into an AAV vector 
backbone (4.11A). We then packaged this all-in-one AAV.sgRNA.Nme2Cas9 into a 
hepatotropic AAV8 capsid to target two genes in the mouse liver: Rosa26 (a commonly 
used safe harbor locus for transgene insertion) as a negative control (Friedrich and 
Soriano, 1991), and Pcsk9, a major regulator of circulating cholesterol homeostasis as a 
phenotypic target (Rashid et al., 2005). SauCas9- or Nme1Cas9-induced indels in 
Pcsk9 in the mouse liver results in reduced cholesterol levels, providing a useful and 
easy-to-score in vivo benchmark for new editing platforms (Ran et al., 2015; Ibraheim 
et al., 2018b). The Nme2Cas9 guides were the same as those used above (Figure 4.6A); 
because Rosa26-OT1 was the only Nme2Cas9 off-target site that we were able to 
validate in cultured mammalian cells (Figure 4.10A and B), the Rosa26 guide also 
provided us with an opportunity to assess on- vs. off-target editing in vivo.  
The tail veins of two groups of mice (n = 5) were injected with 4 x 1011 
AAV8.sgRNA.Nme2Cas9 genome copies (GCs) targeting either Pcsk9 or Rosa26. 
Serum was collected at 0, 14 and 28 days post-injection for cholesterol level 
measurement. Mice were sacrificed at 28 days post-injection and liver tissues were 
harvested (Figure 4.11A). Targeted deep sequencing of each locus revealed ~38% and 
 119 
~46% indel induction at the Pcsk9 and Rosa26 editing sites, respectively, in the liver 
(Figure 4.11B). Because hepatocytes constitute only 65-70% of total cellular content in 
the adult liver (Racanelli and Rehermann, 2006), Nme2Cas9 AAV-induced hepatocyte 
editing efficiencies with sgPcsk9 and sgRosa were approximately 54-58% and 66-71%, 
respectively. We detected only 2.25% liver indels overall (~3-3.5% in hepatocytes) at 
the Rosa26-OT1 off-target site (Figure 4.11B), comparable to the 1% editing that we 
observed at this site in transfected Hepa1-6 cells (Figure 4.6A). At both 14 and 28 days 
post-injection, Pcsk9 editing was accompanied by a ~44% reduction in serum 
cholesterol levels, whereas mice treated with the sgRosa26-expressing AAV 
maintained normal level of cholesterol throughout the study (Figure 4.11C). The ~44% 
reduction in serum cholesterol in the Nme2Cas9/sgPcsk9 AAV-treated mice compares 
well with the ~40% reduction reported with SauCas9 all-in-one AAV when targeting 
the same gene (Ran et al., 2015). We next performed Western blotting using an anti-
PCSK9 antibody to estimate PCSK9 protein levels in the livers of mice treated with 
sgPcsk9 and sgRosa26. Liver PCSK9 was below the detection limit in mice treated 
with sgPcsk9, whereas sgRosa26-treated mice exhibited normal levels of PCSK9 
(Figure 4.11D). Finally, hematoxylin and eosin (H&E) staining and histology revealed 
no signs of toxicity or tissue damage in either group after Nme2Cas9 expression 
(Figure 4.11E). These data validate Nme2Cas9 as a highly effective genome editing 
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Figure 4.11 All-in-one AAV delivery of Nme2Cas9 in vivo 
(A) Workflow for delivery of AAV8.sgRNA.Nme2Cas9 to lower cholesterol levels in 
mice by targeting Pcsk9. Top: schematic of the all-in-one AAV vector expressing 
Nme2Cas9 and the sgRNA (individual genome elements not to scale). BGH, bovine 
growth hormone poly(A) site; HA, epitope tag; NLS, nuclear localization sequence; h, 
human-codon-optimized. Bottom: Timeline for AAV8.sgRNA.Nme2Cas9 tail-vein 
injections (4 x 1011 GCs), followed by cholesterol measurements at day 14 and indel, 
histology and cholesterol analyses at day 28 post-injection.  
(B) TIDE analysis to measure indels in DNA extracted from livers of mice injected 
with AAV8.Nme2Cas9+sgRNA targeting Pcsk9 and Rosa26 (control) loci.  Indel 
efficiencies at the lone off-target site identified by GUIDE-seq for these two sgRNAs 
(Rosa26|OT1) were also assessed by TIDE.  
(C) Reduced serum cholesterol levels in mice injected with the Pcsk9-targeting guide 
compared to the Rosa26-targeting controls. P values are calculated by unpaired two-
tailed t-test.  
(D) Western blotting using anti-PCSK9 antibody reveals strongly reduced levels of 
PCSK9 in the livers of mice treated with sgPcsk9, compared to mice treated with 
sgRosa26. 2ng of recombinant PCSK9 was used as a mobility standard (left-most lane), 
and a cross-reacting band in the liver samples is indicated by an asterisk. GAPDH was 
used as loading control (bottom panel).  
(E) H&E staining from livers of mice injected with AAV8.Nme2Cas9+sgRosa26 (left) 









AAV vectors have recently been used for the generation of genome-edited mice, 
without the need for microinjection or electroporation, simply by soaking the zygotes in 
culture medium containing AAV vector(s), followed by reimplantation into 
pseudopregnant females (Yoon et al., 2018). Editing was obtained previously with a 
dual-AAV system in which SpyCas9 and its sgRNA were delivered in separate vectors 
(Yoon et al., 2018). To test whether Nme2Cas9 could enable accurate and efficient 
editing in mouse zygotes with an all-in-one AAV delivery system, we targeted 
Tyrosinase (Tyr), bi-allelic inactivation of which disrupts melanin production, resulting 
in albino pups (Yokoyama et al., 1990). We first validated an efficient Tyr sgRNA 
(which cleaves the Tyr locus only 17 bp from the site of the classic albino mutation) in 
Hepa1-6 cells by transient transfections (Figure 4.12A). Next, we incubated 
C57BL/6NJ zygotes for 5-6 hours in culture medium containing 3x109 or 3x108 GCs of 
an all-in-one AAV6 vector expressing Nme2Cas9 along with the Tyr sgRNA. After 
overnight culture in fresh media, those zygotes that advanced to the two-cell stage were 
transferred to the oviduct of pseudopregnant recipients and allowed to develop to term 
(Figure 4.12B). Coat color analysis of pups revealed mice that were albino, chinchilla 
(indicating a hypomorphic allele of Tyrosinase), or that had variegated coat color 
composed of albino and chinchilla spots but lacking black pigmentation (Figure 4.12C). 
These results suggest a high frequency of biallelic mutations since the presence of a 
wild-type Tyrosinase allele should render black pigmentation. A total of five pups 
(10%) were born from the 3x109 GCs experiment. All of them carried indels; 
phenotypically, two were albino, one was chinchilla, and two had variegated 
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pigmentation, indicating mosaicism. From the 3x108 GCs experiment, we obtained 4 
pups (14%), two of which died at birth, preventing coat color or genome analysis. Coat 
color analysis of the remaining two pups revealed one chinchilla and one mosaic pup. 
These results indicate that single-AAV delivery of Nme2Cas9 and its guide can be used 
to generate mutations in mouse zygotes without microinjection or electroporation. To 
measure on-target indel formation in the Tyr gene, we isolated DNA from the tails of 
each mouse, amplified the locus, and performed TIDE analysis. We found that all mice 
had high levels of on-target editing by Nme2Cas9, varying from 84% to 100% (Table 
4.1). Most lesions in albino mouse 9-1 were either a 1- or a 4-bp deletion (Figure 
4.12D), suggesting either mosaicism or trans-heterozygosity. Albino mouse 9-2 
exhibited a uniform 2-bp deletion (Figure 4.12D). We cannot conclude that there was 
no mosaicism in mouse 9-2, or that additional alleles were absent from mouse 9-1, 
because only tail samples were sequenced and other tissues could have distinct lesions. 
Analysis of tail DNA from chinchilla mice revealed the presence of in-frame mutations 
that are potentially the cause of the chinchilla coat color. The limited mutational 
complexity suggests that editing occurred early during embryonic development in these 
mice. These results provide a streamlined route toward mammalian mutagenesis 
through the application of a single AAV vector, in this case delivering both Nme2Cas9 
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Figure 4.12 ex vivo genome editing with Nme2Cas9 
(A) Two sites in Tyr, each with N4CC PAMs, were tested for editing in Hepa1-6 cells. 
The sgTyr2 guide exhibited higher editing efficiency and was selected for further 
testing. (B) Seven mice survived post-natal development, and each exhibited coat color 
phenotypes as well as on-target editing, as assayed by TIDE.  
(B) Albino (left) and light gray or variegated (middle) mice generated by treatment of 
zygotes with 3 × 109 GCs, and light gray or variegated mice (right) with 3 × 108 GCs, 
of AAV6.Nme2Cas9:sgTyr. 
(C) Indel spectra from tail DNA of each edited mouse as well as an unedited 
C57BL/6NJ mouse, as indicated by TIDE analysis. Efficiencies of insertions (positive) 
















Table 4.1 Outcomes of ex vivo Nme2Cas9 delivery in mouse zygotes 
(A) Summary of Nme2Cas9.sgTyr single-AAV ex vivo Tyr editing experiments at two 
AAV doses. 
(B) Seven mice survived post-natal development, and each exhibited coat color 
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4.2.6 The structure of Nme2Cas9 reveals the mechanism of PAM recognition 
The crystal structure of Nme1Cas9 ortholog was resolved by Yanli Wang’s group. 
Although the structures and interactions of the N-terminal 820 amino acids of 
Nme2Cas9 should be highly similar to those of Nme1Cas9 (due to their >98% identity 
in these regions), the PID of the two orthologs are far more divergent, resulting in their 
distinct PAM specificities. To investigate the molecular mechanism of Nme2Cas9 
PAM recognition, in collaboration with Yanli Wang’s lab, we determined the crystal 
structure of Nme2Cas9 in complex with a sgRNA, together with a partially duplexed 
target DNA containing a N4CC PAM sequence (Figure 4.13A). dNme2Cas9 was used 
to prevent DNA cleavage. We solved the co-crystal structures with two distinct 
dsDNAs with a complete protospacer in the TS, but with either no protospacer or a 5-
nucleotide protospacer in the NTS. These structures were solved at 3.2 Å and 2.93 Å 
resolution, respectively. In both DNA-bound Nme2Cas9 complexes, the HNH domain 
is completely disordered (Figure 4.13A). Given that these two structures are similar 
overall, and that the latter has higher resolution and better electron density, our 
discussion is limited to the structure of Nme2Cas9-sgRNA in complex with DNA 
containing a 5-nucleotide protospacer in the NTS. Only two NTS protospacer 
nucleotides are observed, while the other three are disordered. The dsDNA is 
positioned in the cleft formed by the PID. In the PAM region, the side-chain of 
Asp1028 accepts a hydrogen bond from the exocyclic amino group of C(-5)' of the NTS 
(Figure 4.13B). T or G residues in this position would present a keto oxygen that cannot 
act a hydrogen bond donor. In addition, if adenine were to replace cytosine, the distance 
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between the side-chain of Asp1028 and the exocyclic -NH2 group would be too great to 
form a favorable hydrogen bond. These observations therefore explain the strong 
requirement for a C at that position, seen in Figure 4.3 In contrast to NTS recognition 
of C(-5)', the side-chain of Arg1033 forms a pair of hydrogen bonds with the base of 
G(-6) on the TS, indicating that Nme2Cas9 (like Nme1Cas9) uses both the TS and the 
NTS for PAM recognition. The other nucleotides within the duplex dsDNA have no 
base contacts with Nme2Cas9. 
To test the importance of the apparent Nme2Cas9 PAM-interacting residues 
Asp1028 and Arg1033, as well as a neighboring residue (Asn1031) as a negative 
control, we mutated each to alanine and examined editing efficiencies in 
transientlytransfected HEK293Tcells. The Asp1028Ala and Arg1033Ala mutations 
completely abolished Nme2Cas9 editing, whereas the Asn1031Ala mutation had no 
effect (Figures 4.13C). These results confirm the importance of the crystallographically 
implicated Asp1028 and Arg1033 interactions in PAM recognition and reveal the basis 







Figure 4.13 The structure of Nme2Cas9 reveals the mechanism of PAM 
recognition 
(A) The overall structure of the Nme2Cas9-sgRNA-dsDNA complex in a pre-catalytic 
state. 
(B) Detailed view of the interaction between the PI domain of Nme2Cas9 and the 5′-
N4CC-3′ PAM sequence. 






4.2.7 Rapidly evolving PIDs are not limited to N. meningitidis  
Finally, we wondered if the rapidly evolving PIDs could be found in other 
bacterial clades from which Cas9s for genome editing had been derived. Haemophilus 
species are in the Gammaproteobacteria class of bacteria and can cause respiratory tract 
infections. Many Haemophilus strains are sequenced, and since we already established 
HpaCas9 from Haemophilus parainfluenzae for genome editing, we focused on other 
closely related Haemophilus species. We found Cas9s from several Haemophilus 
influenzae (HinCas9) species were 93% identical to that of HpaCas9, with PIDs that 
were only 77% identical, suggesting that these Cas9s may have evolved different PAM 
recognitions. 
To investigate whether the HinCas9 ortholog recognized a distinct PAM, we 
replaced the PID of HpaCas9 with that of HinCas9 and used these recombinant 
chimeras for in vitro PAM identification similar to 3. In contrast to HpaCas9’s 
N4GATTT, HinCas9 recognizes an N4GAAA PAM, which corroborates our hypothesis 
that the high diversity found in the PID resulted in unique PAM recognition. These 




Figure 4.14 Rapidly evolving PIDs found in Haemophilus species 
(A) Domain architure of HinCas9 and its homology with HpaCas9. Notice the highly 
divergent C-terminal PID 
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Although compact Cas9 orthologs have been previously validated for genome 
editing, including via single-AAV delivery, their longer PAMs have restricted 
therapeutic development due to target site frequencies that are lower than that of the 
more widely adopted SpyCas9. In addition, SauCas9 and its KKH variant with relaxed 
PAM requirements are prone to off-target editing with some sgRNAs (Kleinstiver et 
al., 2015). These limitations are exacerbated with target loci that require editing within 
a narrow sequence window, or that require precise segmental deletion. We have 
identified Nme2Cas9 as a compact and highly accurate Cas9 with a less restrictive 
dinucleotide PAM for genome editing by AAV delivery in vivo. The development of 
Nme2Cas9 greatly expands the genomic scope of in vivo editing, especially via viral 
vector delivery. The Nme2Cas9 all-in-one AAV delivery platform established in this 
study can in principle be used to target as wide a range of sites as SpyCas9 (due to the 
identical densities of optimal N4CC and NGG PAMs), but without the need to deliver 
two separate vectors to the same target cells. The availability of a catalytically dead 
version of Nme2Cas9 (dNme2Cas9) also promises to expand the scope of applications 
such as CRISPRi, CRISPRa, base editing, and related approaches (Dominguez, Lim 
and Qi, 2016; Komor et al., 2016) Moreover, Nme2Cas9’s hyper-accuracy enables 
precise editing of target genes, potentially ameliorating safety issues resulting from off-
target activities. Perhaps counterintuitively, the higher target site density of Nme2Cas9 
(compared to that of Nme1Cas9) does not lead to a relative increase in off-target 
editing for the former. Similar results have been reported recently with SpyCas9 
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variants evolved to have shorter PAMs (Hu et al., 2018). Type II-C Cas9 orthologs are 
generally slower nucleases in vitro than SpyCas9 (Ma et al., 2015; Mir et al., 2018); 
interestingly, enzymological principles indicate that a reduced apparent kcat (within 
limits) can improve on- vs. off-target specificity for RNA-guided nucleases (Bisaria et 
al., 2017). 
The discovery of Nme2Cas9 and Nme3Cas9 hinged on unexplored Cas9s that 
are highly related (outside of the PID) to an ortholog that was previously validated for 
human genome editing (Esvelt et al., 2013; Hou et al., 2013; Lee et al., 2016; Amrani et 
al., 2018). The relatedness of Nme2Cas9 and Nme3Cas9 to Nme1Cas9 brought an 
added benefit, namely that they use the exact same sgRNA scaffold, circumventing the 
need to identify and validate functional tracrRNA sequences for each. In the context of 
natural CRISPR immunity, the accelerated evolution of novel PAM specificities could 
reflect selective pressure to restore targeting of phages and MGEs that have escaped 
interference through PAM mutations (Deveau et al., 2008; Paez-Espino et al., 2015). 
Our observation that AcrIIC5Smu inhibits Nme1Cas9 but not Nme2Cas9 suggests a 
second, non-mutually-exclusive basis for accelerated PID variation, namely evasion of 
anti-CRISPR inhibition. We also speculate that accelerated variability may not be 
restricted to PIDs, perhaps resulting from selective pressures to evade anti-CRISPRs 
that bind other Cas9 domains. Cas9 inhibitors such as AcrIIC1 that bind more 
conserved regions of Cas9 likely present fewer routes toward mutational escape and 
therefore exhibit a broader inhibitory spectrum (Harrington et al., 2017a). Whatever the 
sources of selective pressure driving Acr and Cas9 co-evolution, the availability of 
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validated inhibitors of Nme2Cas9 (e.g. AcrIIC1-4) provides opportunities for additional 
levels of control over its activities.  
The approach used in this studycan be implemented elsewhere, especially with 
bacterial species that are well-sampled at the level of genome sequence. This approach 
could also be applied to other CRISPR-Cas effector proteins such as Cas12 and Cas13 
that have also been developed for genome or transcriptome engineering and other 
applications. This strategy could be especially compelling with Cas proteins that are 
closely related to orthologs with proven efficacy in heterologous contexts (e.g. in 
eukaryotic cells), as was the case for Nme1Cas9. The application of this approach to 
meningococcal Cas9 orthologs yielded a new genome editing platform, Nme2Cas9, 
with a unique combination of characteristics (compact size, dinucleotide PAM, hyper-
accuracy, single-AAV deliverability, and Acr susceptibility) that promise to accelerate 













4.4 Materials and methods 
Discovery of Cas9 orthologs with differentially diverged PIDs 
Nme1Cas9 peptide sequence was used as a query in BLAST searches to find all Cas9 
orthologs in Neisseria meningitidis species. Orthologs with >80% identity to 
Nme1Cas9 were selected for the remainder of this study. The PIDs were then aligned 
with that of Nme1Cas9 (residues 820-1082) using ClustalW2 and those with clusters of 
mutations in the PID were selected for further analysis. An unrooted phylogenetic tree 
of NmeCas9 orthologs was constructed using FigTree 
(http://tree.bio.ed.ac.uk/software/figtree/). 
 
Purification of Cas9 and Acr orthologs 
Purification was performed as described in previous chapters. Briefly, Rosetta (DE3) 
cells containing the respective Cas9 plasmids were grown at 37°C to an OD600 of 0.6 
and protein expression was induced by 1mM IPTG for 16 hr at 18°C. Cells were 
harvested and lysed by sonication in lysis buffer [50 mM Tris-HCl (pH 7.5), 500 mM 
NaCl, 5 mM imidazole, 1 mM DTT] supplemented with 1 mg/mL Lysozyme and 
protease inhibitor cocktail (Sigma). The lysate was then run through a Ni2+-NTA 
agarose column (Qiagen), and the bound protein was eluted with 300 mM imidazole 
and dialyzed into storage buffer [20 mM HEPES-NaOH (pH 7.5), 250 mM NaCl, 
1 mM DTT]. For Acr proteins, 6xHis-tagged proteins were expressed in E. coli strain 
BL21 Rosetta (DE3). Cells were grown at 37 °C to an optical density (OD600) of 0.6 in 
a shaking incubator. The bacterial cultures were cooled to 18°C, and protein expression 
was induced by adding 1 mM IPTG for overnight expression. The next day, cells were 
harvested and resuspended in lysis buffer supplemented with 1 mg/mL Lysozyme and 
protease inhibitor cocktail (Sigma) and protein was purified using the same protocol as 
for Cas9. The 6xHis tag was removed by incubation of the resin-bound protein with 




Transfections and mammalian genome editing  
Human codon-optimized Nme2Cas9 was cloned by Gibson Assembly into the pCDest2 
plasmid backbone previously used for Nme1Cas9 and SpyCas9 expression (Amrani et 
al., 2018a; Pawluk et al., 2016). Transfection of HEK293T and HEK293T-TLR2.0 
cells was performed as previously described (Amrani et al., 2018a). For Hepa1-6 
transfections, Lipofectamine LTX was used to transfect 500ng of all-in-one 
AAV.sgRNA.Nme2Cas9 plasmid in 24-well plates (~105 cells/well), using cells that 
had been cultured 24 hours before transfection. For K562 cells stably expressing 
Nme2Cas9 delivered via lentivector (see below), 50,000 – 150,000 cells were 
electroporated with 500 ng sgRNA plasmid using 10 µL Neon tips.  
 
Lentiviral transduction of K562 cells to stably express Nme2Cas9 
K562 cells stably expressing Nme2Cas9 were generated as previously described for 
Nme1Cas9 (Amrani et al., 2018a). For lentivirus production, the lentiviral vector was 
co-transfected into HEK293T cells along with the packaging plasmids (Addgene 12260 
& 12259) in 6-well plates using TransIT-LT1 transfection reagent (Mirus Bio). After 24 
hours, culture media was aspirated from the transfected cells and replaced with 1 mL of 
fresh DMEM. The next day, the supernatant containing the virus was collected and 
filtered through a 0.45 µm filter. 10 uL of the undiluted supernatant along with 2.5 ug 
of Polybrene was used to transduce ~106 K562 cells in 6-well plates. The transduced 
cells were selected using media supplemented with 2.5 µg/mL puromycin.  
 
RNP Delivery for mammalian genome editing 
For RNP experiments, the Neon electroporation system was used exactly as described 
(Amrani et al., 2018a). Briefly, 40 picomoles of 3xNLS-Nme2Cas9 along with 50 
picomoles of T7-transcribed sgRNA was assembled in buffer R and electroporated 
using 10 µL Neon tips. After electroporation, cells were plated in pre-warmed 24-well 
plates containing the appropriate culture media without antibiotics. Electroporation 
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parameters (voltage, width, number of pulses) were 1150 V, 20 ms, 2 pulses for 
HEK293T cells; 1000 V, 50 ms, 1 pulse for K562 cells. 
 
GUIDE-seq  
GUIDE-seq experiments were performed as described previously (Tsai et al., 2014), 
with minor modifications (Bolukbasi et al., 2015). Briefly, HEK293T cells were 
transfected with 200 ng of Cas9 plasmid, 200 ng of sgRNA plasmid, and 7.5 pmol of 
annealed GUIDE-seq oligonucleotides using Polyfect (Qiagen). Alternatively, Hepa1-6 
cells were transfected as described above. Genomic DNA was extracted with a DNeasy 
Blood and Tissue kit (Qiagen) 72 h after transfection according to the manufacturer’s 
protocol. Library preparation and sequencing were performed exactly as described 
previously (Bolukbasi et al., 2015). For analysis, all sequences with up to ten 
mismatches with the target site, as well as a C in the fifth PAM position (N4CN), were 
considered potential off-target sites. Data were analyzed using the Bioconductor 
package GUIDEseq version 1.1.17 (Zhu et al., 2017). 
Targeted deep sequencing and analysis  
We used targeted deep sequencing to confirm the results of GUIDE-seq and to measure 
indel rates with maximal accuracy. We used two-step PCR amplification to produce 
DNA fragments for each on- and off-target site. For SpyCas9 editing at DS2 and DS6, 
we selected the top off-target sites based on GUIDE-seq read counts. For SpyCas9 
editing at DS4, fewer candidate off-target sites were identified by GUIDE-seq, and only 
those with NGG (DS4|OT1, DS4|OT3, DS4|OT6) or NGC (DS4|OT2) PAMs were 
examined by sequencing. In the first step, we used locus-specific primers bearing 
universal overhangs with ends complementary to the adapters. In the first step, 2x PCR 
master mix (NEB) was used to generate fragments bearing the overhangs. In the second 
step, the purified PCR products were amplified with a universal forward primer and 
indexed reverse primers. Full-size products (~250 bp) were gel-purified and sequenced 
on an Illumina MiSeq in paired-end mode. MiSeq data analysis was performed as 
previously described (Ibraheim et al., 2018a; Pinello et al., 2016). 
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Off-target analysis using CRISPRseek  
Global off-target predictions for TS25 and TS47 were performed using the 
Bioconductor package CRISPRseek. Minor changes were made to accommodate 
characteristics of Nme2Cas9 not shared with SpyCas9. Specifically, we used the 
following changes to: gRNA.size = 24, PAM = "NNNNCC", PAM.size = 6, 
RNA.PAM.pattern = "NNNNCN", and candidate off-target sites with fewer than 6 
mismatches were collected. The top potential off-target sites based on the numbers and 
positions of mismatches were selected. Genomic DNA from cells targeted by each 
respective sgRNA was used to amplify each candidate off-target locus and then 
analyzed by TIDE. 
 
Mouse strains and embryo collection 
All animal experiments were conducted under the guidance of the Institutional Animal 
Care and Use Committee (IACUC) of the University of Massachusetts Medical School. 
C57BL/6NJ (Stock No. 005304) 
mice were obtained from The Jackson Laboratory. All animals were maintained in a 12 
h light cycle. The middle of the light cycle of the day when a mating plug was observed 
was considered embryonic day 0.5 (E0.5) of gestation. Zygotes were collected at E0.5 
by tearing the ampulla with forceps and incubation in M2 medium containing 
hyaluronidase to remove cumulus cells. 
 
In vivo AAV8.Nme2Cas9+sgRNA delivery and liver tissue processing 
For the AAV8 vector injections, 8-week-old female C57BL/6NJ mice were injected 
with 4 x1011 genome copies per mouse via tail vein, with the sgRNA targeting a 
validated site in either Pcsk9 or Rosa26. Mice were sacrificed 28 days after vector 
administration and liver tissues were collected for analysis. Liver tissues were fixed in 
4% formalin overnight, embedded in paraffin, sectioned and stained with hematoxylin 
and eosin (H&E). Blood was drawn from the facial vein at 0, 14 and 28 days post 
injection, and serum was isolated using a serum separator (BD, Cat. No. 365967) and 
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stored at -80°C until assay. Serum cholesterol level was measured using the Infinity™ 
colorimetric endpoint assay (Thermo-Scientific) following the manufacturer’s protocol 
and as previously described (Ibraheim et al., 2018a). For the anti-PCSK9 Western blot, 
40 μg of protein from tissue or 2 ng of Recombinant Mouse PCSK9 Protein (R&D 
Systems, 9258-SE-020) were loaded onto a MiniPROTEAN® TGX™ Precast Gel 
(Bio-Rad). The separated bands were transferred onto a PVDF membrane and blocked 
with 5% Blocking-Grade Blocker solution (Bio-Rad) for 2 hours at room temperature. 
Next, the membrane was incubated with rabbit anti-GAPDH (Abcam ab9485, 1:2,000) 
or goat anti-PCSK9 (R&D Systems AF3985, 1:400) antibodies overnight. Membranes 
were washed in TBST and incubated with horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit (Bio-Rad 1706515, 1:4,000), and donkey anti-goat (R&D Systems 
HAF109, 1:2,000) secondary antibodies for 2 hours at room temperature. The 
membranes were washed again in TBST and visualized using Clarity™ western ECL 
substrate (Bio-Rad) using an M35A XOMAT Processor (Kodak). 
 
Ex vivo AAV6.Nme2Cas9 delivery in mouse zygotes 
Zygotes were incubated in 15 ul drops of KSOM (Potassium-Supplemented Simplex 
Optimized Medium, Millipore, Cat. No. MR-106-D) containing 3x109 or 3x108 GCs of 
AAV6.Nme2Cas9.sgTyr vector for 5-6 h (4 zygotes in each drop). After incubation, 
zygotes were rinsed in M2 and transferred to fresh KSOM for overnight culture. The 
next day, the embryos that advanced to 2-cell stage were transferred into the oviduct of 







CHAPTER 5: Therapeutic Genome Editing for Amyotrophic Lateral Sclerosis 
5.1 Introduction 
Amyotrophic lateral sclerosis (ALS) is a debilitating motor neuron disease 
affecting 3 in 100,000 adults in the United States. It is progressive, with only ~50% of 
patients surviving >30 months after symptoms emerge (Taylor, Brown and Cleveland, 
2016; Zarei et al., 2015). Although ALS can manifest in different ways, most patients 
experience motor neuron dysfunction, joint subluxation, and muscle loss (Zarei et al., 
2015; Kiernan et al., 2011). There is currently no cure for ALS, and only two FDA-
approved drugs are available for managing symptoms. Although these drugs have 
certainly helped suffering patients, their effect on prolonging survival is moderate (i.e. a 
few months) (Petrov et al., 2017). Alternative therapeutic strategies that target 
underlying causes of this disease may be more effective at preventing ALS progression. 
Although the cause of most ALS cases is unknown (termed “sporadic”), ~10% 
of cases are inherited (termed “familial”). Moreover, mutations in ~20 genes have been 
associated with both ALS forms (Taylor, Brown and Cleveland, 2016). Among these 
genes, mutations in C9ORF72 account for the majority of familial ALS cases and ~5% 
of sporadic ALS cases. Specifically, the intronic GGGGCC repeat expansion in 
C9ORF72 is found in some ALS patients, with disease severity directly correlating with 
the number of repeats (Haeusler, Donnelly and Rothstein, 2016). Evidence has shown 
that this repeat expansion reduces levels of C9ORF72, suggesting that 
haploinsufficiency triggers ALS (Shi et al., 2018). However, others have observed that 
repeat-expanded C9ORF72 RNA transcripts form nuclear foci, perturbing normal 
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nuclear processes (Zu et al., 2013; Peters et al., 2015). Finally, cell culture data suggest 
that abnormal protein translation caused by the repeat expansion, known as repeat-
associated non-ATG (RAN) translation, produces toxic dipeptides that form aggregates 
(Freibaum and Taylor, 2017). Although the exact mechanism underlying the C9ORF72 
repeat expansion in ALS is unclear, all three processes likely contribute to disease 
progression.  
Eliminating the intronic GGGGCC repeat expansion in C9ORF72 at the DNA 
level may be a promising therapeutic approach for C9ORF72-associated ALS. AAV 
delivery of CRISPR-Cas9 with two sgRNAs targeting the flanking region is a viable 
approach. However, the restrictive PAMs of small Cas9 orthologs hinder cleavage close 
to the expanded repeats (Figure 5.1). An inability to cleave close to the repeats leads to 
excision of flanking exons, which may impair the activity or expression of C9ORF72. 
Excision of the C9ORF72 repeat expansion using the hyper-accurate Nme2Cas9 may 
be a more clinically-relevant approach for ALS treatment. Firstly, its small size enables 
packaging into an all-in-one AAV vector, even with two gRNAs. Secondly, the location 
of Nme2Cas9 PAM sites in the target intron enables precise excision of repeats without 








5.2.1 Validating guides that efficiently excise the C9ORF72 repeats 
Efficient targeting by two gRNAs flanking the repeat expansion is critical to the 
success of the deletion approach. To this end, we designed six sgRNAs targeting wt 
C9ORF72 in HEK293T cells. Although wild-type C9ORF72 does not possess 
expanded repeats, the flanking sequence is identical and functional sgRNAs should 
work on expanded C9ORF72. We cloned each candidate sgRNA into a U6-driven 
plasmid and transiently transfected them, along with a plasmid expressing Nme2Cas9, 
into HEK293T cells. We harvested cells after 72 hours, extracted genomic DNA, and 
measured indels using TIDE. While all sites were edited, the most efficient sgRNAs 
targeted TS2 and TS6 on either end of the repeats (Figure 5.1B). Next, we transfected 
both plasmids expressing each sgRNA along with Nme2Cas9 to test for the excision 
efficiency. Our results showed that the repeats were excised in 53% of cells, suggesting 
Nme2Cas9 can efficiently eliminate the repeats (Figure 5.1C). These two sgRNAs will 







Figure 5.1 Efficient editing at sites flanking the repeats by Nme2Cas9.  
(A) Six sites targeted by Nme2Cas9 flanking the repeat expansion. (B) Each site is 
targeted in HEK293T cells by transient transfection along with a plasmid expression 
Nme2Cas9. Indels measured by TIDE (%) are shown for each site. (C) Indel spectrum 
from TS2 and TS6 cotransfections in HEK293T cells measured by TIDE. The red bar 
signifies the expected excision of repeats. 
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5.2.2 Validation of dual-gRNA single AAV for excising C9ORF72 repeats 
Cloning two sgRNAs along with Nme2Cas9 into a single AAV vector is imperative to 
the success of our deletion strategy. Our lab has now developed a more compact AAV 
backbone that allows for the expression of two sgRNAs along with their respective U6 
promoters. This backbone is under 5000 nt in length which makes it ideal for packaging 
(Figure 5.2A). We cloned our top two guides into this vector and transiently transfected 
HEK293T cells. As a control, we transfected the 3 plasmids individually to compare 
excision levels. 72 hours after transfection, we isolated gDNA from each sample and 
analyzed the indel spectrum using TIDE. Oure data suggest that the dual-sgRNA AAV 
system is almost as efficient in excising repeats as the three plasmids separately being 


















Figure 5.2 Validation of dual-sgRNA all-in-one AAV for excising C9ORF72 
repeats 
(A) All-in-one-AAV vector consisting of two sgRNAs and Nme2Cas9. Each sgRNA is 
driven by a U6 promoter, and Cas9 is driven by the U1a promoter.  
(B) Comparison in segmental deletion i.e. excision of the repeats and other indels 
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5.2.3: A strategy for “collapsing” the repeats using a single guide RNA 
While the dual guide strategy using Nme2Cas9 is highly promising, there are 
concerns regarding efficacy and the unpredictable nature of repair outcomes. While 
screening for efficient Nme2Cas9 sgRNAs targeting the flanking regions of the repeat, 
we noticed a peculiar indel pattern associated with TS3. Despite its low efficiency, the 
editing events all resulted in deletions in 6-nucleotide intervals (with ~ 6 or 12nt 
deletions). In other words, targeting within the repeats results in a “collapse” of the 
repeat on itself, resulting in incremental, 6-nucleotide deletions (not shown). This is in 
contrast to almost all other repair outcomes, where indels follow a random trajectory 
dominated by small insertions and deletions (Kosicki, Tomberg and Bradley, 2018). 
This could be in part due to the presence of repeats leading to repair by the 
microhomology-mediated end joining pathway (Iyer et al., 2019). Microhomology-
mediated end joining is an alternative form of the NHEJ pathway that uses 
microhomologous sequences during the alignment of ends being joined that results in 
precise deletions. 
To find out if this phenomenon was unique to this site and/or to Nme2Cas9, we 
used SpyCas9 and targeted six sites within the repeats at either end of the GGGGCC 
repeats. These sites recognize NGG PAMs within the repeats, but the complementarity 
extends into the flanking region, thus providing a unique “handle” to provide 
specificity. We cloned each guide into a U6-driven plasmid and co-transfected 
HEK293T cells along with a plasmid expressing SpyCas9 under the CMV promotor. 72 
hours post transfection, cells were isolated and indels were measured using TIDE. 
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While not every cleavage within the repeats resulted in a collapse, some led to efficient 
collapse at the expected 6-nt intervals. Of note, SpyTS3 resulted efficiently and 
consistently in collapse (Figure 5.3C). 
It is important to note that while this finding warrants future investigation, it is 
possible that in the case of extended repeats, the collapse strategy may not work. For 
example, it may be the case that the three repeats in healthy mammalian cells results in 
the microhomology-mediated end joining pathway, but this may not be the case when 
more repeats are present. Nevertheless, proof-of-concept experiments on expanded 










Figure 5.3. Testing the collapse strategy using SpyCas9 
(A) Schematic of sites targeted by SpyCas9, flanking each end of the repeats. 
(B) Repair outcome from five sites targeted with SpyCas9. Orange and green signify 
collapse while all other indels are in black. 
(C) Indel spectrum of TS1 (shown as an example) compared to TS3, which is the site 
with repair outcomes entirely resulting in collapse. 
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5.2.4 Ongoing and future experiments 
The preliminary studies presented here have paved the way to translate these 
findings to the context of ALS disease models. For the dual guide AAV approach, we 
will take advantage of cortical neurons from embryos expressing C9BAC [bacterial 
artificial chromosome containing parts of human C9ORF72 gene with ~500 repeats 
(Peters et al., 2015)] and will infect them with AAV9.Nme2Cas9 along with both 
sgRNAs. The embryos will be E16 offspring from C9BAC homozygous parents and 
will possess the expanded repeats. Primary cortical neurons are easily cultured and are 
ideal for testing the feasibility of our approach in a neuronal cell type. For the collapse 
approach, the next step is to test the efficiency of collapse on expanded repeats.  
The cellular phenotypes of C9ORF72-related ALS including RNA and 
dipeptide foci should be ameliorated if our approaches are successful. We will use 
RNA fluorescence in situ hybridization (RNA-FISH) to compare the formation of 
nuclear foci in treated vs control mice. Dipeptides produced from RAN translation form 
toxic cytoplasmic and nuclear aggregates in cells with expanded repeats. Among the six 
dipeptides formed in ALS pathology, sensitive rabbit monoclonal antibodies against 
poly glycine-proline (Poly-GP) dipeptides have been developed and used for detecting 
Poly-GP in patient samples. To quantify Poly-GP levels in treated vs. control groups, 
we will employ a sandwich immunoassay using the Meso Scale Discovery platform, an 
ELISA-based approach for detecting dipeptides (Ash et al., 2013). If either approach is 
successful, we expect that Poly-GP quantities will be significantly lower in cells where 
C9ORF72 repeats were excised. 
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5.3 Discussion 
ALS is a progressive motor neuron disease in which the average survival rate 
from onset is 2-4 years, and only 10% of individuals live past 10 years. There is 
currently no cure for ALS, and available medications do not significantly prolong 
survival. Mutations such as the repeat-expansion in C9ORF72 ultimately lead to 
neuronal death, decreased muscle mass, and loss of motor control. Gene editing 
approaches that eliminate ALS-causing mutations may prevent disease progression and 
improve the quality of life of some patients.  
Our preliminary studies demonstrate CRISPR-Cas9’s potential for the treatment 
of ALS caused by C9ORF72 repeat expansion. The next step will be to introduce the 
Nme2Cas9 dual sgRNA AAV9 vector into C9BAC neonates via facial vein injection. 
The goal is to offer hope for ALS patients and to get closer to the ultimate treatment for 
this disorder. 
In addition to ALS, eliminating repeat expansions can also offer therapeutic 
advantages to other repeat-associated diseases. There are at least 40 different disorders 
associated with repeat expansions, most of which affect the central nervous system 
(Paulson, 2018). We envision that our single-AAV can be applied to many of these 






5.4 Materials and methods 
Plasmids used in this chapter 
Nme2Cas9 plasmids were used from chapter 4. For the all-in-one AAV plasmid 
targeting the flanking region of C9ORF72, annealed oligos were sequentially cloned 
into plasmid pEJS1096. SpyCas9 lenti plasmid was obtained from Addgene (#86145). 
Annealed oligos were ligated after BsmbI digestion.  
 
Transfections of HEK293T cells  
Transfection of HEK293T and HEK293T-TLR2.0 cells was performed as previously 
described in chapter 4. For the experiments with separate plasmids, 200ng of Cas9 
plasmid and 200ng of sgRNA plasmid were used. For SpyCas9 lentiviral constructs, 
300 ng of the plasmid was used. To measure indels in all cells 72 hr after transfections, 
cells were harvested and genomic DNA was extracted using the DNaesy Blood and 
Tissue kit (Qiagen). The targeted locus was amplified by PCR, Sanger-sequenced 
(Genewiz), and analyzed by TIDE (Brinkman et al., 2014) using the Desktop Genetics 











Chapter 6: Conclusions and future directions. 
6.1. The future of Cas9 orthologs and their inhibitors 
There are currently thousands of sequenced Cas9 orthologs in the public 
database, of which only about a dozen have been carefully characterized, and a handful 
used for genome editing. With the current pace of sequencing platforms, and the recent 
explosion in microbiome and metagenomic sequencing, there will be thousands more 
sequenced within the coming decades.  Each Cas9 ortholog comes with a unique set of 
features, and by characterizing more and more Cas9s, we are likely to uncover Cas9s 
with desired features. For example, KlaCas9 from the surface of a marine microalgae 
has a unique, NGGGGA PAM and is most efficient at lower temperatures, which could 
enable efficient genome editing in cases where experiments need to be performed at 
room temperatures or below. Such unique features will encourage researchers to 
characterize many more Cas9 orthologs.  
The rate-limiting step in characterizing Cas9 orthologs is determining the PAM, 
and future studies should focus on streamlining the PAM identification process. The in 
vitro PAM identification strategy used in our studies is highly sensitive and identifies 
complex PAMs. Nevertheless, it requires that active protein is successfully purified and 
the sgRNA is correctly predicted (Briner et al., 2014). The study of Cas9 diversity will 
be facilitated by the discovery of high-throughput PAM identification strategies. 
Alternatively, with the growth of artificial intelligence and our continued progress in 
understanding of protein:DNA interactions, one can envisage the possibility of 
predicting PAMs solely based on the PID peptide sequence. Nonetheless, as more and 
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more phage and other MGE sequences become available, we are more likely to be able 
to predict PAMs for a Cas9 of interest. For example, the PAM for HpaCas9 
(N4GATTT) could be predicted based on two hits in phages that infect Haemophilus 
species. While this is currently not possible with most Cas9s, the surge in sequencing 
will make this possible in the near future. 
In addition to Cas9 diversity, Acr diversity remains to be fully appreciated. 
Future studies will take advantage of metagenomes to uncover new Acrs in a high-
throughput fashion. In fact, a recent study took advantage of a systematic 
bioinformatics pipeline to reveal dozens of putative Acrs in diverse phyla (Watters et 
al., 2018). Similar to Cas9, the promise of Acr applications must not be overstated, and 













6.2 The future of CRISPR genome engineering 
The CRISPR genome editing toolbox has been expanding for the past decade. 
Clinical applications of CRISPR will continue to grow and the innovation of new 
technologies will continue to improve our understanding of biology and medicine. 
While Cas9 continues to be the most widely used CRISPR enzyme, other CRISPR 
nucleases have been introduced over the past 5 years that offer complementary features 
to Cas9. For example, the discovery of Cas12 and Cas13 nucleases has expanded the 
CRISPR toolbox (Shmakov et al., 2017a). Cas12 is a DNA nuclease like Cas9, but it 
recognizes more AT rich PAMs, has the ability to process its own guide RNA (which 
enable multiplexing) and creates DNA cuts with overhangs (Zetsche et al., 2015). 
Cas13 is another effector nuclease but instead of DNA, it is an RNA-guided RNA 
cutter (East-Seletsky et al., 2016; Abudayyeh et al., 2016; Abudayyeh et al., 2017). 
Cas13 has been used for RNA editing and knockdown in human cells. It also exhibits 
collateral RNA shredding, i.e. it cleaves other RNAs in addition to the target RNA once 
activated, which has made it a powerful diagnostic tool (Gootenberg et al., 2018). 
Undoubtedly, more CRISPR tools will be added in the near future, and more and more 
will near clinical and diagnostic applications.  
However, it is important to not overstate the promise of CRISPR tools. History 
tells us that such breakthroughs, while powerful, often create a burst of hope among 
scientists and the public, but it takes decades to realize the complexity and nuances. For 
example, the discovery of RNA interference to silence RNAs appeared to be the magic 
bullet in the early 2000s. However, it took close to two decades for the first RNAi drug 
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to be approved by the FDA. CRISPR has certainly revolutionized biomedical sciences, 
but its future clinical implementation must be taken one step at a time. Nme2Cas9 is no 
exception, and below we describe future steps that will ensure that Nme2Cas9 can be 




















6.2.1 The future of Nme2Cas9 
Nme2Cas9 is a powerful genome editing tool that will streamline many genome 
editing applications. Our proof-of-concept in vivo delivery of a single-AAV Nme2Cas9 
vector means that it can now be used for therapeutic purposes. The ability of 
Nme2Cas9 to precisely edit the gene of interest is of paramount importance in 
therapeutic applications, where the ideal number of off-targets is zero. However, there 
are several questions that can be addressed in future studies to improve Nme2Cas9’s 
applications, some of which are outlined below 
The safety of Nme2Cas9 must be investigated in detail. Considering that 
Neisseria species are human commensals/pathogens, the presence of antibodies against 
Nme2Cas9 is a possibility. Furthermore, while we have studied the specificity of 
Nme2Cas9 over a month-long period in mouse models, longer studies are needed to 
ensure safety in the long term. In addition to accuracy, cleavage efficiency is another 
feature of an ideal Cas9. Our comparison of Nme2Cas9 and SpyCas9 suggests that 
SpyCas9 is more efficient in our short-term, transfection-based experiments. While 
increased efficiency may come at an accuracy cost, it may be possible to engineer 
Nme2Cas9 variants with higher activity that retain their accuracy.  
The development of fully modified crRNAs and tracrRNA (containing no 2′-
OH groups) will significantly enhance Nme2Cas9 applications. Modified RNAs have 
been developed for RNAi and for SpyCas9 genome editing, and in both cases have 
increased the stability of the RNA and its efficacy in vivo (Mir et al., 2018a; Khvorova 
and Watts, 2017; Hendel et al., 2015). Chemical modifications such as 2′-O-methyl, 
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phosphorothioate and fluoro RNA have previously been used to synthesize guide RNAs 
for SpyCas9 with superior efficacy and even improved specificity. The development of 
such modified RNAs for Nme2Cas9 will enable in vivo delivery of RNP complex with 
the possibility of prolonged expression. The modified RNA also could ameliorate a 
potential immune response. The crystal structure of Nme2Cas9 can be used to introduce 
modifications in a structure-guided manner.  
Cas9-based applications extend beyond its genome editing capabilities. While 
we demonstrated that Nme2Cas9 can be used as a nickase, there are applications that 
take advantage of Cas9’s ability to guide other proteins to a given genomic locus. For 
example, our lab has fused dSpyCas9 to an engineered ascorbate peroxidase (APEX2) 
for spatially restricted enzymatic tagging of proteins associated with a locus of interest 
(Gao et al. 2018).  One can envision the use of Nme2Cas9-Apex2 fusion to take 
advantage of the higher accuracy of Nme2Cas9, perhaps offering a higher signal to 
noise ratio. Other examples include fusing transcriptional activators/repressors, HDR 
effectors for improved homology repair, and base editors.  
In this thesis, we present new Cas9 orthologs and Acrs to improve existing 
genome editing tools. The simplicity of Cas9s such Nme2Cas9 make it easier than ever 
to manipulate the human genome. However, our knowledge concerning the short- and 
long-term outcomes of Cas9 expression is extremely limited. Consequently, until 
preliminary animal studies have been completed, it is unequivocally dangerous to test 
these systems in humans. Taken together, although CRISPR is a powerful tool, we must 
exercise extreme caution in implementing it. 
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APPENDIX  
Appendix 1: Information related to anti-CRISPRs and Cas9s in chapters 2 and 3 


























































































































































































































































































































































































































































































































































































































































































sgRNA sequences used in chapter 3 with the following format:  































Plasmids used in chapter 3: 
Name 
Insert 
description Backbone purpose 
AE51 HpaCas9     pMSCG7 Bacterial expression 
AE52 SmuCas9    pMSCG7 Bacterial expression 
AE53 KlaCas9    pMSCG7 Bacterial expression 
AE54 BoeCas9 pMSCG7 Bacterial expression 
AE65 Geo_sgRNA  pLKO sgRNA Cassette 
AE55 Hpa_sgRNA pLKO sgRNA Cassette 
AE56 Kla_sgRNA pLKO sgRNA Cassette 
AE58 HpaCas9 pcDest mammalian expression 
AE59 SmuCas9 pcDest mammalian expression 
AE60 KlaCas9  pcDest mammalian expression 
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Appendix 2: Information related to chapter 4 
Sequences: SV40 NLS 3X-HA-Tag  cMyc-like NLS 


































































































































































Spacer Seq  PAM Locus 
Editin
g (%) 
1 TS1 GGTTCTGGGTACTTTTATCTGTCC CCTCCACC AAVS1 ND 
2 TS4 GTCTGCCTAACAGGAGGTGGGGGT TAGACGAA AAVS1 11 
3 TS5 GAATATCAGGAGACTAGGAAGGAG GAGGCCTA AAVS1 15 




5 TS10 GAGCTAGTCTTCTTCCTCCAACCC GGGCCCTA AAVS1 3.5 
6 TS11 GATCTGTCCCCTCCACCCCACAGT GGGGCCAC AAVS1 9 
7 TS12 GGCCCAAATGAAAGGAGTGAGAGG TGACCCGA AAVS1 10 
8 TS13 GCATCCTCTTGCTTTCTTTGCCTG GACACCCC AAVS1 2 
9 TS16 GGAGTCGCCAGAGGCCGGTGGTGG ATTTCCTC LINC01
588 
28 




11 TS18 GGAAGGGAACATATTACTATTGC TTTCCCTC CYBB 1 
12 TS19 GTGGAGTGGCCTGCTATCAGCTAC CTATCCAA CYBB 6 
13 TS20 GAGGAAGGGAACATATTACTATTG CTTTCCCT CYBB 11.2 
14 TS21 GTGAATTCTCATCAGCTAAAATGC CAAGCCTT CYBB 1 
15 TS25 GCTCACTCACCCACACAGACACAC ACGTCCTC VEGF A 15.6 
16 TS26 GGAAGAATTTCATTCTGTTCTCAG TTTTCCTG CFTR 2 
17 TS27 GCTCAGTTTTCCTGGATTATGCCT GGCACCAT CFTR 4 
18 TS31 GCGTTGGAGCGGGGAGAAGGCCAG GGGTCACT VEGFA 9 












22 TS37 GCCGCGGCGCGACGTGGAGCCAGC CCCGCAAA LINC01
588 
ND 




24 TS41 GTCAGATTGGCTTGCTCGGAATTG CCAGCCAA AGA  3 
25 TS44 GCTGGGTGAATGGAGCGAGCAGCG TCTTCGAG VEGFA 3 
26 TS45 GTCCTGGAGTGACCCCTGGCCTTC TCCCCGCT VEGFA 7.4 
27 TS46 GATCCTGGAGTGACCCCTGGCCTT CTCCCCGC VEGFA 6 
28 TS47 GTGTGTCCCTCTCCCCACCCGTCC CTGTCCGG VEGFA 23.1 
29 TS48 GTTGGAGCGGGGAGAAGGCCAGGG GTCACTCC VEGFA 2 
30 TS49 GCGTTGGAGCGGGGAGAAGGCCAG GGGTCACT VEGFA 4 
31 TS50 GTACCCTCCAATAATTTGGCTGGC AATTCCGA AGA  6 
32 TS51 GATAATTTGGCTGGCAATTCCGAG CAAGCCAA AGA  4.5 
33 TS58 
(DS1) 













GTGAGCAGGCACCTGTGCCAACAT GGGCCCGC VEGFA 3.5 
37 TS62 
(DS5) 




GCATGGGCAGGGGCTGGGGTGCAC AGGCCCAG VEGFA 16 
39 TS64 GAAAATTGTGATTTCCAGATCCAC AAGCCCAA FANCJ 7 
40 TS65 GAGCAGAAAAAATTGTGATTTCC AGATCCAC FANCJ ND 
41 
TS66 







































(DS15) GGGGGCGCATGGCTCCGCCCCGCC GGGACCCC VEGFA 5 
50 
TS75 
(DS16) GTTCCCCTTCATTGCGGCGGGCTG CGGGCCAG VEGFA 35 
51 
TS76 



















(DS21) GTGGGCTTGCAGGAGGCAGGTCTG TGGCCCCT LSP1 1 
56 
TS81 
(DS22) TATGTTCCAGCTTCCTGGGTCTGC AGGTCCAG LSP1 39 
57 
TS82 
(DS23) GATTCCAGCCAGACACCCGCCCCC CGGCCCTG LSP1 10 
58 TS83 
(DS24) GCAACAGGAAGCAACTTCTTAGCC AGGGCCGG LSP1 ND 
59 
TS85 
(DS25) CATCCATCGGCGCTTTGGTCGGCA TGGCCCCA FancF ND 
60 
TS86 
(DS26) CCGCCGCTCCAGAGCCGTGCGAAT GGGGCCAT FancF ND 
61 
TS87 
(DS27) TCTCTCTGCGCCTGCTGGAGAACC GGGCCCTC FancF ND 
62 
TS88 
(DS28) GAGGCAAGAGGGCGGCTTTGGGCG GGGTCCAG FancF 33 
63 TS89 GCCCTCATCTCCAATATGGTATGG CGGCCCTT SEC61B 37 
64 TS90 GGCAAGAGCACAAGAGGAAGAGAG AGACCCTC GAPHD 38 






































































































































































































































































































































































75 Tyr_500_FW3 GATAGTCACTCCAGGGGTTG 
TIDE 
analysis 
76 Tyr_500_RV3 GTGGTGAACCAATCAGTCCT 
TIDE 
analysis 
77 Sec61b_TIDE_FW CCGGAGGTCTCTACTTCCCAT 
TIDE 
analysis 
78 Sec61b_TIDE_RV AAATGTCGCCTTCCTCCCAA 
TIDE 
analysis 
79 Gapdh_TIDE_FW TAAAAAGTGCAGGGTCTGGCG 
TIDE 
analysis 
80 Gapdh_TIDE_RV CTAACCAGTCAGCGTCAGAGC 
TIDE 
analysis 
81 Tomm20_TIDE_FW GGATGCCGACTGTGTGTAAAG 
TIDE 
analysis 
82 Tomm20_TIDE_RV CAGCAGCACACCTCACATAT 
TIDE 
analysis 
83 FANCF_TIDE_FW CCAATCAGTACGCAGAGAGTC 
TIDE 
analysis 
84 FANCF_TIDE_RV CCCAGAAGCCAGTGGACTAG 
TIDE 
analysis 
85 DTS3_TIDE_FW GCCCCACAATAAACAGCATC 
TIDE 
analysis 
86 DTS3_TIDE_RV CCCACCCCTATTCCACCTTA 
TIDE 
analysis 
87 DTS7_TIDE_FW  CTCCACCAGGAGTCAGGTCT 
TIDE 
analysis 







Plasmids used in chapter 4 
Name 
Insert 
description Backbone purpose 
pAE70 
Nme3Cas9 PID 
on Nme1Cas9 pMCSG7 
Bacterial expression of Nme1Cas9 
with Nme3Cas9 PID 
pAE71 
Nme2Cas9 PID 
on Nme1Cas9 pMCSG7 
Bacterial expression of Nme1Cas9 
with Nme2Cas9 PID 
pAE113 Nme2TLR1 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE114 Nme2TLR2 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE115 Nme2TLR5 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE116 Nme2TLR11 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE117 Nme2TLR12 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE118 Nme2TLR13 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE119 Nme2TLR14 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE120 Nme2TLR15 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE121 Nme2TLR16 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE122 Nme2TLR17 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE123 Nme2TLR18 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE124 Nme2TLR19 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE125 Nme2TLR20 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE126 Nme2TLR21 pLKO Targeting TLR2.0 with Nme2Cas9 
pAE149 Nme2TLR22 pLKO Targeting TLR2.0 with Nme2Cas9 




































spacer pLKO Targeting TLR2.0 with Nme2Cas9 
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pAE90 Nme2TS1 pLKO Targeting AAVS1 with Nme2Cas9 
pAE93 Nme2TS4 pLKO Targeting AAVS1 with Nme2Cas9 
pAE94 Nme2TS5 pLKO Targeting AAVS1 with Nme2Cas9 
pAE129 Nme2TS6 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE130 Nme2TS10 pLKO Targeting AAVS1 with Nme2Cas9 
pAE131 Nme2TS11 pLKO Targeting AAVS1 with Nme2Cas9 
pAE132 Nme2TS12 pLKO Targeting AAVS1 with Nme2Cas9 
pAE133 Nme2TS13 pLKO Targeting AAVS1 with Nme2Cas9 
pAE136 Nme2TS16 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE137 Nme2TS17 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE138 Nme2TS18 pLKO Targeting CYBB with Nme2Cas9 
pAE139 Nme2TS19 pLKO Targeting CYBB with Nme2Cas9 
pAE140 Nme2TS20 pLKO Targeting CYBB with Nme2Cas9 
pAE141 Nme2TS21 pLKO Targeting CYBB with Nme2Cas9 
pAE144 Nme2TS25 pLKO Targeting VEGFA with Nme2Cas9 
pAE145 Nme2TS26 pLKO Targeting CFTR with Nme2Cas9 
pAE146 Nme2TS27 pLKO Targeting CFTR with Nme2Cas9 
pAE152 Nme2TS31 pLKO Targeting VEGFA with Nme2Cas9 
pAE153 Nme2TS34 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE154 Nme2TS35 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE155 Nme2TS36 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE156 Nme2TS37 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE157 Nme2TS38 pLKO 
Targeting LINC01588 with 
Nme2Cas9 
pAE159 Nme2TS41 pLKO Targeting AGA with Nme2Cas9 
pAE185 Nme2TS44 pLKO Targeting VEGFA with Nme2Cas9 
pAE186 Nme2TS45 pLKO Targeting VEGFA with Nme2Cas9 
pAE187 Nme2TS46 pLKO Targeting VEGFA with Nme2Cas9 
pAE188 Nme2TS47 pLKO Targeting VEGFA with Nme2Cas9 
pAE189 Nme2TS48 pLKO Targeting VEGFA with Nme2Cas9 
pAE190 Nme2TS49 pLKO Targeting VEGFA with Nme2Cas9 
pAE191 Nme2TS50 pLKO Targeting AGA with Nme2Cas9 
pAE192 Nme2TS51 pLKO Targeting AGA with Nme2Cas9 
pAE232 TS64_FancJ1 pLKO Targeting FANCJ with Nme2Cas9 






























Targeting dual site with 
Nme2Cas9 
pAE207 SpyDS1 pLKO Targeting dual site with SpyCas9 
pAE208 SpyDS2 pLKO Targeting dual site with SpyCas9 
pAE209 SpyDS3 pLKO Targeting dual site with SpyCas9 
pAE210 SpyDS4 pLKO Targeting dual site with SpyCas9 
pAE211 SpyDS5 pLKO Targeting dual site with SpyCas9 





Nme2Cas9 all-in-one AAV 










with HA pCdest 




3X NLS in 
pMSCG7 pMSCG7 






Lentivector containing UCOE, 




D16A 4X NLS 
with 3XHA pCVL 
Lentivector containing UCOE, 




H588A 4X NLS 
with 3XHA pCVL 
Lentivector containing UCOE, 






Lentivector containing UCOE, 




























































Targeting dual site with 
Nme2Cas9 
pAE301 TS78 (DS19) pLKO 




















Targeting dual site with 
Nme2Cas9 
pAE306 TS83 (DS24) pLKO 




















Targeting dual site with 
Nme2Cas9 
pAE178 SpyDS7 pLKO Targeting dual site with SpyCas9 
pAE181 SpyDS8 pLKO Targeting dual site with SpyCas9 
pAE263 SpyDS9 pLKO Targeting dual site with SpyCas9 
pAE264 SpyDS10 pLKO Targeting dual site with SpyCas9 
pAE268 SpyDS11 pLKO Targeting dual site with SpyCas9 
pAE312 SpyDS12 pLKO Targeting dual site with SpyCas9 
pAE313 SpyDS13 pLKO Targeting dual site with SpyCas9 
pAE316 SpyDS14 pLKO Targeting dual site with SpyCas9 
pAE318 SpyDS15 pLKO Targeting dual site with SpyCas9 
pAE320 SpyDS16 pLKO Targeting dual site with SpyCas9 
pAE325 SpyDS17 pLKO Targeting dual site with SpyCas9 
pAE326 SpyDS18 pLKO Targeting dual site with SpyCas9 
pAE327 SpyDS19 pLKO Targeting dual site with SpyCas9 
pAE328 SpyDS20 pLKO Targeting dual site with SpyCas9 
pAE329 SpyDS21 pLKO Targeting dual site with SpyCas9 
pAE330 SpyDS22 pLKO Targeting dual site with SpyCas9 
pAE331 SpyDS23 pLKO Targeting dual site with SpyCas9 
pAE332 SpyDS24 pLKO Targeting dual site with SpyCas9 
pAE333 SpyDS25 pLKO Targeting dual site with SpyCas9 
pAE334 SpyDS26 pLKO Targeting dual site with SpyCas9 
pAE335 SpyDS27 pLKO Targeting dual site with SpyCas9 
pAE336 SpyDS28 pLKO Targeting dual site with SpyCas9 
 177 
REFERENCES 
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. 
J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., Lander, E. S., Voytas, D. F., 
Ting, A. Y. and Zhang, F. (2017) 'RNA targeting with CRISPR-Cas13', Nature, 
550(7675), pp. 280-284. 
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, 
D. B., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., Severinov, K., 
Regev, A., Lander, E. S., Koonin, E. V. and Zhang, F. (2016) 'C2c2 is a single-
component programmable RNA-guided RNA-targeting CRISPR effector', Science, 
353(6299), pp. aaf5573. 
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Levesque, S., Rivest, J.-F., 
Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., Laplante, M., Moineau, S., Goulet, 
A. and Doyon, Y. (2019) 'Versatile and robust genome editing with <em>Streptococcus 
thermophilus</em> CRISPR1-Cas9', bioRxiv, pp. 321208. 
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. 
E., Wu, T., Donohoue, P. D., Settle, A. H., Lied, A. M., McGovern, K., Fuller, C. K., 
Cameron, P., Fazzio, T. G., Zhu, L. J., Wolfe, S. A. and Sontheimer, E. J. (2018a) 
'NmeCas9 is an intrinsically high-fidelity genome editing platform', bioRxiv, pp. 
https://doi.org/10.1101/172650. 
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. 
E., Wu, T., Donohoue, P. D., Settle, A. H., Lied, A. M., McGovern, K., Fuller, C. K., 
Cameron, P., Fazzio, T. G., Zhu, L. J., Wolfe, S. A. and Sontheimer, E. J. (2018b) 
'NmeCas9 is an intrinsically high-fidelity genome-editing platform', Genome Biol, 
19(1), pp. 214. 
Ash, P. E., Bieniek, K. F., Gendron, T. F., Caulfield, T., Lin, W. L., Dejesus-
Hernandez, M., van Blitterswijk, M. M., Jansen-West, K., Paul, J. W., 3rd, 
Rademakers, R., Boylan, K. B., Dickson, D. W. and Petrucelli, L. (2013) 
'Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble 
polypeptides specific to c9FTD/ALS', Neuron, 77(4), pp. 639-46. 
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., 
Romero, D. A. and Horvath, P. (2007) 'CRISPR provides acquired resistance against 
viruses in prokaryotes', Science, 315(5819), pp. 1709-12. 
Basgall, E. M., Goetting, S. C., Goeckel, M. E., Giersch, R. M., Roggenkamp, E., 
Schrock, M. N., Halloran, M. and Finnigan, G. C. (2018) 'Gene drive inhibition by the 
anti-CRISPR proteins AcrIIA2 and AcrIIA4 in Saccharomyces cerevisiae', 
Microbiology, 164(4), pp. 464-474. 
Berns, K. I. and Muzyczka, N. (2017) 'AAV: An Overview of Unanswered Questions', 
Hum Gene Ther, 28(4), pp. 308-313. 
Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M., Brodsky, M. H., 
Zhu, L. J. and Wolfe, S. A. (2015) 'DNA-binding-domain fusions enhance the targeting 
range and precision of Cas9', Nat. Methods, 12(12), pp. 1150-6. 
 178 
Bondy-Denomy, J., Davidson, A. R., Doudna, J. A., Fineran, P. C., Maxwell, K. L., 
Moineau, S., Peng, X., Sontheimer, E. J. and Wiedenheft, B. (2018) 'A Unified 
Resource for Tracking Anti-CRISPR Names', CRISPR J, 1, pp. 304-305. 
Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. and Davidson, A. R. (2013) 
'Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system', 
Nature, 493(7432), pp. 429-32. 
Briner, A. E., Donohoue, P. D., Gomaa, A. A., Selle, K., Slorach, E. M., Nye, C. H., 
Haurwitz, R. E., Beisel, C. L., May, A. P. and Barrangou, R. (2014) 'Guide RNA 
functional modules direct Cas9 activity and orthogonality', Mol Cell, 56(2), pp. 333-
339. 
Brinkman, E. K., Chen, T., Amendola, M. and van Steensel, B. (2014) 'Easy 
quantitative assessment of genome editing by sequence trace decomposition', Nucleic 
Acids Res., 42(22), pp. e168. 
Brouns, S. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J., Snijders, A. P., 
Dickman, M. J., Makarova, K. S., Koonin, E. V. and van der Oost, J. (2008) 'Small 
CRISPR RNAs guide antiviral defense in prokaryotes', Science, 321(5891), pp. 960-4. 
Burstein, D., Harrington, L. B., Strutt, S. C., Probst, A. J., Anantharaman, K., Thomas, 
B. C., Doudna, J. A. and Banfield, J. F. (2017) 'New CRISPR-Cas systems from 
uncultivated microbes', Nature, 542(7640), pp. 237-241. 
Certo, M. T., Ryu, B. Y., Annis, J. E., Garibov, M., Jarjour, J., Rawlings, D. J. and 
Scharenberg, A. M. (2011) 'Tracking genome engineering outcome at individual DNA 
breakpoints', Nat Methods, 8(8), pp. 671-6. 
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., 
Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., 
Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, 
N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I. and Porteus, M. H. (2019) 
'Identification of preexisting adaptive immunity to Cas9 proteins in humans', Nat Med, 
25(2), pp. 249-254. 
Charpentier, E., Richter, H., van der Oost, J. and White, M. F. (2015) 'Biogenesis 
pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity', 
FEMS Microbiol Rev, 39(3), pp. 428-41. 
Chen, B., Gilbert, L. A., Cimini, B. A., Schnitzbauer, J., Zhang, W., Li, G. W., Park, J., 
Blackburn, E. H., Weissman, J. S., Qi, L. S. and Huang, B. (2013) 'Dynamic imaging of 
genomic loci in living human cells by an optimized CRISPR/Cas system', Cell, 155(7), 
pp. 1479-91. 
Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, 
L. B., Sternberg, S. H., Joung, J. K., Yildiz, A. and Doudna, J. A. (2017) 'Enhanced 
proofreading governs CRISPR-Cas9 targeting accuracy', Nature. 
Cho, S. W., Kim, S., Kim, J. M. and Kim, J. S. (2013) 'Targeted genome engineering in 
human cells with the Cas9 RNA-guided endonuclease', Nat Biotechnol, 31(3), pp. 230-
2. 
Chylinski, K., Makarova, K. S., Charpentier, E. and Koonin, E. V. (2014) 
'Classification and evolution of type II CRISPR-Cas systems', Nucleic Acids Res, 
42(10), pp. 6091-105. 
 179 
Cong, L. and Zhang, F. (2015) 'Genome engineering using CRISPR-Cas9 system', 
Methods Mol Biol, 1239, pp. 197-217. 
Cyranoski, D. (2016) 'CRISPR gene-editing tested in a person for the first time', 
Nature, 539(7630), pp. 479. 
De Caneva, A., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., 
Kay, M. A., Vlahovicek, K., Zentilin, L. and Muro, A. F. (2019) 'Coupling AAV-
mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver 
metabolic diseases', JCI Insight, 5. 
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., 
Eckert, M. R., Vogel, J. and Charpentier, E. (2011) 'CRISPR RNA maturation by trans-
encoded small RNA and host factor RNase III', Nature, 471(7340), pp. 602-7. 
Ding, Y., Li, H., Chen, L. L. and Xie, K. (2016) 'Recent Advances in Genome Editing 
Using CRISPR/Cas9', Front Plant Sci, 7, pp. 703. 
Dominguez, A. A., Lim, W. A. and Qi, L. S. (2016) 'Beyond editing: repurposing 
CRISPR-Cas9 for precision genome regulation and interrogation', Nat Rev Mol Cell 
Biol, 17(1), pp. 5-15. 
Dong, Guo, M., Wang, S., Zhu, Y., Wang, S., Xiong, Z., Yang, J., Xu, Z. and Huang, 
Z. (2017) 'Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein', 
Nature, 546(7658), pp. 436-439. 
Doudna, J. A. and Charpentier, E. (2014) 'Genome editing. The new frontier of genome 
engineering with CRISPR-Cas9', Science, 346(6213), pp. 1258096. 
East-Seletsky, A., O'Connell, M. R., Knight, S. C., Burstein, D., Cate, J. H., Tjian, R. 
and Doudna, J. A. (2016) 'Two distinct RNase activities of CRISPR-C2c2 enable 
guide-RNA processing and RNA detection', Nature, 538(7624), pp. 270-273. 
Esvelt, K. M., Mali, P., Braff, J. L., Moosburner, M., Yaung, S. J. and Church, G. M. 
(2013) 'Orthogonal Cas9 proteins for RNA-guided gene regulation and editing', Nat 
Methods, 10(11), pp. 1116-21. 
Fonfara, I., Le Rhun, A., Chylinski, K., Makarova, K. S., Lecrivain, A. L., Bzdrenga, J., 
Koonin, E. V. and Charpentier, E. (2014) 'Phylogeny of Cas9 determines functional 
exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas 
systems', Nucleic Acids Res, 42(4), pp. 2577-90. 
Franzosa, E. A. and Xia, Y. (2011) 'Structural principles within the human-virus 
protein-protein interaction network', Proc Natl Acad Sci U S A, 108(26), pp. 10538-43. 
Freibaum, B. D. and Taylor, J. P. (2017) 'The Role of Dipeptide Repeats in C9ORF72-
Related ALS-FTD', Front Mol Neurosci, 10, pp. 35. 
Friedrich, G. and Soriano, P. (1991) 'Promoter traps in embryonic stem cells: a genetic 
screen to identify and mutate developmental genes in mice', Genes Dev, 5(9), pp. 1513-
23. 
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. and Joung, J. K. (2014) 'Improving 
CRISPR-Cas nuclease specificity using truncated guide RNAs', Nat Biotechnol, 32(3), 
pp. 279-284. 
Gallagher, D. N. and Haber, J. E. (2018) 'Repair of a Site-Specific DNA Cleavage: Old-
School Lessons for Cas9-Mediated Gene Editing', ACS Chem Biol, 13(2), pp. 397-405. 
 180 
Gantz, V. M., Jasinskiene, N., Tatarenkova, O., Fazekas, A., Macias, V. M., Bier, E. 
and James, A. A. (2015) 'Highly efficient Cas9-mediated gene drive for population 
modification of the malaria vector mosquito Anopheles stephensi', Proc Natl Acad Sci 
U S A, 112(49), pp. E6736-43. 
Gasiunas, G., Barrangou, R., Horvath, P. and Siksnys, V. (2012) 'Cas9-crRNA 
ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in 
bacteria', Proc Natl Acad Sci U S A, 109(39), pp. E2579-86. 
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I. 
and Liu, D. R. (2017) 'Programmable base editing of A*T to G*C in genomic DNA 
without DNA cleavage', Nature, 551(7681), pp. 464-471. 
Germini, D., Tsfasman, T., Zakharova, V. V., Sjakste, N., Lipinski, M. and Vassetzky, 
Y. (2018) 'A Comparison of Techniques to Evaluate the Effectiveness of Genome 
Editing', Trends Biotechnol, 36(2), pp. 147-159. 
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J. and Zhang, 
F. (2018) 'Multiplexed and portable nucleic acid detection platform with Cas13, 
Cas12a, and Csm6', Science, 360(6387), pp. 439-444. 
Gorski, S. A., Vogel, J. and Doudna, J. A. (2017) 'RNA-based recognition and 
targeting: sowing the seeds of specificity', Nat Rev Mol Cell Biol, 18(4), pp. 215-228. 
Grissa, I., Vergnaud, G. and Pourcel, C. (2007) 'CRISPRFinder: a web tool to identify 
clustered regularly interspaced short palindromic repeats', Nucleic Acids Res, 35(Web 
Server issue), pp. W52-7. 
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. and Taipale, J. (2018) 'CRISPR-
Cas9 genome editing induces a p53-mediated DNA damage response', Nat Med, 24(7), 
pp. 927-930. 
Haeusler, A. R., Donnelly, C. J. and Rothstein, J. D. (2016) 'The expanding biology of 
the C9orf72 nucleotide repeat expansion in neurodegenerative disease', Nat Rev 
Neurosci, 17(6), pp. 383-95. 
Harrington, L. B., Paez-Espino, D., Staahl, B. T., Chen, J. S., Ma, E., Kyrpides, N. C. 
and Doudna, J. A. (2017) 'A thermostable Cas9 with increased lifetime in human 
plasma', Nat Commun, 8(1), pp. 1424. 
Hedlund, B. P. and Staley, J. T. (2002) 'Phylogeny of the genus Simonsiella and other 
members of the Neisseriaceae', Int J Syst Evol Microbiol, 52(Pt 4), pp. 1377-82. 
Heler, R., Samai, P., Modell, J. W., Weiner, C., Goldberg, G. W., Bikard, D. and 
Marraffini, L. A. (2015) 'Cas9 specifies functional viral targets during CRISPR-Cas 
adaptation', Nature, 519(7542), pp. 199-202. 
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., 
Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., Bacchetta, R., Tsalenko, A., Dellinger, D., 
Bruhn, L. and Porteus, M. H. (2015) 'Chemically modified guide RNAs enhance 
CRISPR-Cas genome editing in human primary cells', Nat Biotechnol, 33(9), pp. 985-
989. 
Hou, Z., Zhang, Y., Propson, N. E., Howden, S. E., Chu, L. F., Sontheimer, E. J. and 
Thomson, J. A. (2013) 'Efficient genome engineering in human pluripotent stem cells 
using Cas9 from Neisseria meningitidis', Proc Natl Acad Sci U S A, 110(39), pp. 
15644-9. 
 181 
Ibraheim, R., Song, C.-Q., Mir, A., Amrani, N., Xue, W. and Sontheimer, E. J. (2018a) 
'All-in-One Adeno-associated Virus Delivery and Genome Editing by Neisseria 
meningitidis Cas9 in vivo', bioRxiv, pp. https://doi.org/10.1101/295055. 
Ibraheim, R., Song, C. Q., Mir, A., Amrani, N., Xue, W. and Sontheimer, E. J. (2018b) 
'All-in-one adeno-associated virus delivery and genome editing by Neisseria 
meningitidis Cas9 in vivo', Genome Biol, 19(1), pp. 137. 
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M. and Nakata, A. (1987) 
'Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme 
conversion in Escherichia coli, and identification of the gene product', J Bacteriol, 
169(12), pp. 5429-33. 
Iyer, S., Suresh, S., Guo, D., Daman, K., Chen, J. C. J., Liu, P., Zieger, M., Luk, K., 
Roscoe, B. P., Mueller, C., King, O. D., Emerson, C. P., Jr. and Wolfe, S. A. (2019) 
'Precise therapeutic gene correction by a simple nuclease-induced double-stranded 
break', Nature, 568(7753), pp. 561-565. 
Jackson, S. A., McKenzie, R. E., Fagerlund, R. D., Kieper, S. N., Fineran, P. C. and 
Brouns, S. J. (2017) 'CRISPR-Cas: Adapting to change', Science, 356(6333). 
Jansen, R., Embden, J. D., Gaastra, W. and Schouls, L. M. (2002) 'Identification of 
genes that are associated with DNA repeats in prokaryotes', Mol Microbiol, 43(6), pp. 
1565-75. 
Jasin, M. and Haber, J. E. (2016) 'The democratization of gene editing: Insights from 
site-specific cleavage and double-strand break repair', DNA Repair (Amst), 44, pp. 6-16. 
Jiang, F. and Doudna, J. A. (2017) 'CRISPR-Cas9 Structures and Mechanisms', Annu 
Rev Biophys, 46, pp. 505-529. 
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A. and Charpentier, E. 
(2012) 'A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity', Science, 337(6096), pp. 816-21. 
Keeler, A. M. and Flotte, T. R. (2019) 'Recombinant Adeno-Associated Virus Gene 
Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How 
Did We Get Here?', Annu Rev Virol, 6(1), pp. 601-621. 
Khvorova, A. and Watts, J. K. (2017) 'The chemical evolution of oligonucleotide 
therapies of clinical utility', Nat Biotechnol, 35(3), pp. 238-248. 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., 
Burrell, J. R. and Zoing, M. C. (2011) 'Amyotrophic lateral sclerosis', Lancet, 
377(9769), pp. 942-55. 
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H. Y., Song, D. W., Lee, K. J., 
Jung, M. H., Kim, S., Kim, J. H., Kim, J. H. and Kim, J. S. (2017) 'In vivo genome 
editing with a small Cas9 orthologue derived from Campylobacter jejuni', Nat 
Commun, 8, pp. 14500. 
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z. 
and Joung, J. K. (2015) 'Broadening the targeting range of Staphylococcus aureus 
CRISPR-Cas9 by modifying PAM recognition', Nat Biotechnol, 33(12), pp. 1293-1298. 
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. and Liu, D. R. (2016) 
'Programmable editing of a target base in genomic DNA without double-stranded DNA 
cleavage', Nature, 533(7603), pp. 420-4. 
 182 
Koo, T., Lu-Nguyen, N. B., Malerba, A., Kim, E., Kim, D., Cappellari, O., Cho, H. Y., 
Dickson, G., Popplewell, L. and Kim, J. S. (2018) 'Functional Rescue of Dystrophin 
Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni 
Cas9', Mol Ther, 26(6), pp. 1529-1538. 
Koonin, E. V. and Makarova, K. S. (2009) 'CRISPR-Cas: an adaptive immunity system 
in prokaryotes', F1000 Biol Rep, 1, pp. 95. 
Koonin, E. V. and Makarova, K. S. (2019) 'Origins and evolution of CRISPR-Cas 
systems', Philos Trans R Soc Lond B Biol Sci, 374(1772), pp. 20180087. 
Kosicki, M., Tomberg, K. and Bradley, A. (2018) 'Repair of double-strand breaks 
induced by CRISPR-Cas9 leads to large deletions and complex rearrangements', Nat 
Biotechnol, 36(8), pp. 765-771. 
Larson, M. H., Gilbert, L. A., Wang, X., Lim, W. A., Weissman, J. S. and Qi, L. S. 
(2013) 'CRISPR interference (CRISPRi) for sequence-specific control of gene 
expression', Nat Protoc, 8(11), pp. 2180-96. 
Lau, C. H. and Suh, Y. (2017) 'In vivo genome editing in animals using AAV-CRISPR 
system: applications to translational research of human disease', F1000Res, 6, pp. 2153. 
Lee, C. M., Cradick, T. J. and Bao, G. (2016) 'The Neisseria meningitidis CRISPR-
Cas9 System Enables Specific Genome Editing in Mammalian Cells', Mol Ther, 24(3), 
pp. 645-54. 
Lee, J., Mir, A., Edraki, A., Garcia, B., Amrani, N., Lou, H. E., Gainetdinov, I., 
Pawluk, A., Ibraheim, R., Gao, X. D., Liu, P., Davidson, A. R., Maxwell, K. L. and 
Sontheimer, E. J. (2018) 'Potent Cas9 Inhibition in Bacterial and Human Cells by 
AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins', MBio, 9(6). 
Lesnik, E. A., Sampath, R., Levene, H. B., Henderson, T. J., McNeil, J. A. and Ecker, 
D. J. (2001) 'Prediction of rho-independent transcriptional terminators in Escherichia 
coli', Nucleic Acids Res, 29(17), pp. 3583-94. 
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., 
Li, Y., Sun, Y., Bai, Y., Songyang, Z., Ma, W., Zhou, C. and Huang, J. (2015) 
'CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes', Protein Cell, 
6(5), pp. 363-372. 
Lino, C. A., Harper, J. C., Carney, J. P. and Timlin, J. A. (2018) 'Delivering CRISPR: a 
review of the challenges and approaches', Drug Deliv, 25(1), pp. 1234-1257. 
Liu, C., Zhang, L., Liu, H. and Cheng, K. (2017) 'Delivery strategies of the CRISPR-
Cas9 gene-editing system for therapeutic applications', J Control Release, 266, pp. 17-
26. 
Liu, X. S., Wu, H., Krzisch, M., Wu, X., Graef, J., Muffat, J., Hnisz, D., Li, C. H., 
Yuan, B., Xu, C., Li, Y., Vershkov, D., Cacace, A., Young, R. A. and Jaenisch, R. 
(2018) 'Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the 
FMR1 Gene', Cell, 172(5), pp. 979-992 e6. 
Ma, H., Marti-Gutierrez, N., Park, S. W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., 
Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A. R., Kim, 
D., Kim, S. T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. 
H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J. S., Kaul, S. and 
 183 
Mitalipov, S. (2017) 'Correction of a pathogenic gene mutation in human embryos', 
Nature, 548(7668), pp. 413-419. 
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J., Charpentier, E., Horvath, P., 
Moineau, S., Mojica, F. J., Wolf, Y. I., Yakunin, A. F., van der Oost, J. and Koonin, E. 
V. (2011) 'Evolution and classification of the CRISPR-Cas systems', Nat Rev 
Microbiol, 9(6), pp. 467-77. 
Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., 
Barrangou, R., Brouns, S. J., Charpentier, E., Haft, D. H., Horvath, P., Moineau, S., 
Mojica, F. J., Terns, R. M., Terns, M. P., White, M. F., Yakunin, A. F., Garrett, R. A., 
van der Oost, J., Backofen, R. and Koonin, E. V. (2015) 'An updated evolutionary 
classification of CRISPR-Cas systems', Nat Rev Microbiol, 13(11), pp. 722-36. 
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E. and 
Church, G. M. (2013) 'RNA-guided human genome engineering via Cas9', Science, 
339(6121), pp. 823-6. 
Marraffini, L. A. and Sontheimer, E. J. (2008) 'CRISPR interference limits horizontal 
gene transfer in staphylococci by targeting DNA', Science, 322(5909), pp. 1843-5. 
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., 
Ertl, H. C., Muruve, D. A., Lee, B. and Herzog, R. W. (2011) 'The genome of self-
complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent 
innate immune responses in the liver', Blood, 117(24), pp. 6459-68. 
Mir, A., Alterman, J. F., Hassler, M. R., Debacker, A. J., Hudgens, E., Echeverria, D., 
Brodsky, M. H., Khvorova, A., Watts, J. K. and Sontheimer, E. J. (2018a) 'Heavily and 
fully modified RNAs guide efficient SpyCas9-mediated genome editing', Nat Commun, 
9(1), pp. 2641. 
Mir, A., Edraki, A., Lee, J. and Sontheimer, E. J. (2018b) 'Type II-C CRISPR-Cas9 
Biology, Mechanism, and Application', ACS Chem Biol, 13(2), pp. 357-365. 
Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J. and Soria, E. (2005) 'Intervening 
sequences of regularly spaced prokaryotic repeats derive from foreign genetic 
elements', J Mol Evol, 60(2), pp. 174-82. 
Morgan, G. J., Hatfull, G. F., Casjens, S. and Hendrix, R. W. (2002) 'Bacteriophage Mu 
genome sequence: analysis and comparison with Mu-like prophages in Haemophilus, 
Neisseria and Deinococcus', J Mol Biol, 317(3), pp. 337-59. 
Muller, M., Lee, C. M., Gasiunas, G., Davis, T. H., Cradick, T. J., Siksnys, V., Bao, G., 
Cathomen, T. and Mussolino, C. (2016) 'Streptococcus thermophilus CRISPR-Cas9 
Systems Enable Specific Editing of the Human Genome', Mol Ther, 24(3), pp. 636-44. 
Musunuru, K. (2013) 'Genome editing of human pluripotent stem cells to generate 
human cellular disease models', Dis Model Mech, 6(4), pp. 896-904. 
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Castellanos 
Rivera, R. M., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., Asokan, A., Zhang, F., 
Duan, D. and Gersbach, C. A. (2016) 'In vivo genome editing improves muscle 
function in a mouse model of Duchenne muscular dystrophy', Science, 351(6271), pp. 
403-7. 
 184 
Nishiyama, J., Mikuni, T. and Yasuda, R. (2017) 'Virus-Mediated Genome Editing via 
Homology-Directed Repair in Mitotic and Postmitotic Cells in Mammalian Brain', 
Neuron, 96(4), pp. 755-768 e5. 
Norskov-Lauritsen, N. (2014) 'Classification, identification, and clinical significance of 
Haemophilus and Aggregatibacter species with host specificity for humans', Clin 
Microbiol Rev, 27(2), pp. 214-40. 
Orthwein, A., Noordermeer, S. M., Wilson, M. D., Landry, S., Enchev, R. I., Sherker, 
A., Munro, M., Pinder, J., Salsman, J., Dellaire, G., Xia, B., Peter, M. and Durocher, D. 
(2015) 'A mechanism for the suppression of homologous recombination in G1 cells', 
Nature, 528(7582), pp. 422-6. 
Paez-Espino, D., Sharon, I., Morovic, W., Stahl, B., Thomas, B. C., Barrangou, R. and 
Banfield, J. F. (2015) 'CRISPR immunity drives rapid phage genome evolution in 
Streptococcus thermophilus', MBio, 6(2). 
Paulson, H. (2018) 'Repeat expansion diseases', Handb Clin Neurol, 147, pp. 105-123. 
Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J., Edraki, A., 
Shah, M., Sontheimer, E. J., Maxwell, K. L. and Davidson, A. R. (2016) 'Naturally 
occurring off-switches for CRISPR-Cas9', Cell, 167(7), pp. 1829-1838 e9. 
Pawluk, A., Bondy-Denomy, J., Cheung, V. H., Maxwell, K. L. and Davidson, A. R. 
(2014) 'A new group of phage anti-CRISPR genes inhibits the type I-E CRISPR-Cas 
system of Pseudomonas aeruginosa', MBio, 5(2), pp. e00896. 
Pawluk, A., Davidson, A. R. and Maxwell, K. L. (2018) 'Anti-CRISPR: discovery, 
mechanism and function', Nat Rev Microbiol, 16(1), pp. 12-17. 
Peters, O. M., Cabrera, G. T., Tran, H., Gendron, T. F., McKeon, J. E., Metterville, J., 
Weiss, A., Wightman, N., Salameh, J., Kim, J., Sun, H., Boylan, K. B., Dickson, D., 
Kennedy, Z., Lin, Z., Zhang, Y. J., Daughrity, L., Jung, C., Gao, F. B., Sapp, P. C., 
Horvitz, H. R., Bosco, D. A., Brown, S. P., de Jong, P., Petrucelli, L., Mueller, C. and 
Brown, R. H., Jr. (2015) 'Human C9ORF72 Hexanucleotide Expansion Reproduces 
RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC 
Transgenic Mice', Neuron, 88(5), pp. 902-909. 
Petrov, D., Mansfield, C., Moussy, A. and Hermine, O. (2017) 'ALS Clinical Trials 
Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?', 
Front Aging Neurosci, 9, pp. 68. 
Pinello, L., Canver, M. C., Hoban, M. D., Orkin, S. H., Kohn, D. B., Bauer, D. E. and 
Yuan, G. C. (2016) 'Analyzing CRISPR genome-editing experiments with 
CRISPResso', Nat. Biotechnol., 34(7), pp. 695-7. 
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P. 
and Lim, W. A. (2013) 'Repurposing CRISPR as an RNA-guided platform for 
sequence-specific control of gene expression', Cell, 152(5), pp. 1173-83. 
Racanelli, V. and Rehermann, B. (2006) 'The liver as an immunological organ', 
Hepatology, 43(2 Suppl 1), pp. S54-62. 
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, 
B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A. and Zhang, F. 
(2015) 'In vivo genome editing using Staphylococcus aureus Cas9', Nature, 520(7546), 
pp. 186-91. 
 185 
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., 
Hammer, R. E., Moon, Y. A. and Horton, J. D. (2005) 'Decreased plasma cholesterol 
and hypersensitivity to statins in mice lacking Pcsk9', Proc Natl Acad Sci U S A, 
102(15), pp. 5374-9. 
Rauch, B. J., Silvis, M. R., Hultquist, J. F., Waters, C. S., McGregor, M. J., Krogan, N. 
J. and Bondy-Denomy, J. (2017) 'Inhibition of CRISPR-Cas9 with Bacteriophage 
Proteins', Cell, 168(1-2), pp. 150-158 e10. 
Rees, H. A. and Liu, D. R. (2018) 'Base editing: precision chemistry on the genome and 
transcriptome of living cells', Nat Rev Genet, 19(12), pp. 770-788. 
Sapranauskas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P. and Siksnys, 
V. (2011) 'The Streptococcus thermophilus CRISPR/Cas system provides immunity in 
Escherichia coli', Nucleic Acids Res, 39(21), pp. 9275-82. 
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., 
Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A. and Marson, A. (2015) 
'Generation of knock-in primary human T cells using Cas9 ribonucleoproteins', Proc 
Natl Acad Sci U S A, 112(33), pp. 10437-42. 
Shi, Y., Lin, S., Staats, K. A., Li, Y., Chang, W. H., Hung, S. T., Hendricks, E., 
Linares, G. R., Wang, Y., Son, E. Y., Wen, X., Kisler, K., Wilkinson, B., Menendez, 
L., Sugawara, T., Woolwine, P., Huang, M., Cowan, M. J., Ge, B., Koutsodendris, N., 
Sandor, K. P., Komberg, J., Vangoor, V. R., Senthilkumar, K., Hennes, V., Seah, C., 
Nelson, A. R., Cheng, T. Y., Lee, S. J., August, P. R., Chen, J. A., Wisniewski, N., 
Hanson-Smith, V., Belgard, T. G., Zhang, A., Coba, M., Grunseich, C., Ward, M. E., 
van den Berg, L. H., Pasterkamp, R. J., Trotti, D., Zlokovic, B. V. and Ichida, J. K. 
(2018) 'Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human 
induced motor neurons', Nat Med, 24(3), pp. 313-325. 
Shin, J., Jiang, F., Liu, J. J., Bray, N. L., Rauch, B. J., Baik, S. H., Nogales, E., Bondy-
Denomy, J., Corn, J. E. and Doudna, J. A. (2017) 'Disabling Cas9 by an anti-CRISPR 
DNA mimic', Sci Adv, 3(7), pp. e1701620. 
Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. 
O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., Severinov, K., Zhang, F. and 
Koonin, E. V. (2017a) 'Diversity and evolution of class 2 CRISPR-Cas systems', Nat 
Rev Microbiol, 15(3), pp. 169-182. 
Shmakov, S. A., Sitnik, V., Makarova, K. S., Wolf, Y. I., Severinov, K. V. and Koonin, 
E. V. (2017b) 'The CRISPR Spacer Space Is Dominated by Sequences from Species-
Specific Mobilomes', MBio, 8(5). 
Stanley, S. Y. and Maxwell, K. L. (2018) 'Phage-Encoded Anti-CRISPR Defenses', 
Annu Rev Genet, 52, pp. 445-464. 
Sternberg, S. H., LaFrance, B., Kaplan, M. and Doudna, J. A. (2015) 'Conformational 
control of DNA target cleavage by CRISPR-Cas9', Nature, 527(7576), pp. 110-3. 
Sternberg, S. H., Richter, H., Charpentier, E. and Qimron, U. (2016) 'Adaptation in 
CRISPR-Cas Systems', Mol Cell, 61(6), pp. 797-808. 
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M. and 
Zhang, F. (2015) 'In vivo interrogation of gene function in the mammalian brain using 
CRISPR-Cas9', Nat Biotechnol, 33(1), pp. 102-6. 
 186 
Taylor, J. P., Brown, R. H., Jr. and Cleveland, D. W. (2016) 'Decoding ALS: from 
genes to mechanism', Nature, 539(7628), pp. 197-206. 
Thavalingam, A., Cheng, Z., Garcia, B., Huang, X., Shah, M., Sun, W., Wang, M., 
Harrington, L., Hwang, S., Hidalgo-Reyes, Y., Sontheimer, E. J., Doudna, J., Davidson, 
A. R., Moraes, T. F., Wang, Y. and Maxwell, K. L. (2019) 'Inhibition of CRISPR-Cas9 
ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2', Nat Commun, 10(1), 
pp. 2806. 
Tsai, S. Q. and Joung, J. K. (2016) 'Defining and improving the genome-wide 
specificities of CRISPR-Cas9 nucleases', Nat Rev Genet, 17(5), pp. 300-12. 
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., 
Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J. and Joung, J. K. 
(2014) 'GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-
Cas nucleases', Nat. Biotechnol., 33, pp. 187-197. 
Tycko, J., Myer, V. E. and Hsu, P. D. (2016) 'Methods for Optimizing CRISPR-Cas9 
Genome Editing Specificity', Mol Cell, 63(3), pp. 355-70. 
van Houte, S., Ekroth, A. K., Broniewski, J. M., Chabas, H., Ashby, B., Bondy-
Denomy, J., Gandon, S., Boots, M., Paterson, S., Buckling, A. and Westra, E. R. (2016) 
'The diversity-generating benefits of a prokaryotic adaptive immune system', Nature, 
532(7599), pp. 385-8. 
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. 
S. and Sabatini, D. M. (2015) 'Identification and characterization of essential genes in 
the human genome', Science, 350(6264), pp. 1096-101. 
Watters, K. E., Fellmann, C., Bai, H. B., Ren, S. M. and Doudna, J. A. (2018) 
'Systematic discovery of natural CRISPR-Cas12a inhibitors', Science, 362(6411), pp. 
236-239. 
Wiese, J., Thiel, V., Gartner, A., Schmaljohann, R. and Imhoff, J. F. (2009) 'Kiloniella 
laminariae gen. nov., sp. nov., an alphaproteobacterium from the marine macroalga 
Laminaria saccharina', Int J Syst Evol Microbiol, 59(Pt 2), pp. 350-6. 
Willems, A., Gilhaus, H., Beer, W., Mietke, H., Gelderblom, H. R., Burghardt, B., 
Voigt, W. and Reissbrodt, R. (2002) 'Brackiella oedipodis gen. nov., sp. nov., gram-
negative, oxidase-positive rods that cause endocarditis of cotton-topped tamarin 
(Saguinus oedipus)', Int J Syst Evol Microbiol, 52(Pt 1), pp. 179-86. 
Yamada, M., Watanabe, Y., Gootenberg, J. S., Hirano, H., Ran, F. A., Nakane, T., 
Ishitani, R., Zhang, F., Nishimasu, H. and Nureki, O. (2017) 'Crystal Structure of the 
Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the 
CRISPR-Cas9 Systems', Mol Cell, 65(6), pp. 1109-1121 e3. 
Yokoyama, T., Silversides, D. W., Waymire, K. G., Kwon, B. S., Takeuchi, T. and 
Overbeek, P. A. (1990) 'Conserved cysteine to serine mutation in tyrosinase is 
responsible for the classical albino mutation in laboratory mice', Nucleic Acids Res, 
18(24), pp. 7293-8. 
Yoon, Y., Wang, D., Tai, P. W. L., Riley, J., Gao, G. and Rivera-Perez, J. A. (2018) 
'Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant 
adeno-associated viruses', Nat Commun, 9(1), pp. 412. 
 187 
Zaiss, A. K., Liu, Q., Bowen, G. P., Wong, N. C., Bartlett, J. S. and Muruve, D. A. 
(2002) 'Differential activation of innate immune responses by adenovirus and adeno-
associated virus vectors', J Virol, 76(9), pp. 4580-90. 
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P. F., Pagani, W., 
Lodin, D., Orozco, G. and Chinea, A. (2015) 'A comprehensive review of amyotrophic 
lateral sclerosis', Surg Neurol Int, 6, pp. 171. 
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., 
Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V. and 
Zhang, F. (2015) 'Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas 
system', Cell, 163(3), pp. 759-71. 
Zhang, Y., Heidrich, N., Ampattu, B. J., Gunderson, C. W., Seifert, H. S., Schoen, C., 
Vogel, J. and Sontheimer, E. J. (2013) 'Processing-independent CRISPR RNAs limit 
natural transformation in Neisseria meningitidis', Mol Cell, 50(4), pp. 488-503. 
Zhang, Y., Rajan, R., Seifert, H. S., Mondragón, A. and Sontheimer, E. J. (2015) 
'DNase H activity of Neisseria meningitidis Cas9', Mol. Cell, 60, pp. 242-255. 
Zhang, Z., Theurkauf, W. E., Weng, Z. and Zamore, P. D. (2012) 'Strand-specific 
libraries for high throughput RNA sequencing (RNA-Seq) prepared without poly(A) 
selection', Silence, 3(1), pp. 9. 
Zhu, L. J., Holmes, B. R., Aronin, N. and Brodsky, M. H. (2014) 'CRISPRseek: a 
bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 
genome-editing systems', PLoS One, 9(9), pp. e108424. 
Zhu, L. J., Lawrence, M., Gupta, A., Pagés, H., Kucukural, A., Garber, M. and Wolfe, 
S. A. (2017) 'GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for 
CRISPR-Cas nucleases', BMC Genomics, 18, pp. 379. 
Zu, T., Liu, Y., Banez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T. M., 
Harms, M. B., Falchook, A. E., Subramony, S. H., Ostrow, L. W., Rothstein, J. D., 
Troncoso, J. C. and Ranum, L. P. (2013) 'RAN proteins and RNA foci from antisense 
transcripts in C9ORF72 ALS and frontotemporal dementia', Proc Natl Acad Sci U S A, 
110(51), pp. E4968-77. 
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., 
Maeder, M. L., Joung, J. K., Chen, Z. Y. and Liu, D. R. (2015) 'Cationic lipid-mediated 
delivery of proteins enables efficient protein-based genome editing in vitro and in vivo', 
Nat Biotechnol, 33(1), pp. 73-80. 
 
